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1 SUMMARY 
 
 
The transcription factor c-Myc is an important proto-oncogene and its expression is 
induced by a variety of mitogenic signals promoting cell proliferation, cell growth and 
stem cell maintenance while concomitantely inhibiting terminal differentiation. In order to 
elucidate the role of c-Myc in the HSC niche, a doxycycline-inducible double transgenic 
ColtTA;TreMyc mouse model was used to conditionally overexpress human c-Myc in 
endosteal niche osteoblasts (mutant; mt). These mice display developmental bone 
disorders with signs of osteopetrosis. The animals developed thicker bones with 
concomitantly increased amounts of osteoblasts and osteoclasts. In addition the structure 
of the compact bone compartment was interrupted with cavernal structures, filled with 
ectopic bone marrow. qPCR analysis revealed that the expression of the cell cycle inhibitor 
p57KIP2 was significantly lower in mutant osteoblasts, suggesting that c-Myc dependent 
down-regulation of the cell cylce inhibitor induced elevated cell proliferation of mutant 
osteoblasts resulting in a higher bone-turnover. Most strikingly, the elevated bone 
remodeling caused a fast reduction of dormant hematopoietic stem cells (dHSCs), known 
to harbor the most potent HSCs. BrdU-label retaining assays revealed similar turnover 
kinetics for dormant and homeostatic HSCs, both dividing every 58 days in mutant 
animals. These data suggest that dHSC are not maintained in mutant animals. Besides 
decreased numbers in dHSCs a simultaneous decrease of long- and short-term HSCs (LT-, 
ST-HSCs) was observed, while the number of more differentiated progenitor and mature 
cells did not differ between mutant and control mice. Interestingly, dHSC loss appeared to 
be compensated by elevated Bmi1 expression and down-regulated  p16INK4a cell cycle 
inhibitor in cycling LT-HSCs in order to prevent their premature depletion. Interestingly, 
HSC differentiation capacity in mutant mice was not impaired and the bone marrow 
reconstitution ability of mutant HSCs after bone marrow transplantation was also normal. 
Notably, the proportion of LT- and ST-HSCs was significantly decreased in recipients of 
primary and secondary bone marrow transplantations, indicating that only the number but 
not self-renewal and differentiation capacities of HSCs were reduced in c-Myc 
overexpressing mice. Interestingly, unlike wild type HSCs, HSCs from double transgenic 
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animals could not be efficiently activated by the HSC activators dsRNA PolyI:C or 
lipopolysaccharide (LPS).  
 
Strikingly, 26% of transgenic ColtTA;TreMyc animals developed osteosarcoma often 
associated with simultaneous lung and liver metastasis. Analysis of osteoblasts from tumor 
bearing mice revealed high similarities to human osteosarcoma, with the tumor osteoblasts 
displaying an immature osteoblastic phenotype with deregulated Wnt signaling and high 
expression of the tyrosine kinase receptor c-Kit. Interestingly it was recently shown that c-
Kit is expressed in human osteosarcomas and that its expression negatively correlates with 
patient survival. Thus this mouse model system might be an interesting tool for further pre-
clinical studies, as it is the first osteosarcoma model with spontaneous tumor development 
closely resembling human osteoblastic osteosarcoma. Finally, our model highlights the 
important cross-talk between endosteal osteoblasts, hematopoietic stem cells and 
tumorigenesis, which are also found deregulated in a variety of human bone marrow 
diseases. The mouse model generated and characterized in this work may facilitate to 
elucidate the complex molecular and cellular mechanisms operative in the diseased 
organism and may be used to the development of novel intervention strategies. 
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2 ZUSAMMENFASSUNG 
 
 
 
Eines der wichtigsten Proto-onkogene im Menschen ist der Transkriptionsfaktor c-Myc. Die 
Expression von c-Myc wird durch eine Vielzahl mitogener Signale induziert und spielt eine 
wichtige Rolle in der Regulation von Zellteilung, Wachstum, terminaler Differenzierung 
und Stammzellerhaltung. Die genaue Funktion des Transkriptionsfaktors hängt dabei stark 
vom jeweiligen Zelltyp ab. Um die Funktion von c-Myc in ausgereiften Osteoblasten im 
Knochen genauer beschreiben zu können, verwendeten wir das transgene Mausmodell 
ColtTA;TreMyc (Mutante; mt), in dem die Expression von humanem c-Myc über den 
Collagen I Promotor reguliert wird. Durch die Überexpression von c-Myc kam es zunächst 
zu schweren Entwicklungsstörungen des Knochens mit Anzeichen von Osteopetrose, d.h. 
sichtbar verdickten Knochen mit einem erhöhten Anteil an Osteoblasten und Osteoklasten. 
Die kompakte Hartsubstanz der Knochen war jedoch völlig mit Knochenmarkeinschlüssen 
durchzogen und führte zur Erhöhung der Knochenbrüchigkeit. Verstärktes 
Ostenblastenwachstum und erhöhte Umbaufrequenz sind wahrscheinlich Folge der 
verminderten Expression des Zellzyklus-Inhibitors p57KIP2. Interessanterweise führte diese 
verstärkte Knochenumstrukturierung zu einer drastischen Abnahme der potentesten 
Stammzellpopulation des hämatopoetischen Systems, der sogenannten ruhenden 
Stammzellen (dormant, dHSCs). Analyse der Zellteilungsrate zeigte, dass sich aktivierte 
und ruhende Stammzellen in den mutanten Mäusen im Schnitt nach 58 Tagen teilen, d.h 
dass im transgenen Mausmodell keine ruhenden Stammzellen mehr vorhanden sind. 
Dieser Verlust der dHSC Population ging mit einer erhöhten Expression von Bmi1 und 
gleichzeitiger Herunterregulierung des Zellzyklus-Inhibitors p16INK4a in LT-HSCs einher. 
Möglicherweise um so den stetigen Verlust der Zellen nach erneuter Zellteilung zu 
verhindern. Zusätzlich sind weniger homeostatische Stammzellen (LT-, ST-HSC) 
vorhanden, die sich auch nach Knochenmarkstransplantationen der HSCs in 
immunkomprimierte Mäuse widerspiegelte. Wohingegen keine Unterschiede in der 
terminalen Differenzierung vorlagen. Dies zeigt, dass allein die Anzahl der HSCs, jedoch 
nicht ihre Fähigkeit zur Selbsterneuerung und Differenzierungsfähigkeiten in den 
   -18- 
transgenen ColtTA;TreMyc Mäusen beeinträchtigt waren. HSCs können in Stresssituationen 
wie bakteriellen oder viralen Infektionen schnell aktiviert werden, teilweise durch das 
Zytokin IFNα. Interessanterweise konnten Stammzellen von transgenen Mäusen weder 
durch die Injektion der dsRNA Poly-I:C, welches zur Produktion von IFNα führt, noch 
durch LPS Injektion aktiviert werden.  
 
Zusätzlich entwickelten sich in 26% der transgenen Tiere Osteosarkome, die in Lunge und 
Leber metastasierten, und eine große Ähnlichkeit zu humanen Osteosarkomen aufwiesen. 
Insbesondere waren die Tumor-Osteoblasten genau wie in humanen Osteosarkomen 
undifferenziert und zeigten einige Eigenschaften unreifer Osteoblasten, sowie eine 
Deregulierung des Wnt-Signalweges und erhöhte Expression des Tyrosin-Kinase-Rezeptors 
c-Kit. Erst kürzlich wurde gezeigt, dass in humanen Osteosarkomen ein Zusammenhang 
zwischen c-Kit Expression und der Überlebensdauer der Patienten besteht. 
Zusammengefasst handelt es sich bei dem vorliegenden Maus-Modell um das erste 
Osteosarkom-Modell, in dem Tumore wie beim Patienten spontan entstehen. Es eignet sich 
daher gut als Testmodell zur Erforschung neuer Tumor-Therapien gegen Osteosarkome. 
Darüber hinaus ermöglicht das Mausmodell die genauere Analyse der hämatopoetischen 
Stammzell-Nische und der Interaktion zwischen Osteoblasten und HSCs, die in einer 
Vielzahl von humanen Erkrankungen gestört ist. Dadurch können 
Regulationsmechanismen und Krankheitsentstehung besser untersucht und moduliert 
werden.
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3 INTRODUCTION 
 
 
3.1 The Myc family of proto-oncogenes 
 
Human c-Myc is a transcription factor that is involved in the regulation of about 10-15% of 
all human genes (Kim, et al., 2008; Li, et al., 2003; Coller, et al., 2000). In addition it is a 
major proto-oncogene, which is found deregulated in about 60% of human cancers e.g. 
breast, colon, lymphoma (Gómez-Casares, et al., 2012; Eilers, et al., 2008). The Myc 
family consists of three members, c-Myc, N-Myc and L-Myc, which share an overall 
homology of about 80%. Functionally the Myc proteins are transcription factors that bind 
the so-called E-Box (CACGTG) via a helix-loop-helix domain (Dang, et al., 1999; Lee and 
Reddy, 1999; Fisher, et al., 1992; DePinho, et al., 1987). In this group of transcription 
factors, c-Myc is the best characterized and was identified by Ivanov, et al., 1964 as a 
homolog of v-Myc, a viral inducer of leukemia in chicken (Atchley and Fitch, 1995). 
However c-Myc is not only a relatively weak transactivator, but also has other, not yet fully 
understood functions (Koch, et al., 2007). Activation of c-Myc occurs through mitogenic 
signals e.g. via Wnt. Upon binding of Wnt to its cellular receptors, a cellular complex 
including Dishevelled (Dsh) and Axin is formed, which then complexes with 
Adenomatous-polyposis-coli (APC). APC is normally bound to ß-catenin and is recruited to 
this complex only upon Wnt-signalling. Thus ß-catenin is set free, accumulates in the 
cytoplasm and then migrates to the nucleus where it induces the expression of c-Myc 
(Dang, et al., 1999).  
 
While c-Myc occurs in most tissues and seems to be important for embryonic patterning, L-
Myc was identified by Nau, et al., 1985 to associate with human small cell lung cancer 
(SCLC). N-Myc plays a pivotal role in embryonic development, especially during 
neurogenesis and is highly amplified in neuroblastoma (Knoepfler, et al., 2002; Stanton, et 
al., 1992; Kohl, et al., 1984; Schwab, et al., 1983).  
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Transcriptional functionality in Myc is controlled by interaction via a leucine zipper with 
the Myc-associated factor X (Max) (Blackwood and Eisenman, et al., 1991; Kato, et al., 
1991). In the presence of Myc, the Myc-Max heterodimer activates transcription while in 
the absence of Myc, Max associates with the family of Mad proteins (Mad1, Mxi1 (Mad2), 
Mad3, Mad4 and Mnt) that functionally repress transcription (Quéva, et al., 1998; Ayer, et 
al., 1993; Zervos, et al., 1993). The Myc-Max complex mainly drives cell proliferation 
(Blackwood, et al., 1992; Littlewood, et al., 1990), while Max-Mad interactions show the 
opposite effect, and inhibit cell growth (Zhou, et al., 2001; Grandori, et al., 2000). This is 
mainly the reason for Max expression in resting and differentiated cell populations (Lüscher 
and Larsson, et al., 1999) (Figure 1).  
 
 
Figure	  1:	  Model	  for	  Myc	  and	  Mad	  protein	  interactions	  
Overview	  of	  Myc	  and	  Mad	  protein	   interaction	  partners	  and	  their	  repressors.	  The	  Myc-­‐Max	  heterodimer	  binds	  to	  E-­‐
Box	  sequence	  and	  results	   in	  transcriptional	  activation	  while	  the	  Myc-­‐Max-­‐Miz1	  complex	  binds	  to	   initiator	  sequence	  
elements	   (Inr)	   to	   repress	   Myc	   target	   gene	   expression.	   Either	   Mad-­‐Max	   heterodimer	   or	   Mad-­‐Mlx	   dimers	   repress	  
transcriptional	  activity	  (Lüscher	  and	  Larsson,	  et	  al.,	  1999).	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The biological roles of c-Myc are mainly focused on cell cycle control, apoptosis and 
differentiation, but are very complex as c-Myc deletion or ectopic expression has yielded 
many diverse effects (Eilers, et al., 2008; Adhikary and Eilers, 2005; Eisenman, et al., 2001) 
(Figure 2). Early experiments showed that deletion of one single c-Myc allele in RAT1 cells 
(rat fibroblasts) leads to a three-hour delay in S-phase entry, thus demonstrating the 
importance of c-Myc in cellular proliferation (Schmidt 1999). In contrast activation of c-
Myc in serum-starved fibroblasts induces their entry into the cell cyle, indicating the 
central role that the proto-oncogene plays in cell cycle regulation. The tumorigenic 
potential of the proto-oncogene was highlighted in experiments, where c-Myc was 
overexpressed in lymphoid cells and the mice subsequently developed lymphomas. The 
influence of c-Myc on differentiation during endochondral ossification in the bone was 
impressively shown by Zhou, et al. The group showed, that c- and N-Myc expression is 
sequentially coordinated during cell proliferation and differentiation of the appropriate 
chondrocyte and osteoblast compartments, that are both important for limb skeletal 
development (Zhou, et al., 2011).  
 
Myc is not only able to induce target gene expression but also to repress the transcription 
of down-stream target genes by interrupting the function of other transcriptional activators 
as Miz-1, NF-Y and SP-1 (Rottmann, et al., 2006; Herold, et al., 2002; Gartel, et al., 2001). 
Most importantly, cell growth and differentiation are among the best-studied cellular 
effects of Myc interactions. Therefore it is not surprising that some of the Myc target genes 
belong to cell cycle regulatory proteins like Cyclin D1, Cyclin D2, cyclin-dependent 
kinase 4 (CDK4) and the cell cycle inhibitors p21CIP1 and p15INK4b. By c-Myc dependent 
inhibition of the cell cycle inhibitor p21CIP1, damaged cells fail to arrest in G1 (Adhikary 
and Eilers, 2005). Additionally down-regulation of the cell cycle inhibitor p15INK4b leads to 
the upregulation of Cyclin D1-CDK4/6 complex and promotes cell cycle progression in a 
TGFß-dependent manner and thereby influences cell differentiation (Warner, et al., 1999).   
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Figure	  2:	  Implication	  of	  Myc	  signaling	  
(A)	  Overview	  of	  deregulated	  Myc	  signaling	  pathways	  and	  its	  effect	  on	  cellular	  biology	  (Eilers,	  et	  al.,	  2008).	  (B)	  Selected	  
Myc	  target	  genes	  (Adhikary	  and	  Eilers,	  2005).	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Notably, c-Myc expression is implicated in self-renewal, maintenance of stemness and 
differentiation. While c-Myc overexpression in hematopoietic stem cells (HSC) results in a 
loss of the stem cell pool, c-Myc loss leads to an accumulation of the HSCs in the bone 
marrow due to impaired engraftment capabilities with their surrounding niche cells 
(Laurenti, et al., 2008; Wilson, et al., 2004). In general, it seems that there is a correlation 
between cell proliferation and stem cell maintenance in a c-Myc dependent manner. 
Strikingly, Myc is dispensable in dormant HSCs while it becomes important in transient-
amplifying (multipotent progenitors, MPPs) cell populations and is again no longer relevant 
in terminally differentiated cells. Hence Myc supports the proliferation of actively-dividing 
cells, as it is important for stem cell maintenance, pluripotency and self-renewal capacities 
in HSCs under homeostatic conditions (Smith, et al., 2010; Varlakhanova, et al., 2010; 
Laurenti, et al., 2009; Murphy, et al., 2005; Wilson, et al., 2004). 
 
Myc was first discovered as a proto-oncogene in 1979 and furthermore its role in 
tumorigenesis was studied (Meyer and Penn, 2008). Activation of oncogenic Myc due to 
chromosomal translocation, overexpression, amplification and insertional mutagenesis. 
First insertional mutagenesis was discovered in plasmacytomas due to a recombination of 
the Myc locus and the immunoglobulin (Ig) heavy chain locus. Later, Adams and 
colleagues generated the Eµ -Myc mouse, which specifically develops B-cell lymphomas 
(Adams, et al., 1985). Myc is mainly implicated in Burkitt lymphomas and plasmacytomas, 
and deregulated in a variety of solid cancers e.g. hepato-cellular carcinomas, mammary 
tumors, colo-rectal cancer and head and neck cancer (Park, et al., 2005; Felsher, et al., 
1999; Field and Spandidos, 1990). Interestingly, in human osteosarcomas c-Myc 
amplification was identified in about 8-16% of human patients (Ueda, et al., 1997).  
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3.2 Bone development 
 
3.2.1 Bone structure  
 
Bone itself does not only give bodies a shape, it is also a very important endocrine 
regulator and harbors the bone marrow, which is crucial for blood replenishment 
throughout the whole life. The body contains five different types of bones. The long bones 
e.g. femur, tibia, humerus, the short bones e.g. wrists and ankles, flat bones e.g. skull, ribs, 
sternum, sesamoid bones, and irregular bones like the hips and the spine.  
 
The bone is one of the greatest reservoirs for calcium and phosphate ions and helps 
thereby to regulate the whole body ion metabolism. Bone is composed of different cell 
types: osteoblasts, osteoclasts and osteocytes that are embedded into bone matrix. This 
matrix mainly consists of calcium and phosphate ions that build hydroxyapatite crystals 
and about 30% of collagen (collagen I) fibers. Morphologically the bone can be 
distinguished into two important regions, the epiphysis and the diaphysis. The epiphysis is 
located at the top (proximal) and the bottom (distal) of a bone and builds a joint with 
another bone, while the part between the epiphyses is called diaphysis. Two types of bone 
are distinguished, the spongy bone in the epiphyses and in irregular bones, and the 
compact bone which forms the shaft along long bones and the outer layer. The very outer 
cell layer of a bone is the periosteum and the inner layer is composed of endosteal 
osteoblasts, and therefore called endosteum. These osteoblasts are of mesenchymal origin 
and produce the bone matrix, which is subsequently mineralized. Only about 10% of the 
mature osteoblasts remain as bone lining cells in the inner layer of the bone, while the rest 
terminally differentiates into osteocytes that are embedded into bone matrix and thereby 
build the compact structure of the bone. Bone remodeling occurs throughout life and 
depends not only on active bone elongation and growth, but is also affected by aging, 
body metabolism, repair and bone diseases. Osteoclasts are of hematopoietic origin and 
degrade the bone by enzymatic activity. Importantly, the bone is highly vascularized and 
possesses many nerve fibers that are located in Haversian canals to react fast in response to 
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endocrine signals. Bone caverns are inside the bone, where the bone marrow is homed 
and protected (Figure 3).   
 
 
Figure	  3:	  Bone	  composition	  
(a)	  Bone	  can	  be	  separated	  into	  two	  different	  areas,	  the	  proximal	  and	  distal	  epiphysis	  and	  the	  diaphysis.	  (b)	  The	  inner	  
layer	  of	  the	  epiphyses	   is	  composed	  of	  spongy	  bone,	  while	  the	  shaft	  and	  the	  outer	   layer	  contains	  compact	  bone.	  (c)	  
The	  inner	  cell	  layer	  of	  the	  bone	  is	  called	  endosteum,	  while	  cells	  on	  the	  outside	  form	  the	  periosteum.	  Nerve	  fibers	  and	  
the	  vasculature	  are	  located	  in	  Haversian	  canals	  and	  the	  bone	  marrow	  is	  build	  in	  the	  bone	  marrow	  cavity,	  surrounded	  
by	   the	   endosteum.	   Copyright	   ©	   2009	   Pearson	   Education,	   Inc.,	   publishing	   as	   Benjamin	   Cummings.	   Zitat	   nicht	  
vollständig!	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3.2.2 Bone formation 
 
Bone development occurs in two different ways, endochondral ossification and 
intramembraneous ossification (Figure 4). During embryonic development bone is formed 
by intramembraneous ossification, a process where cells from the neural crest become 
mesenchyme at the sites where the bones will appear. With the help of the transcription 
factor Runt-related transcription factor 2 (RunX2; cbfa1) and growth factors, mainly bone 
morphogenic proteins (BMPs) that are important for the tissues architecture, the condensed 
mesenchymal cells differentiate along the osteoblastic lineages to form mature bone 
producing cells. In contrast, endochondral ossification involves cartilage formation first 
and then the replacement of cartilage by bone cells. This can be separated into five steps. 
In the first step, the mesenchymal cells differentiate into cartilage by Pax1 and Scleraxis, 
which are both transcription factors. In the second step another transcription factor Sox9 
drives chondrocyte development and ends finally in the third step with highly proliferating 
chondrocytes that begin to form the bone shape. In the fourth step chondrocyte 
proliferation stops and chondrocytes start to increase their volume dramatically to become 
hypertrophic. Thereby the chondrocytes start to produce matrix that subsequently becomes 
mineralized. Finally, in the last step, the chondrocytes begin to die and form thereby the 
bone marrow cavity. Blood vessels are moving in and the cells that surrounded the 
cartilage cells start to differentiate into osteoblasts and bone matrix is produced. 
Subsequently, the dying cartilage cells are replaced by bone cells and thereby bone is 
formed. Upon bone matrix mineralization about 50-70% of osteoblasts undergo apoptosis 
while the rest either start to differentiate into osteocytes that are embedded into the bone 
matrix or become bone lining osteoblasts (Tamara, et al., 2006; Lynch, et al., 1994). These 
osteocytes mainly remain metabolically quiescent and do not show active cell 
proliferation.  
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Figure	  4:	  Mechanisms	  of	  endochondral	  and	  intramembranous	  bone	  formation	  
(a)	   Mechanism	   of	   endochondral	   bone	   formation	   by	   replacement	   of	   cartilage	   anlagen	   with	   osteoblasts.	   Through	  
mesenchymal	   stem	   cell	   condensation	   the	   cartilagenious	   skeleton	   is	   formed.	   Hypertrophic	   chondrocytes	   are	  
subsequently	   replaced	   by	   immigrating	   osteoblasts	   and	   the	   vasculature	   connects	   to	   the	   bone	   marrow	   cavity.	   (b)	  
Scheme	   for	  membranous	  bone	   formation.	  Mesenchymal	  progenitors	  differentiate	   into	  osteoblasts	   that	   line	  up	   the	  
bone.	  Upon	  mineralization,	  a	  proportion	  of	  osteoblasts	  differentiate	  into	  osteocytes	  that	  form	  the	  compact	  structure	  
of	  the	  bone.	  Osteoclasts	  are	  involved	  in	  bone	  remodeling	  by	  degradation	  of	  bone	  matrix	  (Hartmann,	  et	  al.,	  2009).	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3.3 Osteoblasts and osteoclasts are key players in the bone 
 
Mesenchymal stem cells differentiate into osteoblasts by RunX2 expression, one of the 
master regulators of bone development. Osteoblasts generate bone, while osteoclasts 
degrade the bone to keep bone remodeling balanced under homeostatic conditions. 
Interestingly, even though hematopoietic stem cells generate osteoclasts through 
macrophage-colony stimulating factor (M-CSF) differentiation, osteoblasts have a great 
influence on osteoclast development too. The receptor activator of NFkB-Ligand (RANK-L) 
is expressed on the surface of osteoblasts and interacts with RANK, which is expressed on 
immature osteoclasts to induce osteoclastogenesis. Another receptor, which is expressed 
on osteoblasts is osteoprotegerin (OPG). This receptor functions as a decoy receptor for 
RANK-L, thereby negatively influencing osteoclastogenesis. And as mentioned above, 
osteoblasts also produce M-CSF that interacts with c-fms (M-CSFR; CD115) on the surface 
of immature osteoclasts to induce terminal osteoclast differentiation (Figure 5). This shows 
that osteoblasts can influence osteoclastogenesis and differentiation by a wide range of 
possibilities.  
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Figure	  5:	  Osteoblastogenesis	  and	  Osteoclastogenesis	  
Upper	   row:	   Overview	   of	   osteoblastogenesis	   and	   osteoclastogenesis	   in	   the	   bone.	  Mesenchymal	   stem	   cells	   start	   to	  
differentiate	  into	  osteoblasts	  upon	  RunX2	  and	  BMP2	  signaling.	  Mature	  osteoblasts	  either	  terminally	  differentiate	  into	  
osteocytes	  or	  become	  apoptotic.	  Sclerostin	  produced	  by	  osteocytes	  negatively	  influences	  mature	  osteoblast	  synthesis	  
and	  is	  inhibited	  by	  parathormone	  (PTH).	  Important	  genes	  expressed	  during	  the	  different	  stages	  of	  osteoblastogenesis	  
are	   indicated	  as	  alkaline	  phosphatase	  (ALP),	  collagen	  I	   (ColI),	  osteopontin	  (OP),	  acidic	  bone	  sialoprotein	  (ASP),	  bone	  
sialoprotein	  (BSP),	  osteocalcin	  (OC).	  Lower	  row:	  Osteoclastogenesis	  is	  induced	  upon	  hematopoietic	  cell	  differentiation	  
from	  macrophage	  progenitors	  and	  is	  stimulated	  by	  inflammatory	  cytokines	  such	  as	  TNFa	  or	  IL-­‐1	  that	  induce	  Pu.1	  (Pu-­‐
Box	  transcription	  factor)	  expression.	  Macrophage-­‐colony	  stimulating	  factor	  (M-­‐CSF)	  induces	  macrophage	  maturation	  
to	   generate	   activated	   osteoclasts	   being	   tartrate-­‐resistant	   acid	   phosphatase	   (TRAP+)	   and	   calcitonin	   receptor	   (CTR+)	  
positive.	  RANK	  receptor	  on	  osteoclasts	  interacts	  with	  RANK-­‐L	  from	  osteoblasts	  to	  induce	  HSC-­‐independent	  osteoclast	  
maturation	  through	  bone	  tissue	  (Monroe,	  et	  al.,	  2012).	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3.4 Transcriptional control of osteoblast development 
 
The main inducer of osteoblast differentiation is RunX2, which is highly expressed in 
osteoblasts, cartilage precursors and MSCs (Ducy, et al., 1997; Komori, et al., 1997; Otto, 
et al., 1999) (Figure 5). It was shown that RunX2 knockout (RunX2-/-) animals were not 
able to induce bone formation, however cartilage skeleton developed with delayed 
chondrocyte maturation (Otto, et al., 1997; Komori, et al., 1997). Haploinsufficiency of 
RunX2 causes a severe delay in bone formation and results in cleidocranial dysplasia 
(CCD), an autosomal dominant disorder. In contrast, overexpression of RunX2 in 
osteoblasts resulted in a terminal osteoblast differentiation block with a loss of bone 
mineralization and porous bones (Liu, et al., 2001). This demonstrated that RunX2 is 
important for early osteoblast differentiation and initiation of bone mineralization and 
normal bone development. These observations impressively show that RunX2 regulates the 
initiation of osteoblast development as well as it controls differentiation and terminal 
function of osteoblasts. Therefore it is not surprising that RunX2 binding sites were 
identified in many genes involved in osteoblast regulation (Xiao, et al., 2005; Thomas, et 
al., 2001; Zhang, et al., 2000; Javed, et al., 2000). Besides Retinoblastoma (pRb) (Thomas, 
et al., 2001), Lian, et al., furthermore identified that osteocalcin (OCN), one of the key 
players that control bone metabolism and formation, has three binding sites for RunX2, 
indicating the high relevance of RunX2 controlled osteoblast differentiation and 
functionality (Lian, et al., 2001). Simultaneously, bone morphogenic proteins (BMP) induce 
osteoblast and cartilage development and then sex-determining region Y Box 9 (Sox9) 
exclusively drives further chondrocyte development (reviewed Zelzer and Olsen, 2003).  
 
Osteoprogenitors then differentiate through osterix (Osx) into immature osteoblasts. Since 
Osx is expressed in RunX2-/- animals but in contrast RunX2 is not expressed in Osx-/- 
animals, it is believed that Osx is downstream of RunX2 during osteoblast development 
(Hu, et al., 2004; Nakashima, et la., 2002). Osx-/- mice show normal cartilage 
development with full mineralization and the presence of terminally differentiated 
chondrocytes that indicate the importance of Osx in osteoblast differentiation (reviewed 
Harada and Rodan, 2003).  
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During osteoblast maturation the differentiation progress of an osteoblastic cell can be 
categorized by its marker expression. One of the expression markers that are expressed 
during early differentiation steps is alkaline phosphatase (ALP). ALP activity is important for 
proper bone mineralization and is mainly controlled by RunX2, BMP and Wnt signaling 
(Rawadi, et al., 2003; Beck, et al., 2000). Fedde, et al., showed that ALP-/- mice developed 
symptoms of hypophosphatasia as a consequence of hypomineralization (Fedde, et al., 
1999). Upon further osteoblast maturation ALP expression fades. One of the most 
abundant proteins in the bone is collagen I. Collagen I is synthesized in mature osteoblasts 
to generate bone matrix that subsequently is mineralized with calcium to form the solid 
bone structure. Collagen I expression is a hallmark of a functional osteoblast. Lynch and 
colleagues observed in rat osteoblast tissue cultures that collagen I synthesis is attributed to 
final osteoblast maturation and is needed for mineralization of bone tissue (Lynch, et al., 
1995).  
 
Other proteins like osteopontin (OPN) and osteocalcin (OCN) are then synthesized in 
mature osteoblasts during active bone mineralization. Osteopontin is an important non-
collagenous protein that is expressed in osteoblasts and osteoclasts respectively. 
Importantly, OPN has an effect on bone remodeling and homeostasis as it influences 
mineral deposition of the bone matrix and promotes osteoclastogenesis (Standal, et al., 
2004; Yoshitake, et al., 1999). The influence of OPN on osteoclasts was shown by 
Yoshitake, et al., where in a mouse model system of osteoporosis, ovariectomy in OPN-/- 
deficient mice did not lead to an increase in osteoclast numbers (Yoshitake, et al., 1999). 
While OPN is only secreted in cells during active cell proliferation, OCN synthesis is only 
observed in mature osteoblasts in the post-proliferative phase (Lian and Stein, 1995; 
Hauschka, et al., 1989). OCN is the most important indicator for bone formation (Lian, et 
al., 1989). OCN deficient animals showed elevated bone formation capacity and bone 
mass without any effect on bone degradation (Ducy, et al., 1996). There exist two different 
forms of OCN - pre-OCN, which is unminerlized and mature OCN, which is the 
mineralized OCN. Unmineralized OCN is synthesized by mature osteoblasts and only in 
the presence of vitamin K, which is its cofactor. It binds to hydroxyapatite to generate the 
mineralized bone matrix. Excessive OCN is then released to the blood stream and 
functions as an endocrine regulator to influence bone formation by energy metabolism 
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(Ferron, et al., 2010 and 2008; Takeda and Karsenty, 2001). In a very last differentiation 
step osteoblasts differentiate to either osteocytes or become apoptotic (reviewed Franz-
Odendaal, et al., 2006). About 50-70% of osteoblast-derived osteocytes are trapped in the 
mineralized bone matrix to generate compact bone, while the remaining non-apoptotic 
10-20% of osteoblasts form the endosteum. Osteocytes mainly express sclerostin as a 
product of the SOST gene that negatively influences bone formation. Sclerostin is directly 
inhibited by parathormone (PTH), which is an inducer of bone formation (Keller, et al., 
2005). On the other hand sclerostin interrupts intracellular Wnt signaling by binding to 
LRP5/6 receptor that actually induces differentiation of mature osteoblasts with a 
simultaneous block in osteoclastogenesis, thereby regulating bone mass and bone 
formation (reviewed Baron and Rawadi, 2007; Li, et al., 2006).  
 
3.5 Key pathways influencing bone formation and degradation 
 
3.5.1 Wnt signaling  
 
Bone formation by osteoblast maturation and differentiation is tightly regulated and 
controlled by a number of pathways. One of the major pathways that influences bone 
metabolism is Wnt signaling. Wnt induces MSCs to differentiate towards osteoblastic cell 
lineages and promotes the maturation of pre-osteoblasts to mature osteoblasts. By 
expression of DKK-1, a direct Wnt antagonist, osteoclastogenesis is efficiently blocked, 
thereby positively influencing bone formation upon induced Wnt signaling. LRP5 and 
LRP6 are Wnt co-receptors and induce canonical Wnt signaling. Kato and colleagues 
showed that LRP5 knockout (LRP5-/-) mice have impaired bone formation and osteoblast 
proliferation, resulting in lower bone mass and matrix deposition (Kato, et al., 2002). In 
contrast in LRP5 (G171V) mutants, excess activity of the Wnt signaling pathway resulted in 
higher bone mass without an influence on the osteoclast compartment. Instead osteoblasts 
from transgenic animals revealed prolonged life-span and an increased mineralization 
capacity (Babij, et al., 2003). Many target genes can be used as a read-out for the 
functionality of the activated Wnt signaling pathway, however ß-Catenin and Axin2 seem 
to be the most significant ones. Interestingly, mice with conditional deletion of ß-Catenin 
   
	   INTRODUCTION	   	  	   	  
-33- 
(ß-Catenin-flox) in osteoblasts, resulted in an early onset of osteoporosis, a severe bone 
disease with reduced bone mass and high risk for fractures. In contrast, conditional 
deletion of Adenomateous polyposis coli (Apc-flox), which normally degrades ß-Catenin 
complex, resulted in severe osteopetrosis. Osteopetrosis is characterized through an 
increase in bone mass with a high bone turnover as a consequence of impaired osteoclast 
activity. These results indicated the important role of ß-Catenin signaling in rather 
modulating osteoclastogenesis and its effect on bone development (Holmen, et al., 2005). 
Most interestingly, OPG, the decoy receptor for RANK-L that negatively influences 
osteoclastogenesis, was found to be a ß-Catenin target and loss of ß-Catenin in 
differentiated osteoblasts results in mice with osteopenia. Osteopenia implies low bone 
mass and high bone resorption by osteoclasts (Glass II, et al., 2005). In addition to APC, 
Axin2 belongs to the ß-Catenin degradation complex too and thereby regulates Wnt 
signaling in a negative feedback-loop (Jho, et al., 2002). Examinations on Axin2-/- mice 
showed that the animals had increased bone mass and elevated differentiation capacities 
with a simultaneous decrease in osteoclastogenesis (Yan, et al., 2009). Notably, even 
though Wnt signaling is a master regulator of bone development that influences osteoblast 
maturation, it primarily seems to act on osteoclastogenesis first, which in turn then 
influences osteoblast behavior as a secondary effect and results in a specific bone 
phenotype (Figure 6). 
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Figure	  6:	  Wnt	  signaling	  in	  the	  bone	  
Wnt	  signaling	  positively	  influences	  mesenchymal	  stem	  cells	  (MSC)	  to	  differentiate	  towards	  osteoblastic	  lineages	  and	  
drives	   the	   maturation	   of	   osteoprogenitors.	   In	   addition	   Wnt	   induces	   osteoprotegerin	   (OPG)	   expression	   in	   mature	  
osteoblasts	  to	  prevent	  osteoclastogenesis.	  Wnt	  blocks	  MSC	  differentiation	  to	  adipocytes,	  inhibits	  final	  maturation	  of	  
osteoblasts	   by	   upregulation	   of	   Wnt	   inhibitor	   dickkopf-­‐1	   (DKK-­‐1)	   and	   prevents	   apoptosis	   of	   mature	   osteoblasts.	  
Positive	  Wnt	  influence	  is	  indicated	  in	  green	  while	  negative	  regulation	  is	  shown	  in	  red	  (Baron,	  et	  al.,	  2006).	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3.5.2 Transforming growth factor beta (TGFß) signaling 
 
Bone morphogenic proteins (BMP) are involved in cell growth and differentiation, 
homeostasis and apoptosis (Chao and Chen, et al., 2005; Siegel and Massagué, 2003; 
Massagué, 2000). From eleven known BMP subtypes, six (BMP2-7) belong to the TGFß 
superfamily,. By binding to its receptor BMPR-2 induces activated SMAD signaling, which 
triggers the transcription of TGFß target genes, e.g. cell cycle inhibitors p15INK4b, p21CIP1, 
p57KIP2 and RunX2 (Lee, et al., 2000). In general TGFß signaling cooperates with Wnt 
signaling in promoting osteoblast differentiation and maturation (Takeuchi, et al., 2010; 
Zhou, et al., 2004; Zhou, et al., 2003;). Mutations in BMPs and their inhibitors, e.g. 
sclerostin and noggin, result in skeletal disorders (Chen, et al., 2012).   
 
3.5.3 Vitamin D and parathormone (PTH) signaling  
 
Calcium is one of the major signal transducers throughout the body and relevant as second 
messenger or in cofactor signaling. One major component of the solid bone structure is 
hydroxyapatite, which is composed of calcium and phosphate ions. Therefore minerals 
highly influence bone metabolism. Two pathways mainly control the mineral metabolism 
in the body, the vitamin D and the parathormone (PTH) signaling cascades. Interstingly, 
Ono, et al., showed that constitutively active PTH and PTHR (receptor) in mature 
osteoblasts resembled the phenotype of animals with chronically elevated PTH serum 
levels. Mice showed increased bone mass due to suppression of osteocytic sclerostin (Ono, 
et al., 2006; Bellido, et al., 2005).   
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3.6 Osteosarcoma 
 
Osteoblasts are cells that do no longer proliferate as much as their progenitors. While 
about 50-70% of osteoblasts finally differentiate to osteocytes, only about 10% form the 
inner layer of the bone and the rest starts to become apoptotic. This shows that the 
classical osteoblast becomes more and more quiescent during aging. Therefore it is not 
suprising that oncogenic transformation of mature osteoblasts happen mainly during active 
cell proliferation and cell growth, which is during skeleton develpment. In this phase most 
of malignant osteosarcoma develop. In general osteosarcoma form about 20% of all bone 
tumors and they are among the most frequent type of cancer developed in children and 
adolescent (Tang, et al., 2009; Clark, et al., 2007; Hayden, et al., 2006; Helman, et al., 
2003). Osteosarcoma is therefore categorized into juvenile and adolescent osteosarcoma 
while a second peak arises in elderly patients (Mirabello, et al., 2009; Tang, et al., 2008) 
Most frequently patients suffer from lung metastasis, which is an indicator for poor 
prognosis and survival (Marina, et al., 2004; Bielack, et al., 2002; Gamberi, et al., 1998). 
Primarily, osteosarcoma arises in areas with active bone growth, like hips, femur, tibia, 
humerus, clavicula and mandibula and it seems that it is to be considered a differentiation 
disease. Most of the tumors show disruption of final differentiation steps in the maturation 
of osteoblasts and cell proliferation of osteoprogenitors (Haydon, et al., 2007; Thomas, et 
al., 2006) (Figure 7). Most frequently disruption of cell cycle regulators p53 and pRb were 
shown to be involved in osteosarcoma onset (Berman, et al., 2008; Walkley, et al., 2008; 
Sandberg, et al., 2003). Interestingly, c-Myc is amplified in about 8-16% of human patients 
(Ueda, et al., 1997). There are some risk factors that promote osteosarcoma onset, such as 
previous radiation therapy, hereditary retinoblastoma gene, Li-Fraumeni syndrome, 
Rothmund-Thomson syndrome, Werner syndrome, Bloom syndrome and Paget disease.  
 
Basically osteosarcoma diagnosis in patients is not easy, as most of the patients suffer from 
pain and swelling, which happens quite often in children and adolescent patients. 
Therefore detection is based on mass or limb formation close to the bones, imaging tests 
(e.g. x-ray, MRI (magnet resonance imaging), CT-Scan), biopsy and pathology. Histological 
sectioning and staining then identifies osteosarcoma osteoblasts in tissues by malignant 
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osteoid production, which is uncalcified bone matrix. Therapy is therefore mainly based 
on surgery, chemotherapy, radiation therapy or the combination of all of them. 
Chemotherapy that is used these days includes methotrexate, doxorubicin, cisplatin, 
etoposide, ifosfamide, cyclophosphamide, epirubicin, gemcitabine and topotecan1∗. There 
exist some osteosarcoma specific markers that show prognostic value like ezrin (cytovillin, 
linked to cell motility and migration), S100A6 (cell proliferation and differentiation), 
Annexin2 (signal transduction and increases bone degradation) and CXCR-4 (C-X-C 
chemokine receptor-4; SDF1R (stromal derived factor 1 receptor); homing, chemoatractant) 
(Tang, et al., 2008). In addition c-Kit expression has been linked to stromal tumors, 
especially to gastro-intestinal stromal tumors (GIST) and is there expressed in a wide range 
on tumor cells. In osteosarcoma, it seems that c-Kit lacks prognostic value, however it 
opens new targeting opportunities (Adhikari, et al., 2011; Ikeda, et al., 2010; Judson, et al., 
2010; Sulzbacher, et al., 2006; Entz-Werle, et al., 2005; Matsuyama, et al., 2005).  
 
 
Figure	  7:	  Hypothesis	  of	  human	  osteosarcoma	  development	  
Scheme	  of	  mesenchymal	  stem	  cell	  differentiation	  (MSC)	  into	  mature	  osteoblasts	  with	  important	  genes	  expressed	  in	  
the	   appropriate	   osteoblast	   populations.	   Hypothesis	   of	   osteosarcoma	   development	   by	   a	   blockage	   in	   the	   final	  
maturation	   step	   from	   early	   osteoblasts	   to	   mature	   osteoblasts	   that	   results	   in	   uncontrolled	   cell	   proliferation	   of	  
immature	  osteoblastic	  cells	  (blockage	  is	  indicated	  by	  red	  lines).	  (Gene	  expressions:	  BMP	  =	  bone	  morphogenic	  protein	  
with	  Id	  target	  genes;	  CTGF	  =	  connective	  tissue	  growth	  factor;	  RunX2	  =	  Runt-­‐related	  transcription	  factor	  2)	  (Adapted	  
Wagner,	  et	  al.,	  2011).	  
  
                                                
1 http://sarcomahelp.org/osteosarcoma.html 
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3.7 Osteoblast – HSC interactions 
 
Stem cells in general possess the ability to self-renew and differentiate into all the cells of a 
specific tissue. These cells are most important and therefore it is not surprising that the 
stem cells need to be protected and tightly controlled. In the bone marrow the 
hematopoietic stem cells (HSCs) serve as a continuous reservoir and replenish the cells of 
the hematopoietic system each day. Especially during injury the stem cells of the bone 
marrow and the periphery need to be activated within a short time. Therefore it is believed 
that HSCs are located in two different stem cell niches under homeostatic conditions - the 
endosteal and the perivascular niche in the trabecular region of the bone (Figure 8). 
 
 
 
Figure	  8:	  Lodgment	  of	  HSCs	  in	  the	  trabecular	  bone	  region	  
Hematopoietic	   stem	   cells	   (HSCs)	   are	   located	   close	   to	   endosteal	   niche	   osteoblasts	   and	   in	   the	   proximity	   of	   Nestin+	  
mesenchymal	  stem	  cells	   (MSCs)	  and	  CXCL12-­‐abundant	  reticular	  cells	   (CAR)	  that	  control	  HSC	  maintenance.	  HSCs	  are	  
also	  found	  to	  be	  located	  close	  to	  sinusoids	  in	  the	  bone	  marrow	  (Ehninger	  and	  Trumpp,	  2011).	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It has previously been shown that HSCs are linked to mature endosteal osteoblasts and that 
these cells control HSC maintenance, differentiation and self-renewal capacities of HSCs 
(Méndez-Ferrer, et al., 2010; Wilson, et al., 2008; Yin and Li, 2006; Kiel, et al., 2005; 
Visnjic, et al., 2004; Calvi, et al., 2003; Zhang, et al., 2003; Nilsson, et al., 2001). 
Interestingly Visnjic, et al. showed that the specific deletion of osteoblasts (col2.3ΔTK) in 
mice resulted in extra-medullary hematopoiesis and a decrease in the number of 
hematopoietic stem and progenitors in the bone marrow (Visnjic, et al., 2004). Calvi and 
colleagues showed that in mice expressing activated parathormone and its receptor  
(PTH/PTHrP) on osteoblasts not only the osteoblast pool but also the HSC population were 
increased in a Notch dependent manner (Calvi, et al., 2003). Additionally, Zhang, et al., 
observed that by conditionally knocking out the bone morphogenic protein receptor type 
IA (BMPRIA) on osteoblasts, not only the amount of spindle-shaped N-Cadherin+ 
expressing osteoblasts (SNO cells) increases but also HSC numbers and thereby the niche 
size (Zhang, et al., 2003).  
 
However not only osteoblasts were considered to be part of the HSC niche as many other 
cell types do have an impact on HSC regulations as well. Therefore it is likely that the 
niche contains several different cell populations that act in specific circumstances on HSC 
control and regulation. Recently, nestin-expressing mesenchymal stem cells (nestin+ MSCs) 
and CXCL12 abundant reticular (CAR) cells were shown to play crucial roles in controlling 
HSC maintenance and regulation (Nagasawa, et al., 2011; Méndez-Ferrer, et al., 2010). 
Interestingly, both cell populations also belong to the mesenchymal cell lineages like 
osteoblasts and show high similarities in their marker expressions. While CAR cells express 
high levels of CXCL12 and stem cell factor (SCF), nestin+ MSCs show in addition to nestin, 
a mesenchymal stem cell marker, high expression of markers that are related to HSC 
maintenance like Angiopoetin-1 (Ang-1), interleukin-7 (IL7), vascular cell adhesion protein 
1 (VCAM, CD106) and osteopontin (OPN) (Lander, et al., 2012; Noll, et al., 2012; 
Ehninger and Trumpp, 2011; Méndez-Ferrer, et al., 2010; Sugiyama, et al., 2006) (Figure 
9).  
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Furthermore, Yamazaki and colleagues identified nonmyelinated Schwann cells (glial cells) 
as regulators for HSC maintenance (Yamazaki, et al., 2011). They showed that denervation 
induces a decrease in TGFß expression with a simultaneous reduction of HSC numbers 
and increased HSC cycling. These observations are in line with earlier findings by Méndez-
Ferrer, et al. 2008, where noradrenalin secretion down-regulates CXCL12 expression and 
thereby releases HSCs from their niche. Recently, leptin-receptor positive stromal cells 
were identified as crucial stem cell factor (SCF) producers, thereby promoting HSC 
maintenance (Lander, et al., 2012; Ding, et al., 2012). Leptin itself is a hormone produced 
by adipocytes to control and regulate energy metabolism in the body. It positively affects 
bone growth while inhibiting osteoclastogenesis and hence influences the HSC niche 
(Takeda, et al., 2002).    
 
Lastly, macrophages were identified as major key players in controlling HSC fate. Winkler 
and colleagues showed that macrophage depletion in mice resulted in a loss of endosteal 
osteoblasts and a concomitant mobilization of HSCs to the periphery (Winkler, et al., 
2010). Most importantly, Chow et al., 2011 observed that specific phagocyte depletion in 
mice results in a down-regulation of CXCL12 expression in nestin+ MSCs and to HSC 
migration to the peripheral blood (Chow, et al., 2011).  
 
Osteoclasts are generated upon differentiation of monocytes into tissue-specific 
macrophages and are found in the bone marrow. Osteoclasts generation is regulated 
through the RANK-L/ RANK interaction and is therefore mainly controlled by osteoblasts. 
Interestingly, loss of osteoclast functionality was also linked to impaired HSC homing 
ability in mice (oc/oc) with impaired endochondral ossification. Lymperi, et al., 2011 
observed similar results when they abolished osteoclast activity by bisphosphonate 
alendronate (ALN) treatment and detected a simultaneous decrease in the HSC pool 
(Lymperi, et al., 2011). These findings confirm the potential role of osteoclast functionality 
on HSC control and regulation. 
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Figure	  9:	  The	  hematopoietic	  stem	  cell	  niche	  
Localization	  of	  hematopoietic	  stem	  cells	  (HSCs)	  in	  their	  niche.	  Factors	  that	  control	  HSC	  maintenance	  are	  produced	  by	  
different	  niche	  cells	  such	  as	  thrombopoietin	  (TPO)	  by	  osteoblasts,	  TGFß	  by	  Nestin+	  Schwann	  cells,	  CXCL12	  by	  CXCL12-­‐
abundant	  reticular	  cells	  (CAR),	  stem	  cell	  factor	  (SCF)	  mainly	  produced	  by	  Leptin-­‐receptor+	  (LepR)	  stromal	  cells	  and	  SCF	  
angiopoetin-­‐1	  (Ang-­‐1)	  from	  Nestin+	  mesenchymal	  stem	  cells	  (MSCs).	  Osteomacs	  release	  calcium	  (Ca2+)	  from	  the	  bone	  
by	  degradation	  (Lander,	  et	  al.	  2012).	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3.8 Hematopoietic stem cells 
 
To date murine hematopoietic stem cells that give rise to all the different cell types in the 
blood, are the best characterized stem cell population.. They are located at the trabecular 
region of the bone within the bone marrow of tibia, femur, hips, sternum and the spinal 
cord. Like other tissue stem cells they possess the ability to self-renew and differentiate 
throughout life (Weissman, 2000). Upon differentiation HSCs give rise to multi-potent 
progenitor cells (MPPs) and these in turn specifically differentiate into committed 
progenitor cells. These include common lymphocyte progenitors (CLPs), megakaryocyte 
erythroid progenitors (MEPs), granulocyte macrophage progenitors (GMPs) and common 
myeloid progenitors (CMPs). Subsequently the committed progenitor cell pools further 
differentiate into the various terminally differentiated cells, the erythrocytes, platelets, 
granulocytes, macrophages, lymphocytes (T- and B-cells) and natural killer cells (NK-cells) 
(Figure 10).  
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Figure	  10:	  Hematopoietic	  hierarchy	  
Dormant	  stem	  cells	   (dHSCs)	  are	  on	  top	  of	  the	  hierarchy	  and	  develop	   into	  slow	  cycling	   long-­‐term	  HSCs	  (LT-­‐HSC)	  and	  
short-­‐term	   HSCs	   (ST-­‐HSCs).	   These	   are	   subsequently	   differentiated	   into	   multipotent	   progenitors	   (MPPs)	   and	   then	  
develop	   into	   committed	   myeloid	   (CMP)	   and	   lymphoid	   progenitors	   (CLP).	   CMPs	   differentiate	   to	   megakaryocyte-­‐
erythroid	   progenitors	   (MEPs)	   and	   granulocyte-­‐macrophage	   progenitors	   which	   terminally	   differentiate	   into	  
erythrocytes,	  platelets	  and	  macrophages.	  In	  contrast	  CLPs	  produce	  B-­‐	  and	  T-­‐cells,	  natural	  killer	  (NK)	  cells	  and	  dendritic	  
cells.	  (Adapted	  Larsson,	  et	  al.,	  2005).	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As there is an intimate relationship between hematopoietic stem and progenitor cells and 
their progenies, there are several cell surface markers used to distinguish the different cell 
populations in the bone marrow by flow cytometry. Several markers from the cluster of 
differentiation (CD) are used in combination with signalling lymphocyte activation 
molecule (SLAM) to identify the cells (Table 1).  
 
Abbreviation Population Cell surface marker 
   
Lin- Lineage  CD4, CD8a, CD11b, Gr1, 
B220, Ter119 
LSK 
 
LSK Lin- Sca+ c-Kit+ 
LSK SLAM 
 
LSK SLAM LSK CD150+ CD48- 
ST-HSC 
 
Short-term HSC LSK CD150+ CD48- CD34+ 
LT-HSC mu 
 
Long-term HSC murine LSK CD150+ CD48- CD34- 
CMP Common myeloid progenitor Lin- Sca-1- c-Kit+ CD34+ 
CD16/32- 
GMP Granulocyte macrophage/ 
monocyte  progenitor 
Lin- Sca-1- c-Kit+ CD34+ 
CD16/32+ 
MEP Megakaryocyte erythroid 
progenitor 
Lin- Sca-1- c-Kit+ CD34- 
CD16/32- 
CLP 
 
Common lymphoid progenitor Lin- Sca-1low c-Kitlow CD127+ 
Granulocyte 
 
Granulocyte Gr1+ CD11b+ 
Erythrocyte progenitor 
 
Erythrocyte progenitor CD71+ Ter119- 
Erythrocytic blasts 
 
Erythrocytic blasts CD71+ Ter119+ 
Erythrocyte 
 
Erythrocyte CD71- Ter119+ 
T-cell 
 
T-lymphocyte CD3+, CD4+, CD8a+ 
Pre-pro B-cell 
 
Pre-pro B-cell IgM- B220+ 
Immature B-cell 
 
Immature B-cell IgM+ B220low 
Mature B-cell 
 
B-lymphocyte IgM+ B220+ 
Monocyte Monocyte CD45+ Gr1- CD11blow/- 
F/480- CD115+ 
   
Table	  1:	  Overview	  of	  cell	  surface	  marker	  expression	  on	  cells	  of	  the	  hematopoietic	  lineages	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3.8.1 Key signaling molecules for HSC functionality 
 
3.8.1.1 Factors regulating self-renewal capacities 
 
Even though HSCs possess highest self-renewal capacities, their functionality cannot be 
tested easily. It is still a major problem to handle the cells under in vitro conditions. 
However, the first experiments by Jacobsen, et al., 1949 demonstrated that mice that were 
given high doses of whole body irradiation suffered from hematopoietic failures and were 
not able to re-generate the cells of the bone marrow  (Jacobsen, et al., 1949). Therefore 
bone marrow transplantations are used to quantify and evaluate HSC repopulating 
capacities in vivo.  
 
The signals important for HSC self-renewal are still not completely unravelled yet, however 
telomerase was discovered to be important (Morisson, et al., 1996). HSC propagation in 
vitro is limited to about 3 days and even if cytokines that are known to maintain HSC 
functionality are added, the cells begin to proliferate and differentiate quite early. These 
cytokines include thrombopoetin (TPO), stem cell factor (SCF, c-KitL), IL-1, 3, 6, 11. 
Recently, Reya, et al., 2003 identified that overexpression of ß-Catenin increased the HSC 
pool in vitro and induced the expression of genes involved in HSC self-renewal like 
homeobox DNA binding protein 4 (HoxB4) or Notch1 (Reya, et al., 2003). In addition 
Perry and colleagues observed that double transgenic animals with an overexpression of ß-
Catenin and a loss of the Phosphatase and Tensin homolog protein (Pten) showed an 
upregulation of the inhibitor of differentiation 2 (Id2) and the myeloid leukemia cell 
differentiation protein-1 (Mcl-1), an anti-apoptotic factor. This led to the maintenance of 
the HSC self-renewal capacity, however the differentiation abilities were lost (Perry, et al., 
2011). The role of homeobox proteins was identified early on and was linked to self-
renewal capacities of HSCs. This effect seems to be emphasized by TPO (Magnusson, et 
al., 2007; Beslu, et al., 2004; Kirito, et al., 2003) (Figure 11).  
 
 
   
	   INTRODUCTION	   	  	   	  
-46- 
Another marker, which was shown to be important for HSC self-renewal maintenance is 
the B lymphoma Mo-MLV insertion region 1 homolog (Bmi1). Bmi1 belongs to the 
polycomb group and was shown to regulate p16INK4a and p19ARF cell cycle inhibitors by 
repressing both activities. Importantly, Bmi1 deficient (Bmi1-/-) mice showed normal 
expression of p16INK4a and p19ARF and resulted in a loss of self-renewing HSCs with 
impaired hematopoiesis (Oguro, et al., 2006; Park, et al., 2003). In addition it was shown 
that Bmi1 plays a major role in DNA repair mechanisms. Chagraoui, et al., 2006 observed 
chromosomal instabilities in HSCs of Bmi1-/- mice, leading to an accumulation of DNA 
damage upon impaired cell cycle control (Chagraoi, et al., 2006). Another important HSC 
self-renewal regulator is c-Myc. The transcription factor was shown to regulate HSC self-
renewal and maintenance in a dose-dependent manner (Reavie, et al., 2010; Wilson, et al., 
2008). Under physiologic conditions LT-HSCs exhibit low c-Myc expression, ST-HSCs and 
MPPs have high c-Myc levels while in contrast c-Myc expression in terminally 
differentiated cells is dispensable. While high c-Myc expression leads to a loss of HSC self-
renewal capacities and an exhaustion of the stem cell pool as a consequence of normal 
cell proliferation, c-Myc deficiency leads to an accumulation of self-renewing HSCs that 
are no more able to differentiate (Wilson, et al., 2008).  
 
 
Figure	  11:	  Overview	  of	  key	  signaling	  molecules	  of	  HSC	  -­‐	  niche	  interactions	  
(Adapted	  Celso	  and	  Scadden,	  2011)	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3.8.1.2 Dormany and activation of HSCs 
 
Interestingly, cell cycle analysis of stem cells from the hematopoietic system revealed that 
about 70-90% of LT-HSCs remain in G0 while among more differentiated progenies the 
percentage of cells in G0 decreases to about 10% (Pietras, et al., 2011; Passegué, et al., 
2005; Wilson, et al., 2008). One of the first questions was therefore, whether cell cycle 
status of HSCs correlates with stemness and the HSCs` functional properties of self-renewal 
and differentiation. Most interestingly, Passegué and colleagues observed that all cells of 
the hematopoietic system that remain in G0 possess long-term reconstitution capacities 
during bone marrow transplantation assays in vivo (Figure 12) (Passegué, et al., 2005). As 
the majority of LT-HSC populations were quiescent, the next question was then to check 
the frequency of cell divisons. Therefore label-retaining assays with 5-bromo-2'-
deoxyuridine (BrdU) were performed in vivo. Initial BrdU treatment of mice ensured that 
all the cells are labeled, as BrdU incorporates into the DNA and is only diluted out upon 
cell divisions. Interestingly, only about 15% of LT-HSCs retained their BrdU label during a 
BrdU-free chase period of about 100 days, while 85% of these LT-HSCs became activated 
and lost their label. Mathematic modeling of the doubling times revealed that the 15% 
BrdU-psoitive LT-HSCs remained completely quiescent and that the cells only divide once 
within about 149 days and only about five times during a life circle of a mouse. In contrast 
activated HSCs cycle about every 30 days (van der Wath, et al., 2009; Wilson, et al. 2008). 
Serial bone marrow transplantation assays of the different HSC compartments revealed that 
these quiescent or dormant stem cells indeed possess the highest repopulating capacities. 
Therefore stem cell quiescence can be correlated to the highest stem cell functionality and 
thus identifies the most potent hematopoietic stem cells (Wilson, et al., 2008). It seems that 
these most potent stem cells serve as a stem cell reservoir for emergency cases as their 
metabolic activity is down-regulated and they are kept in quiescence (Trumpp, et al., 
2010).  
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Figure	  12:	  Quiescent	  LT-­‐HSCs	  possess	  the	  highest	  engraftment	  capacities	  
Correlation	  between	  cell	  cycle	  status	  and	  reconstitution	  capacities	  of	  LT-­‐HSCs	  (red)	  and	  KTLS	  HSCs	  (blue).	  As	  little	  as	  
50	  cells	  in	  G0	  (quiescent)	  of	  the	  cell	  cycle	  of	  either	  LT-­‐HSCs	  or	  KTLS	  HSCs	  showed	  100%	  reconstitution	  after	  3-­‐4	  weeks	  
and	  9-­‐12	  weeks	  post	  transplantation	  (Adapted	  Passegué,	  et	  al.,	  2005).	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3.8.1.3 Factors controlling HSC dormancy 
 
Under homeostatic conditions dormant HSCs are kept quiescent and divide only rarely 
(Wilson, et al., 2008). This already indicates that these stem cells need to be tightly 
controlled and regulated to prevent accidental activation of this important stem cell pool. 
Recently, some key signaling molecules have been identified that are crucial in controlling 
HSC dormancy and activation. To these factors belong molecules that are expressed 
directly in the HSC niche by cells, which stay in close interaction to dormant HSCs. One 
important cell adhesion interaction that controls HSC quiescence is the Angiopoetin-Tie 
system. Arai and colleagues demonstrated that HSCs that express the receptor tyrosine 
kinase Tie2 are quiescent and additional expression of angiopoetin1, the ligand for Tie2, in 
endosteal osteoblasts further increased HSC quiescence by binding HSCs to their niche 
(Arai, et al., 2004). In addition thrombopoetin (TPO), a hormone that regulates 
megakaryocyte differentiation, was shown to be involved in maintaining quiescence of 
HSCs. Transgenic wherein the the TPO receptor was knocked out, showed a reduction in 
the frequency of quiescent HSCs during aging in a TPO dependent manner (Arai, et al., 
2009; Qian, et al., 2007; Yoshihara, et al., 2007).  
 
The most potent regulators for HSC quiescence, self-renewal and differentiation are cell 
cycle associated genes that directly influence cell cycle entry and exit of these cells. 
During the last years several genetic mouse models have been establish to better 
understand the influence of cell cycle related genes on HSC maintenance and quiescence 
(Figure 13).  
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Figure	  13:	  Genetic	  mouse	  models	  that	  contributed	  to	  the	  understanding	  of	  cell	  cycle	  control	  in	  HSCs	  
(adapted	  Pietras,	  et	  al.,	  2011)	  
	  
 
There are two important groups of cell cycle inhibitors, the CIP/KIP family and the 
INK4a/ARF family. The cyclin dependent kinase inhibitors (CDKI) of the CIP/KIP family, 
p21CIP1, p27KIP1 and p57KIP2, are crucial to control G1/S transition of a cell by inhibiting 
cyclinE-CDK2 complex and in addition inhibit the cyclinA/CDK2 complex in early S-
Phase. The same family also controls cell quiescence by negatively regulating the cyclinD-
CDK4/6 complex and by prevention of G0 exit and G1 entry. The INK4a/ARF family 
comprises four family members, p15INK4b, p16INK4a, p18INK4c and p19INK4d. This family is 
especially important in arresting the cells in early G1 phase by preventing Retinoblastoma 
(Rb) tumor suppressor phosphorylation under stress conditions. Recently, it has been 
shown that especially p21CIP1 expression can be attributed to HSC cell cycle control during 
stress conditions (Pietras, et al., 2011; Foudi, et al., 2009; Cheng, et al., 2000a). For p27KIP1 
it was recently identified that the protein directly cooperates with p130 to actively repress 
cell cycle progression into G1 phase of the cell cycle (Pippa, et al., 2012). However its 
impact on HSCs is rather low and deletion of p27KIP1 resulted in an accumulation of the 
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progenitor compartment (Cheng, et al., 2000b).  It has been shown that especially p57KIP2 is 
highly important for keeping HSCs in quiescence (Tesio and Trumpp 2011; Pietras, et al., 
2011; Matsumoto, et al., 2011). Matsumoto and colleagues observed that the specific 
deletion of p57KIP2 in HSCs results in a severe defect in self-renewal capacities and induces 
cell cycle entry, which can be rescued by knock-in of p27KIP1 into the p57KIP2 locus 
(Matsumoto, et al., 2011). This highlights the important role of p57KIP2 in controlling HSC 
quiescence. Furthermore it seems that the CIP/KIP family members are differentially 
expressed in the different hematopoietic cell compartments and contribute in different 
manners to cell cycle control and cell functionality (Figure 14) (Tesio and Trumpp, 2011). 
 
  
Figure	  14:	  Expression	  level	  of	  cell	  cycle	  inhibitors	  depend	  on	  the	  hematopoietic	  stem	  cell	  type	  
Differences	  in	  the	  expression	  level	  of	  cell	  cycle	  inhibitors	  of	  the	  CIP/KIP	  and	  INK4a	  family	  in	  hematopoietic	  stem	  cell	  
populations	  (LT-­‐HSCs,	  ST-­‐HSCs,	  MPPs)	  (Tesio	  and	  Trumpp,	  2011).	  
 
 
Most interestingly, p16INK4a is only weakly expressed in HSCs and the deletion of this gene 
by interrupting the INK4a gene locus has only minor effects on HSC activity. This is mainly 
due to blocking of p16INK4a by the polycomb repressor Bmi1. In addition Bmi1 expression is 
low during cellular senescence when p16INK4a expression is increased. Notably, Bmi1 is a 
c-Myc target gene and was found to be involved in lymphoma onset by downregulating 
p16INK4a expression (Guney, et al., 2006; Van Lohuizen, et al., 1999). In contrast Bmi1-
deficiency is lethal in adult animals as a consequence of a lack of self-renewal capacities 
of HSCs and an exhaustion of the HSC pool over time (Pietras, et al., 2011; Chagraoui, et 
al., 2011; Park, et al., 2003). Bmi1 has also been shown to block p19ARF expression, and it 
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thereby influences the p53 damage response pathway. Expression level of p18INK4c directly 
correlates to HSC quiescence: in quiescent HSCs p18 INK4c is highly expressed, while little 
p18 INK4c expression identifies actively proliferating HSCs (Passegué, et al., 2005) (Figure 
15).  
 
 
Figure	  15:	  Cell	  cycle	  regulation	  of	  hematopoietic	  stem	  cells	  
Cell	   cycle	   inhibitors	   regulate	   cell	   cycle	   entry	   of	   hematopoietic	   stem	   cells	   (HSCs).	   The	   INK4	   family	   with	   p15INK4b,	  
p16INK4a,	  p18INK4c,	  p19INK4d	  blocks	  G0/G1	  transition	  by	  CyclinD-­‐CDK4/6	  complex	  inhibition	  while	  the	  CIP/KIP	  family	  with	  
p21CIP1,	  p27KIP1,	  p57KIP2	  prevents	  G1/S	  transition.	  Bmi1	  physiologically	   represses	  p16
INK4a	  and	  under	  stress	  conditions	  
prevents	  p19ARF	  expression.	  (Pietras,	  et	  al.,	  2011)	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3.8.1.4 Forced activation of dormant stem cells 
 
Recently, our group and others showed that the quiescent stem cell pool can be actively 
pushed into cell cycle by interferon (IFN) treatment (Baldridge, et al., 2010; Essers, et al., 
2009). Only a few hours after interferon administration in vivo dormant stem cells leave Go 
and enter G1 phase of the cell cycle (Trumpp, et al., 2010; Essers, et al., 2009). Notably, 
interferon treatment in animals leads to direct binding of interferon to its interferon 
receptor (INFR). Hence this causes further down-stream signaling and it seems that this 
correlates with an upregulation of the GPI-linker stem cell antigen (Sca-1), which seem to 
be crucial to induce cell proliferation in this process (Figure 16). In contrast in vitro 
treatment of HSCs and other cells with interferon results in an inhibition of cell 
proliferation. Importantly, interferon treatment does only lead to stem cell activation by 
induction of cell proliferation but not to a mobilization of the cells to the periphery (Essers, 
et al., 2009).  
 
Figure	  16:	  Activation	  of	  dormant	  stem	  cells	  by	  interferon	  
Interferon	  alpha	   (IFNα)	   leads	   to	   the	   activation	  of	   dormant	  hematopoietic	   stem	  cells	   (HSCs).	   IFNα	   signaling	   induces	  
Stat1	   expression	   that	   leads	   to	   the	   upregulation	   of	   stem	   cell	   antigen	   (Sca1)	   and	   the	   transcription	   of	   IFN-­‐inducible	  
target	  genes	  (Trumpp,	  et	  al.,	  2010).	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Interferons in general comprise a large family of immune-response genes that are involved 
in cell growth regulation, anti-viral response and activation of the immune system (Doly, et 
al., 1998). In practice most often interferon treatment in animals is replaced by 
Polyinosinic:polycytidylic acid (PolyI:C; pI:C) as this efficiently mimics viral immune 
response and also leads to HSC activation. Another immune response inducer that 
activates dormant HSCs is the bacterial endotoxin lipopolysaccharide (LPS). Notably, all 
three types of immune response inducers have slightly different mechanisms that lead to 
intrinsic interferon production (Figure 17) (Trinchieri; et al., 2010). While IFN directly 
binds to the IFNα receptor (IFNAR), LPS and pI:C induce intrinsic interferon production that 
subsequently activates interferon signaling upon binding to the IFNAR.   
 
 
Figure	  17:	  Toll-­‐like	  receptor	  signaling	  cascades	  that	  induce	  interferon	  production	  in	  a	  cell	  
(1)	   Interferon	   alpha	   (IFNα)	   directly	   binds	   to	   the	   IFNA-­‐receptor	   (IFNAR)	   on	   a	   cell	   and	   leads	   to	   induced	   interferon	  
production.	  (2)	  Intrinsic	  toll-­‐like	  receptor	  (TLR)-­‐independent	  interferon	  production	  through	  PolyI:C	  (pI:C)	  that	  binds	  to	  
helicase	  receptor	  retinoic	  acid	   inducible	  gene	  1	   (RIG-­‐1)	  and	  melanoma	  differentiation-­‐associated	  protein	  5	   (MDA5).	  
(3)	  Lipopolysaccharide	  (LPS)	  TLR-­‐4	  dependent	  intrinsic	  interferon	  production	  (Adapted	  Trinchieri,	  et	  al.,	  2010).	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Interferon signaling plays also an important role directly in the bone. It was recently shown 
that IFNγ has two main effects in osteoclasts. It inhibits and simultaneously promotes 
osteoclastogenesis, while the net outcome triggers bone resorption (Gao, et al., 2007). The 
interaction of the RANK receptor on osteoclasts with RANK-L, which is secreted by 
osteoblasts, is crucial for osteoclast development (Monroe, et al., 2012; Wada,et al., 2006). 
However, RANK itself has no intrinsic enzymatic activity and needs for signal transduction 
other molecules, especially TNF-receptor associated factor 6 (TRAF6). Subsequently NFkB 
and Jun N-terminal kinase (JNK) signaling cascades are activated and induce AP-1 and 
NFATc target gene expression, which leads to further osteoclastogenesis by inducing the 
differentiation of pre-osteoclasts to functional mature osteoclasts. On the other hand 
TRAF6 signaling is also induced through Toll-like receptors (TLRs) and TLR4, 7 and 9 are 
expressed on osteoclasts. Importantly, the effect of TLR signaling in osteoclasts highly 
depends on the maturation status of the cells. In pre-osteoclasts TLR signaling inhibits final 
maturation, while in mature osteoclasts it promotes cell proliferation and 
osteoclastogenesis (Caetano-Lopes, et al., 2009; Takayanagi, et al., 2002) (Figure 18). 
 
 
 
Figure	  18:	  Effects	  of	  interferon	  signaling	  in	  osteoclasts	  
Interaction	  between	  RANKL	  and	  RANK	  leads	  to	  TRAF6	  and	  c-­‐Fos	  signaling	  induced	  osteoclastogenesis	  and	  interferon	  
(IFNß)	   production	   in	   immature	   osteoclasts.	   IFNß	   negative	   feed-­‐back	   loop	   induces	   the	   expression	   of	   IFN-­‐inducible	  
genes	  that	  slow	  down	  RANKL-­‐RANK	  induced	  c-­‐Fos	  signaling	  (Takayanagi,	  et	  al.,	  2002).	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3.9 Generation of doxycycline-inducible ColtTA;TreMyc animals 
 
Interestingly, our group recently showed that c-Myc is also involved in normal 
hematopoietic stem cell (HSC) maintenance and differentiation (Laurenti, et al., 2009; 
Wilson, et al., 2008). Osteoblasts are bone-lining cells that are part of the HSC niches and 
thus are involved in the regulation of HSCs. The aim of this work was to analyze the effect 
of c-Myc amplification in osteoblasts on bone development and its influence on HSCs.  
 
In our laboratory an inducible transgenic mouse line for human c-Myc overexpression in 
mature osteoblasts had already been established (Jaworski and Trumpp, thesis 2009). Mice 
in which the expression of the tetracycline transactivator (tTA) was controlled by the 
osteoblast specific collagen I promoter (col1α1) was crossed with mice transgenic for the 
tetracycline response element (TRE) and oncogenic human c-Myc (MYC). The tissue 
specific col1α1 promoter regulated the expression of the tTA transactivator, which then in 
turn bound to TRE and induced Myc expression. Thus human c-Myc was selectively 
overexpressed in mature osteoblasts. Furthermore c-Myc expression could be repressed by 
doxycycline. Upon addition of doxycycline, an antibiotic of the tetracycline family, the 
antibiotic interacted with the tetracycline transactivator, thereby blocking TRE interaction 
and thus inhibiting c-Myc overexpression (Figure 19). 
 
Initial studies had shown that c-Myc overexpression during embryonic development led to 
neonatal death of newborns as a consequence of bone developmental disorders (Jaworski 
and Trumpp, thesis 2009). In order to suppress this strong phenotype in embryos, 
doxycycline was added to the drinking water of the mouse matings until the weaning age 
of the newborns, thereby preventing human c-Myc overexpression in bone cells of the 
embryo. In three week old ColtTA;TreMyc (mutant, mt) mice human c-Myc overexpression 
was subsequently induced by the removal of doxycycline containing drinking water until 
this stage mutant mice showed normal development (Jaworski and Trumpp, thesis 2009). 
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Figure	  19:	  Generation	  of	  double	  transgenic	  ColtTA;TreMyc	  animals	  
(A)	   Transgenic	   mice	   with	   the	   osteoblast	   specific	   promoter	   collagen	   I	   (col1α1)	   and	   transgenic	   for	   tetracycline	  
transactivator	   (tTA)	   are	   crossed	   with	   mice	   transgenic	   for	   the	   tetracycline	   response	   element	   (TRE)	   and	   oncogenic	  
human	   c-­‐Myc	   (MYC)	   to	   generate	   ColtTA;TreMyc	   littermates	   (mutant	   animals).	   (B)	   Doxycycline-­‐inducible	   Tet-­‐off	  
system:	  human	  c-­‐Myc	  expression	  is	  turned	  on	  in	  the	  absence	  of	  doxycycline	  (Dox)	  and	  it	  is	  repressed	  by	  doxycycline	  
addition.

  
 
  -59- 
4 AIM 
 
 
The human bone is an endocrine organ that is important beyond the simple task of 
providing a skeleton. Within the bones many complex processes take place such as the 
genesis and maintenance of the cells for the hematopoietic system or continuous bone 
remodeling. The effects of the human proto-oncogene c-Myc are cell dependent. Therefore 
the major aim of this thesis was to study the effect of human c-Myc overexpression in 
mature osteoblasts. In particular the following aspects should be analyzed: 
 
• What effect has c-Myc overexpression on bone structure and morphology? It is 
known that bone development involves a complex interplay between bone-matrix 
generating cells, the osteoblast and bone-matrix degrading cells, the osteoclasts. In 
many human diseases this interplay is destroyed or impaired. Thus the 
morphological as well as molecular properties will be closely monitored in order to 
further elucidate the role of osteoblasts in the human bone. 
 
• Can c-Myc overexpression induce tumor formation? c-Myc is a proto-oncogene 
that is involved in a great number of cellular processes and is frequently involved 
in human tumors. The aim of this work will be to determine, whether c-Myc 
overexpression in fact has a tumorigenic effect and to further characterize the 
tumors. As currently human osteosarcoma models are rare and very artifical, it will 
be interesting to see whether the ColtTA;TreMyc mouse model will be useful as an 
alternative. 
 
• Does c-Myc overexpression in endosteal osteoblasts influence hematopoietic stem 
cells (HSCs)? Osteoblasts form an important part of the stem cell niche which is 
responsible for regulating the self-renewal and differentiation processes of the 
HSCs. The effects that c-Myc overexpression exerts on signalling pathways within 
the osteoblasts, will help to further elucidate the crosstalk between osteoblasts and 
the HSCs and also with other cells of the hematopoietic niche. 
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5 RESULTS 
  
5.1 Validation of mouse alpha1(I)-collagen promoter specificity 
 
Collagen is one of the most abundant proteins in mammals and is predominantly expressed 
in connective tissues and bones where it helps to stabilize these tissues. An abbreviated 
version of the collagen promoter is specifically activated during bone development (Marko, 
et al., 2003; Dacquin, et al., 2002). Since the 2.3-kb proximal fragment of the mouse 
alpha1(I)-collagen promoter was used in the transgenic mice, the specificity of this 
promoter in the transgenic mouse line was assessed. Therefore the mRNA expression levels 
of human c-Myc in the bone marrow and bones of mutant mice (Figure 20) were analyzed 
by quantitative real time PCR (qRT-PCR). 
 
 
Figure	  20:	  Human	  c-­‐Myc	  mRNA	  expression	  in	  ColtTA;TreMyc	  animals	  is	  restricted	  to	  mature	  osteoblasts	  
Human	   c-­‐Myc	   mRNA	   expression	   level	   in	   different	   cell	   compartments	   of	   the	   bone	   marrow	   (BM)	   and	   the	   bone	   of	  
mutant	  20-­‐week	  old	  ColtTA;TreMyc	  animals	  detected	  by	  qRT-­‐PCR	  (Lin-­‐	  =	  lineage	  negative	  cells,	  LSK	  =	  Lin-­‐	  Sca1+	  c-­‐Kit+,	  
HSC	  =	  LSK	  CD150+	  CD48-­‐	  CD34-­‐,	  immature	  OBs	  =	  CD45-­‐	  CD31-­‐	  Ter119-­‐	  Sca-­‐1+	  CD51+,	  mature	  OBs	  =	  CD45-­‐	  CD31-­‐	  Ter119-­‐	  
Sca1-­‐	  CD51+).	  Expression	  levels	  are	  indicated	  as	  fold	  changes	  against	  healthy	  control	  mature	  osteoblasts	  (blue	  dotted	  
line	  =	  mature	  OBs	  co)	  and	  normalized	  to	  SDHA	  and	  OAZ	  (n	  =	  7,	  n.d.	  =	  not	  detectable).	  
 
  
   
	   RESULTS	   	  	   	  
-62- 
Human c-Myc mRNA was only detected in mature osteoblasts of mutant animals, while it 
was not detectable in immature osteoblasts as well as in different cells of the 
hematopoietic system including lineage negative cells (Lin-), hematopoietic progenitors 
(LSK) and hematopoietic stem cells (HSC). Especially in control osteoblasts only very little 
human c-Myc expression could be detected due to high DNA sequence homology 
between mouse and human c-Myc. This analysis confirms that the collagen promoter is 
specifically activated in mature osteoblasts. 
 
During embryogenesis the collagen promoter becomes active at embryonic day 14.5 
(E14.5) as soon as bone development begins (Figure 2A). To further confirm that the 
expression of human c-Myc is indeed restricted to mature osteoblasts, histological sections 
of embryonic femurs from day E17.5 were performed. For this purpose the 
ColtTA;TreMyc;TreH2B-GFP mouse line (mt) was used, which expresses a fusion protein 
between histone H2B and GFP in addition to the c-Myc transgene. In addition for the 
purpose of control experiments the mouse line ColtTA;TreH2B-GFP (co) without any 
human c-Myc expression was used. The expression of both elements is controlled by the 
tetracycline response element (Gossen and Bujard, 1992). In this mouse line only cells 
with an active alpha1(I)-collagen promoter show GFP expression, indicating c-Myc 
overexpression in GFP-positive cells.  
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Figure	  21:	  Collagen	  promoter	  specificity	  and	  the	  identification	  of	  GFP-­‐positive	  osteoblasts	  by	  histology	  
Collagen	  promoter	  activity	  starts	  at	  embryonic	  day	  E14.	  In	  transgenic	  animals	  human	  c-­‐Myc	  expression	  is	  turned	  on	  
by	   interaction	   of	   the	   tetracycline-­‐transactivator	   (tTA)	   with	   the	   tetracycline-­‐responsive	   element	   (Tre)	   (A).	   CD45	  
expression	  in	  hematopoietic	  bone	  marrow	  cells	  (red)	  and	  GFP-­‐positive	  expression	  in	  osteoblasts	  (grün)	  show	  collagen	  
promoter	  specificity	  in	  control	  (B)	  and	  mutant	  (C)	  E17.5	  femurs.	  Dapi	  is	  used	  as	  counterstaining.	  
	  
 
 
Analysis of the histological sections demonstrated that GFP positive cells in the femur of 
control and mutant mice do not express the hematopoietic cell marker CD45 (Figure 21). 
This confirms the specificity of the collagen promoter as simultaneous GFP and c-Myc 
expression was strictly restricted to non-hematopoietic cells in mutant animals. In addition 
control animals showed promoter activity by GFP-expression without any c-Myc transgene 
correlation.  
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5.2 Histological analysis of transgenic ColtTA;TreMyc animals 
 
It was previously shown that overexpression of human c-Myc in mature osteoblasts during 
embryonic development had a major influence on bone maturation as well as the life-span 
of the animals (Jaworski and Trumpp). After the specificity of the collagen promoter for 
mature osteoblasts had been demonstrated next I went on to elucidate the influence of c-
Myc on bone development in adult animals. Therefore mice were treated with doxycycline 
containing drinking water until weaning age. Starting from three weeks of age, c-Myc 
expression was induced in mature osteoblasts. Bone morphology was analyzed in 20-week 
old animals. Strikingly ColtTA;TreMyc animals showed enhanced bone thickening and 
shorter bones (Figure 22B, left picture). Furthermore histological sections of demineralized 
femurs from 20-week old animals were performed. 
	  
Figure	  22:	  Irregular	  bone	  structure	  of	  ColtTA;TreMyc	  animals	  	  
Staining	   on	   decalcified	   paraffin	   sections	   indicates	   differences	   in	   bone	   thickness	   and	   bone	   structural	   organisation	  
between	   control	   (co)	   and	  mutant	   (mt)	   femurs.	   Blue/green	   staining	   detects	  mineralized	   bone	   consisting	  mainly	   of	  
collagen,	   produced	   by	   osteoblasts	   while	   pink/red	   staining	   highlights	   compact	   bone	   with	   mainly	   osteocytes;	   10x	  
magnification	  (A),	  40x	  magnification	  (B,	  right	  picture).	  Differences	  in	  the	  phenotype	  of	  control	  and	  mutant	  bones	  of	  
20-­‐week	   old	   animals	   in	   bone	   thickness	   and	   length	   (Black	   arrowheads	   =	   bone	   thickness,	   red	   arrowheads	   =	   bone	  
marrow	  (BM)	  in	  mutant	  bone	  caverns).	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The tissues were stained according to Masson Goldner staining and revealed that the 
mutant bones mainly consist of connective tissue. In contrast to control bones the compact 
bone structure seemed to be completely lost in mutant animals. The bones were thicker 
and exhibited irregular cavernous structures comprising bone marrow cells within the 
bone, thereby braking down the solid composition of a normal bone. Even though bones 
were partially demineralized for a short period of 4 days prior to the histological sections, 
the mutant bones still contained significant amounts of mineralized bone matrix, shown by 
collagen presence and green stained areas (Figure 22). In contrast, the control bone mainly 
consists of terminally differentiated osteocytes that are no more able to synthesize collagen 
and are only embedded into the bone matrix. Osteocytes are stained in pink. This indicates 
that the mutant bones contain significantly higher levels of collagen. Taken together these 
data suggest that there are more osteoblasts in mutant bones while in the bones of control 
animals contain more terminally differentiated osteocytes.  
 
 
5.3 Analysis of the osteoblast compartment in ColtTA;TreMyc animals 
5.3.1 Detection of mature osteoblasts by flow cytometry 
 
To corroborate the findings of the histological sections, I next quantified the amount of 
osteoblasts present in the bones of control and mutant animals by flow cytometry. The 
gating strategy employed to identify osteoblast in the stroma is shown in Figure 5. First, 
hematopoietic cells were excluded based on CD45 and Ter119 positivity. Next, CD31 
positive endothelial cells were excluded. Within the remaining population, mature and 
immature mesenchymal populations were defined by CD51 and Sca1. The osteoblast 
marker CD51 is also known as the vitronectin receptor or integrin alpha-V. In addition 
Sca1, the stem cell antigen, enabled to distinguish mature osteoblasts from more primitive 
cell populations in the stroma. 
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Figure	  23:	  Identification	  of	  mature	  osteoblasts	  by	  flow	  cytometry	  
Representitive	  FACS	  plot	   indicates	   the	  gating	   strategy	  used	   to	   identify	  osteoblast	  populations	   from	  control	   (co)	   (A)	  
and	   mutant	   (mt)	   (B)	   animals	   in	   the	   stromal	   compartment.	   Stromal	   cells	   can	   be	   separated	   into	   four	   groups	   as	  
indicated:	  a	  =	  most	  primitive	  stromal	  cells	  CD45-­‐	  CD31-­‐	  Ter119-­‐	  Sca-­‐1+	  CD51-­‐,	  b	  =	   immature	  osteoblasts	  (OBs)	  CD45-­‐	  
CD31-­‐	  Ter119-­‐	  Sca-­‐1+	  CD51+,	  c	  =	  other	  stromal	  cells	  CD45-­‐	  CD31-­‐	  Ter119-­‐	  Sca-­‐1-­‐	  CD51-­‐,	  d	  =	  mature	  osteoblasts	   (OBs)	  
CD45-­‐	  CD31-­‐	  Ter119-­‐	  Sca-­‐1-­‐	  CD51+).	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Mutant osteoblasts are phenotypically indistinguishable from control osteoblasts by FACS 
Figure 23). However quantification of the FACS data showed, that the percentage of 
osteoblasts was significantly increased in mutant animal. The increase was about two fold 
compared to control animals. In contrast the level of immature osteoblasts were not 
significantly different in control and mutant mice.  
 
To confirm these observations, histo-morphometric analysis of skeleton measures was 
performed. Here the number of osteoblasts per bone perimeter is determined in 
histological sections. The analysis revealed about 15 osteoblast per bone perimeter in 
control animals, while in mutant mice the number of osteoblast was almost doubled to 
about 30. Thogether this indicates that c-Myc overexpression in osteoblasts results in 
increased numbers of mature osteoblast in ColtTA;TreMyc animals (Figure 24).  
 
Figure	  24:	  Quantification	  of	  stromal	  compartments	  reveals	  increased	  osteoblast	  numbers	  in	  transgenic	  animals	  	  	  
Box	  plot	  analysis	   indicates	   the	  percentage	  of	  mature	  osteoblasts	   (CD45-­‐	  CD31-­‐	  Ter119-­‐	  Sca-­‐1-­‐	  CD51+)	  and	   immature	  
osteoblasts	   (CD45-­‐	   CD31-­‐	   Ter119-­‐	   Sca-­‐1+	   CD51+)	   within	   stromal	   cells	   (CD45-­‐	   CD31-­‐	   Ter119-­‐)	   of	   ColtTA	   (co)	   and	  
ColtTA;TreMyc	   (mt)	   animals	   (co:	   n	   =	   21,	   mt:	   n	   =	   30)	   (A).	   Histo-­‐morphometric	   bone	   measurements	   comparing	   wt	  
(control	  osteoblasts)	  to	  mt	  animals	  (ObN/B	  pm	  (mm-­‐1)	   	  =	  number	  of	  osteoblasts	  per	  bone	  perimeter,	  measured	  per	  
mm)	  (wt	  =	  co:	  n	  =	  6;	  mt:	  n	  =	  6)	  (B).	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5.3.2 Cell proliferation of mature osteoblasts 
 
c-Myc controls the cell cycle and cell proliferation in a cell type specific manner. The 
previous set of experiments demonstrated that as a consequence of c-Myc overexpression 
in mature osteoblasts the percentage of osteoblasts in mutant animals is significantly 
increased. Therefore, I next assessed the cell proliferation rate of the mutant osteoblasts to 
see whether their increased proliferation accounts for the observed expansion. In addition 
the mRNA expression level of different cell cycle regulator genes was analyzed by qRT-
PCR.  
 
To analyze the cell proliferation rate of osteoblasts in vivo, a 5-Bromo-2-deoxy-uridine  
(BrdU) assay was performed. Therefore the animals were injected with BrdU intra-
peritoneally 16-24 hrs before the analysis. While all cells take up BrdU, only actively 
proliferating cells incorporate the thymidine analogue BrdU into the DNA.  
 
 
Figure	  25:	  Cell	  proliferation	  and	  cell	  cycle	  regulators	  of	  mutant	  mature	  osteoblasts	  are	  impaired	  
Scatter	   plot	   analysis	   shows	   the	   percentage	   of	   BrdU+	   cells,	   representing	   the	   fraction	   of	   actively	   proliferating	   cells	  
among	   mature	   osteoblasts	   (A).	   mRNA	   expression	   of	   different	   cell	   cycle	   regulators	   as	   determined	   by	   qRT-­‐PCR.	  
Expression	  values	  are	  normalized	  to	  SDHA	  and	  OAZ	  and	  fold	  changes	  of	  mutant	  osteoblasts	  are	  compared	  to	  mature	  
osteoblasts	  of	  control	  animals	  (blue	  dotted	  line)	  (B)	  (n	  =	  3	  for	  p16	  -­‐	  p19;	  n	  =	  10	  for	  p21	  –	  CyclinD1).	  
 
For FACS analysis stromal cells were gated for mature osteoblasts (for gating strategy 
compare Figure 23) and the percentage of actively proliferating osteoblasts was determined 
(Figure 25). No significant differences in the cell proliferation rates of control and mutant 
mature osteoblasts could be detected. Thus despite the role of c-Myc in promoting cell 
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cycle progression, the cell proliferation rate was only slightly increased in mutant 
osteoblasts (Figure 25, A). This confirms that the bone lining osteoblasts tend to be a more 
quiescent cell population compared to the hematopoietic cells where the proliferation rate, 
after a similar BrdU pulse, is usually about 30% (Kim, et al., 2012; Hauge, et al., 2001).  
 
To gain more insight into the regulation of proliferation in osteoblasts, I next performed 
qRT-PCR analysis for several cell cycle regulators was performed on sorted mature 
osteoblasts (singlets, CD45- CD31- Ter119- Sca-1- CD51+) from control and mutant 
animals. The cell cycle is tightly controlled by two groups of cell cycle regulators: the 
cyclins and the cyclin-dependent kinases (CDKs). Therefore qRT-PCR on Cyclin D1 and 
the CDKs of the cip/kip and the INK4a/ARF families was performed to better understand 
the cell proliferation behavior of c-Myc overexpressing osteoblasts.  
 
The mRNA expression level of the cell cycle regulators p21CIP1 and p27KIP1 of the cip/kip 
family was unaffected by c-Myc overexpression (Figure 25, B). Also the expression for the 
CDKs  p15INK4b, p18INK4c and p19INK4d of the INK4a/ARF family was unchanged, while in 
contrast p57KIP2 was significantly down-regulated in mutant osteoblasts. Previous work had 
identified a role of p57KIP2 in retaining cells in G1 phase of the cell cycle (Kim, et al., 2008; 
Nishimori, et al., 2001; Urano, et al., 1999; Drissi, et al., 1999). The down-regulation of 
p57KIP2 might therefore drive c-Myc overexpressing osteoblasts into proliferation, even 
though this could not be confirmed by BrdU analysis. An explanation for the modified 
BrdU incorporation might be because incubation times were too short to see any 
significant effects. In contrast the observed increase in osteoblast numbers in transgenic 
animals as identified by histo-morphometric analysis and by quantitative flow cytometry 
(Figure 24) appears to corroborate the hypothesis that c-Myc induces cell proliferation.  
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5.3.3 Analysis of osteoblast maturation and differentiation 
 
Interestingly, previous work had demonstrated that p57KIP2 not only was involved in cell 
cycle regulation but also in promoting osteoblast differentiation. The down-regulation of 
p57KIP2 might therefore also affect the balance between proliferation and differentiation. 
Therefore, as c-Myc has been described to have an influence on osteoblast differentiation, 
a next set of experiments was performed to assay genes involved in osteoblast maturation 
and differentiation. The differentiation of MSCs towards the osteoblastic lineage involves 
many intermediate steps including a variety of transcription factors and highlights the 
complexity of osteoblast cell maturation. Osteoblasts themselves are mature even though 
they possess the ability to finally differentiate into osteocytes. 
  
In a first step the expression levels of differentiation markers were compared for immature 
and mature osteoblasts from non-manipulated regular C57BL/6 mice. As expected earlier 
the maturation of osteoblasts can be directly linked to the expression of specific genes 
(Wei, et al., 2012; Neve, et al., 2010; Franz-Odendaal, et al., 2006; Hauge, et al., 2001; 
Harada, et al., 1999; Ducy, et al., 1997). While in immature osteoblasts mRNA expression 
for Sca-1 was high and low for osteocalcin, the opposite was the case in mature 
osteosblasts.  
 
QRT-PCR analysis of mature, mutant osteoblasts showed that in mutant osteoblasts 
collagen I production was increased as the gene encoding for collagen I synthesis is about 
4-fold upregulated in mutant osteoblasts. This nicely corroborates the finding of 
histological sectioning and staining with Masson Goldner of mutant bones, where mutant 
femurs show more collagen presence as compared to control bones (Figure 22, green = 
collagen). Apart from collagen mutant osteoblasts seem to be unchanged in all the other 
markers and did not show significant changes compared to control osteoblasts. This 
indicates that c-Myc overexpression directly influences collagen I mRNA expression levels 
in mutant osteoblasts but none of the other maturation and differentiation markers. 
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Figure	  26:	  Analysis	  of	  osteoblast	  maturation	  genes	  shows	  elevated	  collagen	  expression	  in	  mutant	  osteoblasts	  
Early	  and	  late	  maturation	  marker	  expression	  of	  sorted	  immature	  osteoblasts	  (CD45-­‐	  CD31-­‐	  Ter119-­‐	  Sca-­‐1+	  CD51+)	  (A)	  
and	  mature	  osteoblasts	  (CD45-­‐	  CD31-­‐	  Ter119-­‐	  Sca-­‐1-­‐	  CD51+)	  (B)	  from	  C57BL/6	  mice	  (RunX2,	  Sca-­‐1,	  RANK-­‐L,	  OCN:	  n=8;	  
Osx,	  ALP,	  MCSF,	   Sparc,	  OPN,	  Col1a1,	   ifitm5:	  n	  =	  4).	  Comparison	  of	  early	  and	   late	  maturation	  marker	  expression	  of	  
mutant	  mature	  osteoblasts	  as	  fold	  changes	  against	  control	  osteoblasts	  (blue	  dotted	  line)	  (C).	  All	  genes	  are	  normalized	  
to	  SDHA	  and	  OAZ.	  Expression	  values	  of	  early	  and	  late	  maturation	  marker	  in	  sorted	  mutant	  osteoblasts,	  represented	  as	  
fold	   changes	   against	  mature	  osteoblasts	   from	  control	   animals	   (blue-­‐dotted	   line)	   and	  normalized	   to	   SDHA	  and	  OAZ	  
(RunX2,	  ifitm5:	  n	  =	  7;	  Osx,	  OPN,	  MCSF,	  RANK-­‐L,	  Sca-­‐1:	  n	  =	  4;	  Col1a1,	  Ogn,	  Postn:	  n	  =3;	  ALP,	  OCN:	  n	  =	  5;)	  (C).	  	  
(RunX2	   =	   runt-­‐related	   transcription	   factor	   2,	   Osx	   =	   osterix,	   ALP	   =	   alkaline	   phosphatase,	   Sca-­‐1	   =	   stem	   cell	   antigen,	  
MCSF	   =	  macrophage	   colony	   stimulating	   factor,	   Sparc	   =	   osteonectin,	   RANK-­‐L	   =	   receptor	   activator	   of	   nuclear	   factor	  
kappa-­‐B	  ligand,	  OPN	  =	  osteopontin,	  OCN	  =	  osteocalcin,	  col1a1	  =	  collagen	  type	  I	  alpha	  1,	  ifitm5	  =	  interferon-­‐inducible	  
transmembrane	  protein	  5;	  Ogn	  =	  osteoglycin;	  Postn	  =	  Periostin).	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5.3.4 The Wnt signaling pathway in osteoblast maturation 
 
Wnt signaling is a key pathway that plays a major role in embryogenesis and cell 
physiology and is frequently aberrant during tumorigenesis (Jeong, et al., 2012; Lai, et al., 
2009; Taketo, et al., 2006; Glassil, et al., 2005; Moon, et al., 2004). In bone development 
the role of Wnt signaling is mainly to regulate the differentiation of osteoblast progenitors – 
the mesenchymal stem cells (MSCs) - to osteoblasts. Furthermore, Wnt signaling controls 
the final maturation step of pre-osteoblasts to functional mature osteoblasts. Thus I wanted 
to test whether c-Myc overexpression also affected Wnt-signaling in mutant osteoblasts. 
Therefore mRNA expression levels of genes involved in Wnt signaling were determined in 
sorted mutant osteoblasts by qRT-PCR.  
 
 
Figure	  27:	  Expression	  level	  of	  genes	  involved	  in	  Wnt	  signaling	  are	  unchanged	  in	  mature	  osteoblasts	  
Fold	   changes	   represent	   the	   ratio	   between	   mutant	   osteoblasts	   against	   control	   osteoblasts	   (blue-­‐dotted	   line)	  
(normalized	  to	  SDHA	  and	  OAZ)	  (Lrp5/6	  =	  LDL-­‐receptor	  related	  protein	  5/6,	  Wnt3a	  =	  wingless-­‐type	  MMTV	  integration	  
site	   family,	  DKK-­‐1	  =	  Dickkopf,	  Apc	  =	  adenomatous	  polyposis	  coli,	  Axin2	  =	  axis	   inhibition	  protein2,	  Gsk3b	  =	  glycogen	  
synthase	  kinase	  3	  beta)	  (Lrp5/6,	  Axin2,	  Gsk-­‐3b:	  n	  =	  7,	  DKK-­‐1,	  Apc:	  n	  =	  10,	  Wnt3a,	  ß-­‐Catenin	  n	  =	  14).	  
 
Interestingly, canonical Wnt signaling was not affected by human c-Myc overexpression in 
mature osteoblasts (Figure 27). None of the assayed genes showed any significant 
difference in the expression levels compared to mature control osteoblasts. This indicates 
that human c-Myc exerts no direct influence on Wnt activity in this important osteoblast 
differentiation pathway in mutant mature osteoblasts. However whether is has an influence 
on osteoprogenitors from ColtTA;TreMyc mutants still needs to be determined. 
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5.3.5 Transgenic animals show normal mineralization capacities in vitro 
 
Taken together this indicates slight but significant effects of human c-Myc overexpression 
in mature osteoblasts as for example upregulated collagen I synthesis and p57KIP2 down-
regulation. I next analyzed whether c-Myc overexpression has any functional 
consequences in osteoblasts as a result of thickening of the bones. 
 
Mineralization of the bone, the last step of osteoblast differentiation, can be easily assessed 
by von Kossa staining, which detects calcium deposition in tissues and organs by a silver 
nitrate reaction (Bonewald, et al., 2003). In bones, von Kossa staining indicates 
mineralized areas, showing the functionality of osteoblasts. However as the bone has to be 
demineralized for histological sections, von Kossa staining on mineralized bones of mutant 
and control animals was not possible. Osteoblasts from tibia and femur of control and 
mutant animals were isolated and cultured in vitro for 14 days followed by von Kossa 
staining.  
 
The microscopic analysis revealed that mutant and control osteoblasts were equally able to 
produce mineralized bone material in vitro (Figure 28). Thus mutant osteoblatss possess 
normal mineralization properties.  
 
Osteoblast functionality was tested independently by detection of alkaline phosphatase 
activity (ALP) (Miao, et al., 2002). ALP expression starts in pre-osteoblasts and lasts until 
final differentiation to mature osteoblasts. The ALP staining of the mutant osteoblasts 
revealed no significant difference between control and c-Myc overexpressing osteoblasts 
(Figure 28). Thus mutant osteoblasts can be categorized as functional bone forming cells at 
least based on these findings in vitro. These results indicate that the human c-Myc 
overexpressing mature osteoblasts are functional. Therefore, the aberrant phenotype of the 
mutant bone (Figure 22) cannot be attributed to functional defects of osteoblasts.  
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Figure	  28:	  Mutant	  osteoblasts	  show	  normal	  mineralization	  capacity	  in	  vitro	  
Von	   Kossa	   staining	   on	   confluent	   osteoblast	   layers	   in	   vitro	   (left:	   control	   osteoblast	   culture	   (co),	   right:	   mutant	  
osteoblast	   culture	   (mt).	   Arrowheads	   point	   out	   silver	   precipitations,	   4x	   magnification	   (A),	   10x	   magnification.	   (B).	  
Alkaline	   phosphatase	   staining	   (ALP)	   on	   osteoblast	   cultures.	   Pink	   staining	   identifies	   ALP	   positive	   osteoblasts	   (co	   =	  
control,	  mt	  =	  mutant,	  neg.	  =	  negative	  control,	  HEK	  293	  cells),	  4x	  magnification	  (C),	  10x	  magnification	  (D).	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5.4 Analysis of the osteoclast compartment 
5.4.1 Identification of osteoclasts by flow cytometry 
 
Bone turnover is a strictly balanced process between bone formation and resorption. As I 
previously showed that the percentage of osteoblasts is significantly increased upon human 
c-Myc overexpression, I next investigated whether the number of bone resorbing cells, the 
osteoclasts, was simultaneously affected in transgenic animals as well (Figure 24). The 
number of osteoclasts in mutant animals was determined by gating on CD45+ Gr1- 
CD11blow/- cell populations in the bone marrow to distinguish between immature 
osteoclasts (F4/80- CD115+) and mature osteoclasts (F4/80+ CD115+) (Jacquin, et al., 2005). 
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Figure	  29:	  Gating	  strategy	  for	  the	  identification	  of	  osteoclasts	  by	  FACS	  
Representive	  FACS	  plot	  indicates	  osteoclast	  populations	  from	  control	  (co)	  (A)	  and	  mutant	  (mt)	  (B)	  animals	  in	  the	  bone	  
marrow.	  Different	  sub-­‐populations	  can	  be	  distinguished	   in	  phagocyte	  compartments	  as	   indicated	  (C)	   (a	  =	   immature	  
osteoclasts	  CD45+	  Gr1-­‐	  CD11blow/neg	  F4/80+	  CD115-­‐,	  b	  =	  mature	  osteoclasts	  CD45+	  Gr1-­‐	  CD11blow/neg	  F4/80+	  CD115+	  c	  =	  
other	  phagocytes	  CD45+	  Gr1-­‐	  CD11blow/neg	  F4/80-­‐	  CD115-­‐,	  d	  =	  monocytes	  CD45+	  Gr1-­‐	  CD11blow/neg	  F4/80-­‐	  CD115+).	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FACS analysis revealed no major differences in the osteoclast staining pattern between 
control and mutant bone marrow cells. When osteoclast populations were quantified, a 
slight increase in the number of mature osteoclasts was observed in mutant animals (Figure 
30). However statistical analysis showed that this difference was not statistically significant. 
Notably, additional histo-morphometric analysis of the osteoclast numbers appeared to 
confirm the FACS analysis data. Here, the increase in osteoclast number was statistically 
significant. The increase in osteoclast numbers in mutant bones demonstrates that c-Myc 
overexpression in mature osteoblasts results in higher osteoblast and osteoclast numbers. 
Furthermore, these results are in line with the increased bone thickness in the transgenic 
animals and osteoclast numbers might be higher as a compensatory mechanism in 
response to imbalanced bone turnover.  
 
 
Figure	  30:	  Osteoclast	  numbers	  are	  increased	  in	  transgenic	  animals	  
Box	   plot	   analysis	   indicates	   the	   percentage	   of	   mature	   and	   immature	   osteoclasts	   populations	   on	   phagocyte	  
compartments	   in	   the	  bone	  marrow	  of	   control	   (co)	  and	  mutant	   (mt)	  animals	   (co:	  n	  =	  10;	  mt:	  n	  =	  9)	   (A).	  Analysis	  of	  
histo-­‐morphometric	  bone	  measurements	  comparing	  wt	  (control	  bone)	  to	  mt	  animals	  (OcN/B	  pm	  (mm-­‐1)	  	  =	  number	  of	  
osteoclasts	  per	  bone	  perimeter,	  measured	  per	  mm)	  (wt	  =	  co:	  n	  =	  6;	  mt:	  n	  =	  6)	  (B).	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5.4.2 ColtTA;TreMyc animals have normal osteoclastogenesis 
 
Osteoclasts are derived from hematopoietic stem cells and are mainly generated by 
differentiation of circulating monocytes. Differentiation signals like interleukin-6 (IL-6), IL-
1, macrophage-colony stimulating factor (M-CSF), receptor activator of NFkB ligand 
(RANK-L), osteoprotegerin (OPG) as well as transforming growth factor beta (TGFb) are 
produced by osteoblasts and induce differentiation of monocytes towards osteoclasts 
(Udagawa, et al., 1999; Yasuda, et al., 1999; Udagawa, et al., 1995). Thus osteoblasts 
control osteoclast differentiation. To further investigate whether c-Myc overexpression in 
osteoblasts influences synthesis of osteoclast differentiation factors, mRNA expression 
levels of these factors were evaluated by qRT-PCR.  
 
Amongst osteoclast differentiation factors only OPG expression was significantly down-
regulated. OPG is produced by mature osteoblasts and is a decoy receptor for RANK-L. 
Binding of RANK-L to OPG on stromal cells blocks functional crosstalk between RANK-L 
on osteoblasts and RANK on osteoclast precursor cells, affecting osteoclastogenesis. It is 
therefore possible that in mutant animals not the differentiation towards osteoclasts is 
affected but rather the control of osteoclastogenesis. In addition vitamin D repceptor (VDR) 
expression was 2.5-fold upregulated in mutant osteoblasts. Calcitriol (1,25(OH)2D), a 
metabolic derivative of vitamin D, is generated in the kidney and stimulates osteoblasts. 
Osteoblasts in turn produce RANK-L which interacts with RANK and induces 
osteoclastogenesis. The newly formed osteoclasts resorb bone to mobilize calcium from 
the bone to the periphery. Taken together, upregulation of vitamin D leads to an increase 
in osteoclast formation, while at the same time the downregulation of OPG prevents 
inhibition of osteoclastogenesis. These observations are in line with the increase of 
osteoclasts in these animals (Figure 30, B).  
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Figure	  31:	  Elevated	  parathormone	  levels	  in	  mutant	  animals	  indicates	  imbalanced	  bone	  homeostasis	  
Expression	  values	  of	  mRNA	  osteoclast	  differentiation	   factors	  and	  vitamin	  D	   receptor	   (VDR)	  are	   represented	  as	   fold	  
changes	   against	   control	   osteoblasts	   (blue	   dotted	   line).	   Values	   are	   normalized	   to	   SDHA	   and	  OAZ	   (VDR	   =	   vitamin	   D	  
receptor,	   RANK-­‐L	   =	   Receptor	   Activator	   of	   NF-­‐kB	   ligand,	   OPG	   =	   osteoprotegerin,	   M-­‐CSF	   =	   macrophage-­‐colony	  
stimulating	  factor,	  IL-­‐6	  =	  interleukin	  6),	  (VDR,	  RANK-­‐L,	  M-­‐CSF:	  n	  =	  4,	  OPG:	  n	  =	  6,	  IL-­‐6:	  n	  =	  7)	  (A).	  Parathormone	  (PTH,	  
parathyroid	  hormone)	  serum	  levels	  (pg/ml)	  in	  control	  (co)	  and	  mutant	  (mt)	  animals	  (n	  =	  6)	  (B).	  
 
 
In addition, osteoclastogenesis is induced by parathormone (PTH). PTH is secreted by cells 
of the parathyroid gland and increases calcium serum levels. PTH increases vitamin D-
Calcitriol levels and thus RANK-L expression is induced and on the other hand it binds to 
the PTH-receptor (PTHR) on osteoblasts again inducing RANK-L expression and thus 
positively influencing osteoclastogenesis. Therefore in a next step PTH concentrations were 
measured in the serum of control and mutant animals. PTH serum levels were significantly 
higher in transgenic animals, indicating a higher rate of osteoclast formation (Figure 31B). 
Taken together it seems that c-Myc overexpression in osteoblasts has a simultaneous effect 
on the osteoclast compartment and therefore keeps the ratio of osteoblasts to osteoclasts 
balanced, while leading to increased turnover of bone.   
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5.5 Tumorigenesis 
 
5.5.1 Transgenic animals develop bone tumors 
 
As demonstrated, upon overexpression of human c-Myc in mature osteoblasts, mice 
developed thicker bones but surprisingly mutant animals did not show health defects. 
However, with increased age (20-30 weeks) animals started to show signs of sickness such 
as loss of appetite and weight, weariness and faintness. In addition mice died earlier 
compared to ColtTA controls and most interestingly, the overall life span of transgenic 
ColtTA;TreMyc mice was dramatically reduced (mean survival of 120 days) compared to 
control animals (> 200 days) (Figure 32).  
 
Figure	  32:	  Transgenic	  ColtTA;TreMyc	  mice	  have	  a	  reduced	  life	  span	  
Survival	   curve	   of	   ColtTA	   (co)	   and	   ColtTA;TreMyc	   (mt)	   transgenic	   animals	   shows	   a	   mean	   survival	   time	   of	   mutant	  
animals	  of	  about	  120	  days	  while	  control	  mice	  die	  >	  200	  days	  (co:	  n	  =	  6,	  mt:	  n	  =	  46).	  
	  
 
While control animals are healthy at 200 days of age, double transgenic mice die on 
average after 120 days, starting as early as day 60. Therefore, 20-30 week old animals with 
signs of morbidity were dissected to get further insights into the cause of death.  
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Figure	  33:	  Tumor	  and	  metastasis	  formation	  in	  ColtTA;TreMyc	  animals	  
20-­‐30	  week	  old	  ColtTA;TreMyc	  animals	  develop	  tumors	  (black	  arrows)	  and	  metastases	  (white	  arrows)	  (A).	  Frequency	  
of	  tumor	  development	  in	  transgenic	  animals	  (B),	  simultaneous	  tumor	  and	  metastasis	  formation	  and	  site	  of	  metastasis	  
development	  (C)	  (n	  =	  20).	  
	  
	  
In 76% of the cases ColtTA;TreMyc mice died with no clear death indication. Notably,  it 
could have been due to the development of paralyzed hind legs and a dramatic weight loss 
due to reduced food intake.  
 
Strikingly, the remaining 24% of double transgenic animals developed tumors (Figure 33). 
These tumors were always developed in close proximity to the bones e.g. mainly femur, 
tibia, mandibula, arms and hips. In addition, in 81% of tumor bearing animals, 
simultaneous metastasis formation was detected in lungs and liver (38%). Furthermore 
12% of the mice developed metastasis in the brain, gut and cheeks or the rib cage.  
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To visualize the localization and the outgrowth of the tumors micro-CT imaging (small 
animal computer tomography) was performed on animal skeletons. 
	  
Figure	  34:	  Micro-­‐CT	  imaging	  of	  single	  and	  double	  transgenic	  mouse	  skeletons	  
X-­‐ray	   image	   of	   a	   skeleton	   of	   a	   ColtTA	   control	   animal	   (A),	   a	   tumor-­‐bearing	   ColtTA;TreMyc	   mouse	   (site	   of	   tumor	  
development	  indicated	  with	  white	  arrowhead)	  and	  	  a	  ColTA;TreMyc	  mutant	  with	  paralyzed	  hind	  legs	  (indicated	  with	  
red	  arrowhead)	  (B).	  	  
 
X-ray analysis with micro-CT scan clearly showed an effect of human c-Myc 
overexpression in mature osteoblasts on the skeleton of mutant animals (Figure 34). Again 
an overall increase in bone mass was noticed, confirming earlier results by histo-
morphometric analysis of the bones and quantitative flow cytometry (Figure 24). 
Furthermore, the site of tumor development was clearly attributable and identified in more 
condensed areas in the x-rays. This suggests that the tumors definitely arose from bones.  
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Thus, overexpression of human c-Myc in ColtTA;TreMyc animals led to bone 
malformations and tumor development. As the only difference between ColtTA;TreMyc 
animals and controls is the overexpression of human c-Myc in mature osteoblasts, the 
cause of tumorigenesis is apparently the modified osteoblast compartment. To confirm 
human c-Myc overexpression in these tumors, its mRNA levels were analyzed in tumor 
cells and cells isolated from metastatic tissues by qRT-PCR.  
 
 
Figure	  35:	  Human	  c-­‐Myc	  mRNA	  expression	  in	  tumors	  and	  metastatic	  tissues	  
Box	  plot	  analysis	  indicate	  mRNA	  expression	  values	  of	  human	  c-­‐Myc,	  shown	  in	  fold	  changes	  against	  control	  osteoblasts	  
(blue	  dotted	  line)	  and	  normalized	  to	  SDHA	  and	  OAZ	  (n.d.	  =	  not	  detectable;	  control	  tissue:	  n	  =	  3,	  mature	  OBs	  mt:	  n	  =	  7,	  
tumor:	  n	  =	  6,	  lung	  and	  liver	  metastasis:	  n	  =	  4).	  
 
Determination of human c-Myc mRNA expression in tumors and metastatic tissues showed 
very high expression levels in all samples. Especially tumors (10-fold increase compared to 
controls) and the metastatic liver tissues (40-fold) showed the highest expression levels of 
human c-Myc. Interestingly, human c-Myc expression levels in lung metastatic tissues were 
increased only to about the same extent as was human c-Myc expression in mutant mature 
osteoblasts (Figure 35). Taken together, human c-Myc was overexpressed in all 
tumorigenic tissues analyzed, indicating that the source of oncogenic transformation must 
have been the modified mature osteoblast.  
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5.5.2 ColtTA;TreMyc animals show metastatic osteosarcoma development 
 
To further characterize the tumors and metastases histological sections and stainings were 
performed.  
 
 
Figure	  36:	  H&E	  staining	  of	  tumor	  and	  metastasis	  identifies	  malignant	  osteoid	  
H&E	   staining	   on	   histological	   sections	   of	   tumor	   (A),	   lung	   (B),	   liver	   (C)	   tissues.	  White	   arrowheads	   depict	   malignant	  
osteoid	  in	  tumor	  tissue,	  black	  arrowhead	  exhibit	  lung	  metastasis,	  red	  arrowhead	  points	  out	  liver	  metastasis.	  	  
	  
 
Histological sections revealed that the tumors had a heterogeneous appearance, while the 
metastases appeared to be more uniform. Interestingly, osteoid was identified in all the 
different histological sections. Osteoid is unmineralized bone matrix and normally 
synthesized by osteoblasts. Furthermore, it is a marker for active bone formation. The 
presence of malignant osteoid clearly categorized the tumors as osteosarcomas (Figure 36) 
(Schajowicz, et al., 1982). Especially in the tumors malignant osteoid was abundantly 
expressed, while its presence was lower in liver metastases and sparse in lungs.   
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The term osteosarcoma implies that the cell of origin is an osteoblast. Besides fibroblasts, 
osteoblasts are the main producers of collagen I which is most prominent in connective 
tissues and bone. Thus, in a next step the osteosarcomas were analyzed by 
immunofluorescence stainings against collagen I. 
 
 
Figure	  37:	  Collagen	  I	  expression	  in	  tumor	  and	  metastatic	  tissues	  
Immunofluorescence	  staining	  against	  Collagen	   I,	   in	   liver	  control	  tissue	  (A),	   tumor	  (B),	   lung	  metastatic	  tissue	  (C)	  and	  
liver	  metastatic	  tissue	  (D).	  Tissues	  were	  counterstained	  with	  Dapi	  (green:	  Collagen	  I,	  blue:	  nuclei;	  20x	  magnification)	  
 
Immunofluorescence staining of tumor and metastatic tissues revealed that collagen I was 
diffusely expressed in osteosarcoma sections and more centrally in metastatic tissues 
(Figure 37). In liver tissue from control mice collagen I expression was restricted to vessels, 
where fibroblasts and endothelial cells are present. In contrast, in liver and lung metastasis, 
collagen I was exclusively expressed in the middle of the metastasis. This confirms the 
presence of malignant osteoblasts, which are normally absent in lung and liver tissues. 
H&E staining had already revealed that osteosarcomas were more heterogeneous and 
therefore it was not surprising to detect collagen I expression in all parts of the tumors. 
Taken together, both osteosarcomas and metastatic tissues contained a high proportion of 
collagen I produced most likely by osteoblasts. 
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To quantify the portion of osteoblasts within these tumors flow cytometric analysis was 
performed on collagenase/dispase-digested tumors.  
 
 
Figure	  38:	  Tumors	  mainly	  contain	  osteoblasts	  and	  show	  impaired	  cell	  cycle	  regulation	  
Representitive	  FACS	  analysis	  indicates	  the	  gating	  strategy	  to	  identify	  osteoblast	  populations	  in	  control	  bones	  (co)	  and	  
tumors	   within	   the	   stromal	   compartment.	   Cells	   are	   identified	   as	   mature	   osteoblasts	   (CD45-­‐	   CD31-­‐	   Ter119-­‐	   Sca-­‐1-­‐	  
CD51+)	   and	   immature	  osteoblasts	   (CD45-­‐	  CD31-­‐	   Ter119-­‐	   Sca-­‐1+	  CD51+)	   (A).	  Quantification	  of	  osteoblast	  populations	  
within	   stromal	   cells	  by	  FACS	   (co:	  n=12,	  mt:	  n	  =	  20,	   tumor:	  n	  =	  22)	   (B).	   Fold	  changes	  of	  genes	   involved	   in	  cell	   cycle	  
regulation	  of	  osteosarcoma	  cells	  against	  mature	  control	  osteoblasts	   (blue	  dotted	   line)	  and	  normalized	  to	  SDHA	  and	  
OAZ	  (p16,	  p18,	  p19:	  n	  =	  6,	  p21:	  n	  =	  7,	  p27,	  p57,	  CyclinD1:	  n	  =	  5).	  
 
 
Flow cytometry showed that the malignant osteosarcoma osteoblasts showed a very 
distinct expression pattern than normal osteoblasts. First of all the stromal compartment 
(CD45- CD31- Ter119- cells) seemed to be much bigger in osteosarcomas compared to 
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control osteoblasts. Interestingly, while control bones contained similar amounts of mature 
and immature osteoblasts the osteosarcomas almost exclusively showed the presence of 
mature osteoblasts (Figure 38, A). This was confirmed by quantification of the osteoblast 
compartment. Here tumors contained about 20% of mature osteoblasts (Figure 38, B). By 
comparison the stroma from normal bone contained only about 10% of osteoblasts. Taken 
together this indicates the presence of mature osteoblasts as the most prominent cell type 
in osteosarcomas.  
 
Next, mRNA expression levels of cell cycle related genes were assessed by qRT-PCR. 
Therefore, mature osteoblasts were sorted from collagenase/dispase-digested tumors and 
mRNA expression values were analyzed. As expected, the expression of cell cycle related 
genes was deregulated in osteosarcoma cells (Figure 38, C). p19INK4d and p27KIP1 did not 
show any differences in their expression compared to normal mature osteoblasts. In 
contrast, p18 showed a strong down-regulation while mRNA expression levels of p16INK4a, 
p21CIP1 and cyclinD1 were highly upregulated. Additionally p57KIP2 expression was slightly 
elevated compared to controls. However, this was not significant. p16INK4a is a cell cycle 
dependent kinase that arrests the cells in G1 phase, while p21
CIP1 blocks cell cycle 
progression in G1/S transition. As cyclin D1 expression is simultaneously increased, this 
might indicate that p16INK4a is outcompeted and that therefore the cells are no longer 
arrested in G1. This would in turn results in aberrant cell proliferation and tumor 
progression.  
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5.5.3 Malignant osteosarcoma osteoblasts are highly tumorigenic 
 
Osteosarcomas are heterogeneous tumor cell populations, which do not solely consist of 
osteoblasts. Therefore it was hypothesized that aberrant cell proliferation was mainly 
linked to the predominating osteoblasts. However the tumor initiation capacity of these 
mutant mature osteoblasts was not proven yet. Thus, the tumorigenic potential of 
osteosarcoma cells was evaluated by xeno-transplantation assays in vivo in NOD scid IL2 
receptor gamma chain knockout mice (NSG) mice. These are immuno-compromised mice 
that allow tumor cell growth in vivo. 
 
Figure	   39:	   Xeno-­‐transplantation	   of	   mouse	   osteosarcoma	   cells	   in	   NSG	   mice	   result	   in	   fast	   tumor	   growth	   and	  
metastases	  formation	  
Experimental	  design	  of	  the	  tumor	  transplantation	  assay.	  Tumors	  are	  either	  directly	  transplanted	  sub-­‐cutaneously	  or	  
sorted	   for	  mature	   osteoblast	  markers	   and	   then	   injected	   intra-­‐femorally	   (A).	  Mature	   osteoblasts	   are	   isolated	   from	  
mouse	   bones	   and	   directly	   transplanted	   intra-­‐femorally	   (B).	   Xeno-­‐transplantation	   of	   primary	   mouse	   osteosarcoma	  
cells	   in	   NSG	  mice	   and	   their	   tumor	   initiating	   potential	   (1	   =	   negative	   control;	   2,	   3	   =	   106	  mouse	   osteosarcoma	   cells	  
injected;	  sub-­‐cutaneous	  tumor	  of	  transplanted	  mouse	  osteosarcoma	  cells	   (red),	   liver	  metastasis	   (blue),	  normal	   liver	  
tissue	   (black)).	   Kaplan-­‐Meier	   curve	   of	   mice	   intra-­‐femurally	   injected	   with	   osteoblasts	   from	   control	   bones	   (black),	  
mutant	  osteoblasts	  (grey),	  bulk	  tumor	  (red)	  and	  104	  purified	  osteoblasts	  from	  tumor	  material	  (pink)	  (co	  OBs:	  n	  =	  6,	  mt	  
OBs:	  n	  =	  17,	  tumor:	  n	  =	  29,	  tumor	  OBs:	  n	  =	  6)	  (C).	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For xeno-transplantations tumor cells enriched for osteoblasts by sucrose gradient were 
injected sub-cutaneously into NSGs. Alternatively, tumor cells were sorted for osteoblast 
markers (CD45- CD31- Ter119- Sca1- CD51+) and then transplanted intra-femorally (Figure 
39, A). In addition, we performed experiments to address whether whether c-Myc 
overexpressing osteoblasts from mice with no apparent tumors, also displayed tumorigenic 
potential.  
 
The xeno-transplantation of primary mouse osteosarcoma cells in vivo showed that the 
cells derived from the primary tumor were highly tumorigenic, as tumor formation was 
already detectable 14 days post transplantation. Interestingly, regardless of the site of 
transplantation, animals showed very fast tumor development, which were about 14 days 
for sub-cutaneous transplants and about 40 days for intra-femoral tansplantations (data not 
shown). Importantly, sub-cutaneously xeno-transplanted mice showed metastasis formation 
in various organs (liver and spleen). This indicates that mouse tumor osteoblasts possess a 
high metastasis initiating capacity (Figure 39, C).  
 
Comparison of the xeno-transplantation experiments in a Kaplan-Meier survival curve 
demonstrated that all different malignant osteoblast populations had tumorigenic potential 
(Figure 39, C). The fastest tumor growth (20 days) was observed in animals, which were 
transplanted with purified osteoblasts from tumors. Transplantation of osteoblast enriched 
tumors resulted in a median growth phase of about 40 days. Most importantly, human c-
Myc overexpressing osteoblasts from transgenic animals with non-overt tumor growth also 
led to tumor formation in vivo. Here, tumor development took more time and tumor 
growth was only observed about 60 days post transplantation. This illustrates the influence 
of c-Myc overexpression on the oncogenic potential of mature osteoblasts.  
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5.5.4 In vitro studies on osteosarcoma cells 
5.5.4.1 Characterization of mouse osteosarcoma cells in vitro 
  
As demonstrated, tumor development occurred in only about 26% of ColtTA;TreMyc 
transgenic mice and these mice died quickly after the tumor developed. Thus, the time for 
in vivo studies was limited. Thus, to characterize the osteosarcoma cells further, an in vitro 
approach was therefore applied and tissue cultures of malignant cells from mouse primary 
osteosarcomas were established (Figure 40). 
 
Two different bone tumors (OS_1706tm and OS_9850tm) were excised from 
ColtTA;TreMyc mice and cultivated in tissue culture conditions. In addition a lung 
metastasis (OS_9850lung met) from an animal with a bone tumor was exised and cultured 
in vitro. The cells started to actively proliferate about 14 days after plating of the primary 
osteosarcoma cells in vitro. Light microscopic analysis of the tissue cultures showed no 
major morphological differences to commercially available cell lines such as mouse pre-
osteoblastic cells (MC-3T3) and human osteosarcoma cell lines (SAOS-2, MG63) (Figure 
40). This indicates that the digestion and fractionating method to enrich for osteosarcoma 
cells in vitro is a convenient system to establish osteosarcoma cell lines, without cross-
contamination by other cell types. However, phenotypically healthy and malignant 
osteoblasts cannot be distinguished at this point. 
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Figure	  40:	  Establishment	  of	  primary	  osteosarcoma	  tissue	  culture	  
Bone	  tumors	  were	  exised	  from	  transgenic	  animals	  and	  purified	  with	  a	  sucrose	  gradient.	  The	  isolated	  osteoblasts	  were	  
then	   seeded	   into	   tissue	   culture	   dishes	   (A).	   Establishment	   of	   xeno-­‐transplantations	   with	   three	   different	   in	   vitro	  
cultures:	  two	  primary	  osteosarcoma	  (tumor	  mouse	  1706,	  9850)	  and	  one	  lung	  metastasis	  (lung	  mouse	  9850)	  (B).	  Light	  
microscopic	   analysis	   shows	   osteosarcoma	   cell	   morphology:	   MC-­‐3T3:	   mouse	   pre-­‐osteoblastic	   cell	   line	   (a),	   human	  
SAOS-­‐2	  (b),	  human	  MG63	  (c),	  OS_1706tm,	  (d),	  OS_9850tm	  (e),	  	  OS_9850lung	  met	  (f),	  10x	  magnification	  (C).	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5.5.4.2 Osteosarcoma cells retain their tumorigenic potential in vitro 
 
To check that the tumorigenic potential of the newly established osteosarcoma and 
metastasis cell lines was not altered, one million cells were transplanted sub-cutaneously 
into NSG mice and tumor development was monitored.  
	  
Figure	  41:	  Osteosarcoma	  tissue	  cultures	  are	  highly	  tumorigenic	  
Tissue	  cultured	  osteosarcoma	  cell	   suspensions	  were	   sub-­‐cutaneously	   transplanted	   into	  NSG	  mice.	  Red	  circle	  marks	  
human	  SAOS-­‐2	  tumors	  (1),	  black	  circle	  marks	  mouse	  pre-­‐osteoblast	  non-­‐tumorigenic	  MC-­‐3T3	  transplants	  (2)	  (A),	  black	  
circle	  indicates	  MC-­‐3T3	  negative	  control	  (1),	  red	  circle	  indicates	  mouse	  osteosarcoma	  transplants	  OS_1706tm	  (2)	  (B).	  
 
The tissue cultured osteosarcoma cells induced fast tumor growth in vivo (Figure 41). Cell 
lines (OS_1706tm, OS_9850tm, OS_9850lung met) showed sub-cutaneous tumor growth 
as early as 14 days after the transplantation. This was comparable to transplantations with 
the human osteosarcoma cell line SAOS-2, where tumor growth occurred in the same time 
frame. The mouse pre-osteoblastic cell line MC-3T3 was used as a negative control in 
these experiments and did not lead to tumor outgrowth. This indicated that the established 
in vitro cultures had preserved the tumorigenic potential of our newly established 
osteosarcoma cell lines under in vitro conditions. 
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5.5.4.3 Tissue culturing does not affect osteoblast behavior 
 
In a second step, the purity of the established tissue cultures was analyzed by FACS. Flow 
cytometric analysisof the extracted and cultivated osteosarcoma cells revealed that in vitro 
culturing preserved very pure cell populations. The cells retained their typical marker 
expression and were therefore still identifiable as osteoblasts (Figure 42, A, B). 
Furthermore, the osteoblast cultures contained only a mixture of matureand immature 
osteoblasts, confirming that the extraction and cultivating methods used are highly specific 
for osteoblast enrichment in vitro. 
 
However comparison of the expression profiles of the two primary osteosarcoma cell lines 
to the lung metastasis cell line showed a very distinct difference. The tumor cell line 
consisted almost exclusively of mature osteoblasts while the lung metastasis cell line 
comprised about 50% of mature and 50% of immature osteoblasts (Figure 42), C. 
 
Next cells were screened for specific genes involved in osteoblast maturation and their 
mRNA expression levels were quantified (Figure 42, D). Not surprisingly, the tissue 
cultured osteosarcoma cells did not show any significant differences in their mRNA 
expression profiles compared to control osteoblasts. This further demonstrates that the in 
vitro conditions seemed to preserve the mature functional osteoblast status of the cells. 
This is in accordance with the finding that osteosarcoma cultures contained almost solely 
mature osteoblast populations.  
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Figure	  42:	  Osteosarcoma	  tissue	  cultures	  are	  highly	  enriched	  for	  osteoblasts	  
Detection	  of	  mature	  (CD45-­‐	  CD31-­‐	  Ter119-­‐	  Sca1+	  CD51+)	  and	  immature	  osteoblasts	  (CD45-­‐	  CD31-­‐	  Ter119-­‐	  Sca1-­‐	  CD51+)	  
in	  stromal	  cells	  under	  in	  vitro	  conditions	  (14	  days	  post	  seeding).	  Gating	  strategy	  (A)	  and	  classification	  of	  stromal	  cells	  
in	   vitro	   (B).	   Differences	   between	   pre-­‐osteoblastic	   cells	   (MC-­‐3T3)	   and	   osteosarcoma	   cells	   in	   vitro	   (OS_1706tm,	  
OS_9850tm;	   OS_9850lung	  met).	   Cells	   are	   pre-­‐gated	   on	   CD45-­‐	   CD31-­‐	   Ter119-­‐	   fractions	   and	   identified	   as	   immature	  
osteoblasts	   (Sca1+	   CD51+)	   or	   mature	   osteoblasts	   (Sca1-­‐	   CD51+)	   (C),	   gene	   expression	   analysis	   of	   genes	   involved	   in	  
osteoblast	  maturation	   indicated	   as	   fold	   changes	   of	   tissue	   culture	   tumor	   osteoblasts	   against	   control	   tissue	   culture	  
osteoblasts.	   Control	   osteoblasts	   are	   indicated	   as	   fold	   changes	   against	  mean	   (h-­‐cMyc:	   n	   =	   6;	   all	   others:	   n	   =	   4;	   not	  
significant)	  (D).	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Finally, cells were tested for their mineralization properties in vitro. For this purpose, cells 
were seeded into 6-well tissue culture dishes for 14 days and then stained by von Kossa 
staining to detect mineralized areas by silver nitrate precipitations. In comparison 
histological sections of osteosarcomas were analyzed. In contrast to bone material, 
preparation of this staining was possible, because osteosarcomas were less rigid and it was 
therefore possible to cut these tumors.  
 
 
Figure	  43:	  Osteosarcoma	  reveal	  calcium	  deposition	  
Von	   Kossa	   staining	   on	   confluent	   osteoblast	   layers	   in	   vitro:	   osteoblasts	   from	   control	   animals	   (co)	   and	   mouse	  
osteosarcoma	   cell	   culture	   (OS_1706tm),	   arrowheads	   indicate	  mineralization	   by	   silver	   nitrate	   precipitations	   (upper	  
row:	  10x,	  lower	  row:	  20x	  magnification)	  (A).	  Histological	  sections	  of	  a	  primary	  osteosarcoma	  sample	  (tumor	  1706)	  and	  
its	  liver	  metastasis.	  Mineralized	  areas	  are	  indicated	  by	  red	  line	  (tumor)	  and	  blue	  line	  (metastasis	  in	  liver	  tissue)	  (upper	  
row:	  4x,	  lower	  row:	  10x	  magnification)	  (B).	  
 
 
Von Kossa staining showed that both the osteosarcoma cell lines (OS_1706tm, OS_9850tm 
data not shown) and histological sections of primary osteosarcoma samples (mouse 
number 1706; mouse number 9850 data not shown) and liver metastasis (to mouse 
number 1706) showed the mineralization properties of normal osteoblasts. Hence it 
seemes that osteoblasts in tumor tissue retained their osteoblast functionality under in vitro 
and in vivo conditions (Figure 43). 
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5.5.4.4 Establishment of an in vitro transplantation model for the characterization of 
metastasis initiation 
 
In addition to osteosarcoma development, about 80% of transgenic animals simultaneously 
developed metastasis to the lung and liver. This has also been observed in human patients. 
Here, lung metastasis development has an influence on survival and prognosis of the 
disease (Osborne, et al., 2012; Kataoka, et al., 2012; Ta, et al., 2009; Longhi, et al., 2006;). 
Therefore, it is of great importance to further study metastasis initiation and to analyze the 
circulation of tumor cells in the blood stream with the long-term goal to pharmaceutically 
prevent engraftment of tumor cells in specific organs. Our osteosarcoma mouse model was 
thus used to establish a xeno-transplantation assay, in which tumor cells can be tracked 
after transduction with the luciferase gene (Figure 44). 
 
 
Figure	  44:	  Flow	  diagram	  for	  tissue	  culture	  xeno-­‐transplantations	  
The	  three	  different	  tissue	  cultures	  were	  infected	  with	  venus-­‐luciferase	  double	  positive	  lenti-­‐viral	  particles	  and	  sorted	  
for	  osteoblast	  markers	  and	  venus-­‐fluorescence.	  Cells	  were	  then	  transplanted	  either	  sub-­‐cutaneously,	  intra-­‐femorally	  
or	  intra-­‐veneously.	  	  
 
Bioluminescence imaging is one of the most sensitive assays used to track luciferase-
positive living cells in luciferase-negative recipient animals. Therefore, established cell 
lines, OS_1706tm, OS_9850tm and OS_9850lung met, were infected with double-positive 
(venus-luciferase) lenti-viral particles (Figure 44) (compare supplementary data Figure 71). 
The luciferase positive cells were injected into NSG mice and monitored by 
bioluminescence imaging.  
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Figure	  45:	  Luciferase	  transduced	  osteosarcoma	  tissue	  cultures	  are	  highly	  tumorigenic	  
NSG	  mice	  were	  transplanted	  with	  either	  1x105	  infected	  luciferase-­‐positive	  osteosarcoma	  or	  lung	  metastasis	  cells:	  sub-­‐
cutaneously	  (1:	  OS_1706tm,	  2:	  OS_9850lung	  met,	  3:	  OS_9850tm)	  (a),	  intra-­‐femorally	  (1:	  OS_1706tm,	  2:	  OS_9850lung	  
met,	   3:	   OS_9850tm)	   (b),	   intra-­‐veneously	   ((1:	   OS_9850lung	   met,	   2:	   OS_1706tm,	   3:	   PBS	   negative	   control)	   (c/d).	  
Measurements	   were	   carried	   out	   either	   14	   days	   (sub-­‐cutan),	   16	   days	   (i.F.)	   or	   18	   days	   (i.v.)	   after	   the	   xeno-­‐
transplantation.	   Luciferase-­‐positivity	   is	   indicated	   with	   a	   colour-­‐scale	   (right	   bar)	   (A).	   Tissue	   culture	   cell	   lines	   were	  
transplanted	   either	   sub-­‐cutaneously,	   intra-­‐veneously	   and	   intra-­‐femorally	   and	   tumor	   growth	   monitored	   by	  
bioluminescent	  imaging	  (orange	  line)	  (neg:	  negative	  control	  MC-­‐3T3	  cells	  n	  =	  6,	  co:	  positive	  control	  SAOS-­‐2	  n	  =	  4,	  OS	  
TC	  =	  osteosarcoma	  and	  lung	  metastasis	  tissue	  culture	  cell	  lines	  n	  =	  24)	  (B).	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Bioluminescence imaging confirmed the earlier data (chapter 5.5.4.2: tumorigenic 
potential of cell lines) that the established cell lines possess high tumorigenic potential 
(Figure 45). All three different cell lines showed in vivo engraftment capacities, 
independent of the site of transplantation, while negative controls never showed any tumor 
development. Mice were generally sacrificed upon visible tumor growth or 3-6 weeks post 
transplantation. Post mortem analysis showed tumor development in sub-cutaneous as well 
as in intra-femoral transplantations in 100% of the cases. In addition about 80% of the 
animals developed metastasis to the lungs and the liver (data not shown), independent of 
the cell line used. Generally, mice injected i.v. showed metastasis to the lungs and liver. 
Interestingly animals intra-veneously transplanted with OS_9850lung met showed faster 
engraftment of the cells to the lungs and the liver. Intriguingly, our lung metastasis cell line 
colonized the bone marrow, which was never observed in osteosarcoma cell line 
transplantations. This highlights the close relationship between bone marrow and lung 
metastatic niches that seem to be the preferential targets for metastatic engraftments in 
other tumor types e.g. breast cancer and pancreatic cancer (Shiozawa, et al., 2011; 
Ibrahim, et al., 2010; Guise, et al., 2006; Strewler, et al., 2006; Kaplan, et al., 2006;). 
 
Kaplan-Meier survival analysis revealed that osteosarcoma tissue cultures induce tumor 
growth within about 30 days while the control SAOS-2 cells developed tumors within 
about 75 days. In negative control transplantations with MC-3T3 cells tumor growth could 
never be observed.  
 
This transplantation model can now be used as a system to study metastasis initiation and 
formation. Furthermore it can help to elucidate clonogenicity in osteosarcomas. 
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5.5.5 Osteosarcomas show normal osteoclastogenesis  
 
The experiments thus far had shown that the osteosarcomas comprise large amounts of 
tumorigenic osteoblasts. This raised the question whether osteoclasts are present in 
osteosarcoma and to what extend. Therefore, histological sections and FACS stainings for 
osteoclast populations in the tumors were performed.  
 
First, Tartrate-resistant acid phosphatase (TRAP) stainings were conducted on paraffin-
embedded tissues to identify the enzymatic activity in osteoclast precursor cells and 
mature osteoclasts. Microscopic analysis of histological sections from osteosarcoma 
revealed that TRAP positive cells occurred all over the tumors with no preferential 
localization to specific areas within the tumors. Furthermore, bone located in the 
immediate vicinity of tumor growth was analyzed. In contrast to control bones, the amount 
of TRAP positive cells was much higher in tumor bones.  
 
Next, flow cytometric analysis was used to identify and quantify osteoclast populations in 
the tumors. The tumors contained about 10% of mature osteoclasts (Figure 46). This 
amount was significantly higher in comparison to the 2-4% osteoclasts normally found in 
control or mutant bones. Thus it seemed that concomitantly with the large amount of 
osteoblasts within the osteosarcomas, the numbers of osteoclasts increased as well. This 
seemed to indicate that even though osteosarcoma showed a tumorigenic bone excess, the 
system tried to keep the balance between osteoblasts and osteoclasts. 
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Figure	  46:	  Osteosarcomas	  contain	  osteoclast	  populations	  
TRAP	   positively	   stained	   osteoclasts	   are	   indicated	   by	   red	   arrowheads	   in	   histological	   sections	   of	   control	   bone	   (co),	  
tumor	  bone	  and	  tumors.	  (upper	  row:	  10x	  magnification,	  lower	  row:	  40x	  magnification)	  (A).	  Gating	  strategy	  to	  identify	  
osteoclasts	  in	  osteosarcomas	  by	  FACS.	  Four	  different	  sub-­‐populations	  are	  distinguished:	  immature	  osteoclasts	  (CD45+	  
Gr1-­‐	  CD11blow/-­‐	   F4/80+	  CD115-­‐)	   (a),	  mature	  osteoclasts	   (CD45+	  Gr1-­‐	  CD11blow/-­‐	  F4/80+	  CD115+)	   (b),	  other	  phagocytes	  
(CD45+	  Gr1-­‐	  CD11blow/-­‐	  F4/80-­‐	  CD115-­‐)	  (c),	  monocytes	  (CD45+	  Gr1-­‐	  CD11blow/-­‐	  F4/80-­‐	  CD115+)	  (d)	  (B).	  Box	  plot	  analysis	  
shows	  the	  percentage	  of	  osteoclasts	  in	  phagocyte	  populations	  of	  control	  bones	  (co),	  mutant	  bones	  (mt)	  and	  tumors	  
(co:	  n	  =	  10,	  mt:	  n	  =	  9,	  tumor:	  n	  =	  5)	  (C).	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Next, mRNA expression of genes involved in osteoclastogenesis were evaluated in 
osteosarcoma samples. Finally, the expression was compared to control osteoblasts. 
 
 
Figure	  47:	  Osteosarcoma	  osteoblasts	  have	  reduced	  M-­‐CSF	  expression	  
Fold	  changes	  of	  mRNA	  expression	  values	  against	  mature	  control	  osteoblasts,	  normalized	  to	  OAZ	  and	  SDHA	  (VDR:	  n	  =	  
3,	  RANK-­‐L,	  OPG,	  M-­‐CSF:	  n	  =	  8,	  IL-­‐6:	  n	  =	  6).	  
 
Macrophage-colony stimulating factor (M-CSF) is one of the key compounds that drive 
osteoclastogenesis, and is released by osteoblasts. Thereby osteoblasts exert a big influence 
on osteoclasts differentiation (Fujita, et al., 2012; Fan, et al., 2001). The mRNA expression 
profile showed that M-CSF levels were significantly down-regulated in malignant 
osteoblasts compared to control mature osteoblasts (Figure 47). This might indicate that 
malignant osteoblasts have a defect compared to normal and c-Myc overexpressing 
osteoblasts (Figure 31). Interestingly, all the other regulators of osteoclastogenesis, RANK-L, 
OPG and IL-6, were not affected and expressed normally. In contrast vitamin D receptor 
(VDR) showed a slight increase in mRNA expression, although this was not statistically 
significant.  
 
Bone remodeling can also be analyzed by measuring metabolic processes in peripheral 
blood of mutant and control mice. Thus, the concentration of proteins that play major roles 
in bone formation and degradation were evaluated in the serum of control, mutant and 
tumor-bearing mice by ELISA. 
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Figure	  48:	  Tumor-­‐bearing	  animals	  have	  increased	  bone	  remodeling	  
Serum	  analysis	  of	  control	  (co),	  mutant	  (mt)	  and	  tumor-­‐bearing	  mice	  (tumor).	  RANKL	  (A),	  OPG	  (B),	  TRAP	  (C)	  and	  OCN	  
(D)	  concentrations	  were	  measured	  by	  ELISA.	  
	  
 
Comparison of proteins measured in the serum of control, mutant and tumor-bearing 
animals revealed that TRAP activity in the serum of osteosarcoma mice was about two-fold 
higher (22 U/L) compared to either control (10 U/L) or mutant (12 U/L) animals (Figure 48). 
This correlated with the observations made by histological TRAP staining (Figure 46) that 
demonstrated increased numbers of osteoclast populations in tumor bones and primary 
tumors. In contrast, protein concentrations of RANK-L, OPG and OCN did not differ in the 
serum of control, mutant and tumor-bearing mice. This is extremely interesting, as I had 
previously shown that OCN is highly expressed in mature osteoblasts and almost not 
detectable in osteosarcoma osteoblasts. OCN is essential for bone mineralization and 
energy metabolism, thereby functioning as an endocrine factor. Therefore it seems that 
OCN does not have an influence on the regulation of endocrine OCN metabolism in 
osteosarcoma mice.   
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5.5.6 Malignant osteoblasts fail to terminally differentiate 
 
As demonstrated earlier, mutant osteoblasts have a mostly normal mRNA expression 
profile. Whether this was also the case in osteoblasts isolated from osteosarcomas was 
determined in the next step by qRT-PCR.  
 
 
Figure	  49:	  Osteosarcoma	  osteoblasts	  resemble	  the	  phenotype	  of	  immature	  osteoblasts	  
The	   mRNA	   expression	   is	   indicated	   as	   fold	   changes	   against	   control	   mature	   osteoblasts	   (blue	   dotted	   line).	   Early	  
osteoblast	  	  differentiation	  markers	  are	  RunX2,	  ALP	  and	  Osx	  and	  late	  differentiation	  factors	  are	  OCN,	  OPN,	  Col1a1,	  Ogn	  
and	  Postn	  (RunX2,	  OCN:	  n	  =	  7,	  ALP,	  Osx,	  OPN:	  n	  =	  3,	  Col1a1:	  n	  =	  4,,Ogn,	  Postn:	  n	  =	  6).	  Normalization	  to	  OAZ	  and	  SDHA.	  
 
Strikingly, qRT-PCR revealed increased mRNA expression of early bone maturation 
markers, RunX2, ALP, Osx in osteosarcoma cells. While ALP was 10-fold upregulated, 
RunX2 and Osx were expressed even higher and showed an increase of up to 20-fold in 
osteosarcoma osteoblasts compared to control mature osteoblasts. In contrast, genes that 
are normally expressed in terminally differentiated osteoblasts were significantly down-
regulated, OCN, Ogn and Postn (Figure 49) and were hardly detectable anymore. In 
addition, OPN and Collagen were expressed normally and did not show any significant 
differences compared to normal controls. This seems to indicate that tumorigenic 
osteoblasts are trapped in a pre-mature osteoblast stage. Thus human c-Myc over-
expression appears to induce oncogenic transformation of mature osteoblasts showing a 
pre-mature signature profile, probably by preventing final maturation and keeping the cells 
in an immature phase.  
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5.5.7 Osteosarcoma osteoblasts have deregulated Wnt signaling 
 
Wnt signaling is one of the key pathways involved in osteoblast differentiation and 
maturation. The observed premature profile of osteosarcoma osteoblasts led to the 
hypothesis that Wnt signaling might be impaired in these cells. Thus, mRNA expression 
levels of genes involved in the canonical Wnt signaling pathway were analyzed by qRT-
PCR.  
 
Most interestingly, some of the genes involved in Wnt signaling were differentially 
expressed in osteosarcoma osteoblasts compared to control osteoblasts (Figure 50). 
Importantly, Wnt3a and ß-Catenin mRNAs were highly upregulated and showed a 40-fold 
increase in their expression level in osteosarcoma cells. In contrast, DKK-1, one of the 
major antagonists of Wnt3a, showed a simultaneous increase as well. Other genes 
involved in Wnt signaling like Lrp5/6, APC, Axin2 and GSK3b were not affected by c-Myc 
overexpression and showed normal expression levels. Thus c-Myc overexpression seems to 
have a major effect on canonical Wnt signaling, which is deregulated in osteosarcoma 
osteoblasts.  	  
Wnt signaling is involved in many cellular processes and a list of Wnt target genes can be 
found online (http://www.stanford.edu/group/nusselab/cgi-bin/wnt/target_genes). Several 
genes involved in bone maturation and differentiation are regulated by the Wnt signaling 
pathway e.g. RunX2, DKK-1, Sox2, Sox9, OCN, E-Cadherin (E-Cadh, CDH-1). To assess 
the effect of upregulated Wnt signaling in osteosarcoma osteoblasts, in a next step the 
mRNA expression levels of these Wnt target genes were analyzed. While RunX2 and DKK-
1 were 15-fold upregulated, Sox2, Sox9, OCN and E-Cad were significantly down-
regulated in mouse osteosarcoma cells (Figure 50). These results are in line with earlier 
publications reporting deregulated expression of Wnt target genes (Luu, et al., 2004). Thus, 
human c-Myc affects the expression of genes that are regulated through the canonical Wnt 
signaling pathway in ColtTA;TreMyc induced osteosarcoma.   
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Figure	  50:	  Deregulated	  expression	  of	  Wnt	  signaling	  genes	  in	  osteosarcomas	  
Evaluation	  of	  mRNA	  expression	  of	  genes	  involved	  in	  Wnt	  signaling.	  Expression	  values	  of	  Wnt	  signaling	  genes	  and	  Wnt	  
target	   genes	   (A)	   are	   plotted	   in	   fold	   changes	   compared	   to	   control	   mature	   osteoblasts	   (blue	   dotted	   line)	   and	  
normalized	   to	   SDHA	   and	  OAZ	   (Lrp5/6:	   n	   =	   13,	  Wnt3a:	   n	   =	   6,	   DKK-­‐1:	   n	   =	   11,	   Apc,	   Axin2,	  Gsk3b,	   ß-­‐Catenin:	   n	   =	   13,	  
RunX2:	   n	   =	   13,	   DKK-­‐1:	   n	   =	   11,	   Sox2:	   n	   =	   10,	   Sox9:	   n	   =	   13,	   OCN:	   n	   =	   7,	   E-­‐Cad:	   n	   =	   7).	   Protein	   expression	   of	  
phosphorylated	  and	  de-­‐phosphorylated	  ß-­‐Catenin	  protein	  in	  300μg	  cell	  lysates	  and	  actin	  was	  used	  as	  a	  reference	  (1:	  
control:	  MDA-­‐MB231,	  2:	  OS_1706tm,	  3:	  OS_1706tm	  irradiated,	  4:	  tumor_14715,	  5:	  tumor_20928,	  6:	  tumor_12888,	  7:	  
tumor_20691)	   (actin:	   43kDa,	   phosphorylated	   and	   dephosphorylated	   ß-­‐Catenin:	   92kDa)	   (B).	   FACS	   plot	   analysis	   and	  
quantification	  of	  ß-­‐Catenin	  protein	  expression	  in	  tumor	  tissue	  (red),	  mature	  osteoblasts	  from	  tumor	  bones	  (blue)	  and	  
mature	  control	  osteoblasts	  (grey).	  Cells	  are	  pre-­‐gated	  on	  CD45-­‐	  CD31-­‐	  Ter119-­‐	  (n	  =	  3)	  (C).	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Analysis of mRNA expression revealed that Wnt signaling gene ß-Catenin is significantly 
upregulated in osteosarcoma osteoblasts. ß-Catenin is an interesting protein as it is active 
in an unphosphorylated status and thus transmigrates from the cytoplasm to the nucleus 
where it starts to induce the transcription of Wnt target genes.  
 
Therefore, I analyzed ß-Catenin phosphorylation status in order to check the activity status 
of the signaling pathway. However in western blot analysis using phospho-ß-Catenin-
specific antibodies, no differences in bands detected by the phospho-antibody compared 
to bands detected by a total ß-Catenin antibody were observed. This indicates that almost 
all the ß-Catenin protein within the tumors is in a phosphorylated state. Thus, it was not 
surprising that even specific induction of phospho-ß-Catenin by irradiation of a tumor 
sample did not further increase its phosphorylation. In contrast, FACS analysis for ß-
Catenin in tumor bone, osteosarcoma osteoblasts and control osteoblasts revealed that in 
tumor bone as well as in osteosarcoma osteoblasts ß-Catenin was expressed in 55% and 
80% of the cells respectively. Thus, almost all of the osteosarcoma osteoblasts expressed 
this important signaling molecule while in control osteoblasts only about 25% of the cells 
stained ß-Catenin positive. This indicates that c-Myc overexpression in osteoblasts has a 
major influence on ß-Catenin regulation, most likely through the Wnt signaling pathway.  
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5.5.8 Aberrant p53 signaling in malignant osteoblasts 
 
Tumorigenesis is a multi-step process where mutations of cell cycle regulators often lead to 
uncontrolled cell proliferation. pRb and p53 are master cell cycle regulators that control 
both, cell growth and cell death. p53 is inactivated and mutated in more than 50% of 
human cancers and is aberrantly expressed in about 20% of osteosarcomas. Therefore p53 
expression levels were analyzed.  
 
Figure	  51:	  p53	  activity	  is	  lost	  in	  osteosarcoma	  osteoblasts	  
Fold	   changes	   of	   p53	   and	  mdm2	  mRNA	   expression	   level	   in	   control,	  mutant	   and	   osteosarcoma	  osteoblasts	   (tumor).	  
Expression	  levels	  are	  indicated	  as	  fold	  changes	  against	  control	  mature	  osteoblasts	  and	  normalized	  to	  SDHA	  and	  OAZ	  
(p53:	   co:	   n	   =	   9,	  mt:	   n	   =	   8,	   tumor:	   n	   =	   11;	  mdm2:	   co:	   n	   =	   7,	  mt:	   n	   =	   6,	   tumor:	   n	   =	   19)	   (A).	   Protein	   expression	   of	  
phosphorylated	  and	  de-­‐phosphorylated	  p53	  in	  300μg	  cell	   lysates	  and	  actin	  was	  used	  as	  a	  reference	  (neg.	  control	  1:	  
K562,	   pos.	   control	   2:	  MDA-­‐MB231,	   3:	   OS_1706tm,	   4:	   OS_1706tm	   irradiated,	   5:	   tumor_14715,	   6:	   tumor_20928,	   7:	  
tumor_12888,	  8:	  tumor_20691)	  (actin:	  43kDa,	  phosphorylated	  and	  dephosphorylated	  p53:	  53kDa)	  (B).	  
	  
	  
	  
Analysis of control and mutant mature osteoblasts, as well as osteosarcoma osteoblasts 
demonstrated a slightly decreased expression of p53 in mutant and osteosarcoma 
osteoblasts (Figure 51). However this was not statistically significant. P53 activity is tightly 
controlled by mouse double minute 2 (mdm2) protein, which binds to p53 and thus blocks 
p53 activity. To test whether the regulation of p53 in mutant and osteosarcoma osteoblasts 
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was impaired, the expression level of mdm2 was analyzed. Evaluation of mdm2 mRNA 
expression level showed no significant difference between control and mutant osteoblasts. 
Osteosarcoma osteoblasts showed a markedly reduced mRNA expression level. However 
mdm2 and p53 expression varied greatly, making interpretations difficult (between 0.1-fold 
down-regulation to 2-fold upreguation). Here low p53 expression levels go along with low 
mdm2 levels resulting in little cell cycle inhibition in osteosarcoma osteoblasts. However, 
p53 protein activity also depends on the protein´s phosphorylation status. Therefore the 
phosphorylation status of p53 was analyzed by western blot.  
 
Strikingly, western blot analysis of p53 protein expression of tissue cultured ostesosarcoma 
samples and primary tumors showed clear differences (Figure 51, B). Phosphorylated p53 
was only detected in tissue-cultured osteosarcoma cells (lane 3, OS_1706tm) and MDA-
MB231 (lane 2) cells. The latter one is a breast cancer cell line, which was used as a 
positive control. p53 phosphorylation can be induced by DNA damage induction through 
irradiation. As expected, irradiation of the osteosarcoma cell line (lane 4) resulted in 
increased p53 phosphorylation, indicating p53 functionality. In contrast all primary 
osteosarcoma samples showed normal p53 expression levels (lane 5-8) but did not show 
any p53 phosphorylation. This indicates that p53 protein activity is blocked in our mouse 
osteosarcoma mouse model.  
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5.5.9 Tyrosine kinase receptor c-Kit is upregulated in mouse osteosarcoma 
 
Another protein often involved in oncogenic transformation of different tissues is the stem 
cell factor receptor c-Kit (CD117) (Chibon and Coindre, 2011; Adhikari, et al., 2010; 
Alava, et al., 2007). c-Kit is a membrane-bound receptor that dimerizes upon ligand 
binding and a subsequent auto-phosphorylation loop then triggers a c-Kit-specific 
intracellular signaling cascade. The receptor tyrosine kinase (RTK) c-Kit is frequently 
mutated in human cancers e.g. soft tissue sarcomas, gastro-intestinal stromal tumors and 
breast cancer. Therefore, its role in our osteosarcoma model was investigated. In a first set 
of experiments mRNA expression levels of c-Kit were tested by qRT-PCR. 
	  
Figure	  52:	  Increased	  c-­‐Kit	  expression	  in	  osteosarcoma	  osteoblasts	  	  
Expression	  of	  c-­‐Kit	  mRNA	  in	  control,	  mutant	  and	  osteosarcoma	  osteoblasts	  (tumor).	  Expression	  level	  are	  indicated	  as	  
fold	  changes	  against	  control	  mature	  osteoblasts	  and	  normalized	  to	  SDHA	  and	  OAZ	  	  (co:	  n	  =	  5,	  mt:	  n	  =	  7,	  tumor:	  n	  =	  6)	  
(A).	  Protein	  expression	  of	  phosphorylated	  and	  de-­‐phosphorylated	  c-­‐Kit	  in	  300μg	  cell	  lysates	  and	  actin	  as	  a	  reference	  
control	  (pos.	  control	  1:	  CCRF-­‐HSB2,	  pos.	  control;	  2:	  Jurkat,	  3:	  tumor_20928,	  4:	  tumor_20928	  treated,	  5:	  tumor_14715,	  
6:	   tumor_14715	   treated,	   7:	   tumor_15564,	   8:	   tumor_15564	   treated)	   (actin:	   43kDa,	   phosphorylated	   and	   de-­‐
phosphorylated	   c-­‐Kit:	   precursor:	   125kDa,	   mature:	   145kDa;	   arrowhead	   points	   out	   c-­‐Kit	   precursor	   in	   non-­‐induced	  
Jurkat	  cells)	  (B).	  FACS	  analysis	  of	  c-­‐Kit	  protein	  expression	  in	  tumor	  tissue	  (red),	  immature	  osteoblasts	  in	  tumor	  tissue	  
(blue)	   and	   mature/	   immature	   control	   osteoblasts	   (grey).	   Cells	   are	   pre-­‐gated	   on	   CD45-­‐	   CD31-­‐	   Ter119-­‐	   (n	   =	   3)	   (C).	  
Quantification	  of	  c-­‐Kit	  expression	  by	  flow	  cytometry	  (co,	  mt:	  n	  =	  10,	  tumor:	  n	  =	  14)	  (D).	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Comparison of c-Kit mRNA expression levels between control, mutant and osteosarcoma 
osteoblasts showed a 8-fold upregulation of c-Kit in osteosarcoma osteoblasts (Figure 52). 
To corroborate these findings, c-Kit expression was assayed by flow cytometry. Stromal 
cells from control and mutant bones as well as osteosarcomas were separated from 
hematopoietic cells by negative gating on CD45- CD31- Ter119- markers. In the stromal 
cell compartment the cells were further separated into mature (Sca-1- CD51+) and 
immature osteoblasts (Sca-1+ CD51+) and c-Kit expression was evaluated on both cell 
populations. Strikingly, osteosarcoma osteoblasts showed a significantly higher c-Kit 
expression compared to mature and immature osteoblasts from both control and mutant 
animals (Figure 52). More precisely, 40% of tumorigenic osteoblasts were c-Kit positive 
while only about 2% of control and mutant mature osteoblasts show c-Kit positivity. This 
nicely correlates with the upregulation of c-Kit mRNA expression and suggests a 
deregulated c-Kit signaling in osteosarcoma cells. Thus, in a next step the activity status of 
c-Kit receptor tyrosine kinase was tested by western blot.  
 
In tumors c-Kit is frequently mutated resulting in spontaneous hyper-activity of the tyrosine 
kinase and leads to uncontrolled cell growth and proliferation. Thus analysis of the 
phosphorylation status of c-Kit indicates the degree of kinase activity and the functionality 
of the receptor. Analysis of total c-Kit protein expression by western blot showed that the 
mature 145kDa protein was expressed in all osteosarcoma samples. Precursors of c-Kit 
protein (120kDa) were only detectable in established cell lines used as a postitive control 
(lane 1: CCRF-HSB2 = human leukemia cell line). In contrast the T-cell line Jurkat 
(arrowhead, lane 2) expressed c-Kit only weakly and served as a negative control. 
Phosphorylated c-Kit was expressed in the positive control as well as in all primary tumor 
samples (lane 3, 5, 7). Specificity of the phospho-specific c-Kit antibody was tested by 
treating the samples with λ-phosphatase to remove phosphate residues at tyrosine 719 that 
was recognized by phospho-c-Kit antibody. c-Kit was phosphorylated at Tyr719 in all 
primary osteosarcoma samples, as phospho-specific c-Kit antibody detection occurred only 
in non-treated samples (lane 3, 5, 7).  
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A role of c-Kit in osteosarcoma onset and a correlation as a prognostic marker is discussed 
in the field and seems to be independent of c-Kit mutation status (Adhikari, et al., 2011; 
Ikeda, et al., 2010; Judson, et al., 2010; Sulzbacher, et al., 2006; Entz-Werle, et al., 2005; 
Matsuyama, et al., 2005). Nilotinib (Tasigna®, Novartis) is a specific c-Kit tyrosine kinase 
inhibitor, which is currently employed in cancer patients. Thus, we next tested the effect of 
Nilotinib treatment on osteosarcoma cell proliferation was tested in vitro. Osteosarcoma 
tissue culture cell lines (OS_1706tm, OS_9850tm, OS_9850lung met) and freshly isolated 
primary osteosarcoma cells (20928tm, 20691tm, 1706 s.c. tm_1/2) were incubated and 
then treated with different Nilotinib concentrations up to 10 µM for 72hrs and 
subsequently cell proliferation rate was determined in comparison to untreated controls. 
 
Nilotinib treatment of osteosarcoma tissue cultures as well as of mouse primary 
osteosarcoma cells revealed an overall effect of the drug on cell proliferation in vitro 
(Figure 53). All the primary tumors showed a higher sensitivity to Nilotinib compared to 
tissue culture cell lines. In detail Nilotinib treatment of primary osteosarcoma samples 
resulted in successful inhibition of cell proliferation in all four tumors. In contrast cell line 
OS_1706tm seemed not to respond to Nilotinib treatment. Cell line OS_9850tm and the 
lung metastasis tissue culture OS_9850lung met showed decreased cell proliferation rates 
upon treatment and responded more sensitively. These results suggest that c-Kit signaling 
plays a major role in mouse osteosarcoma cell proliferation. In the future it will be 
interesting to evaluate the effect of Nilotinib treatment on osteosarcoma formation in vivo. 
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Figure	  53:	  Primary	  osteosarcoma	  cell	  growth	  is	  inhibited	  by	  Nilotinib	  treatment	  in	  vitro	  
Experimental	  set	  up	  of	  Nilotinib	  (TKI)	  treatment	  in	  vitro.	  Osteosarcoma	  tissue	  culture	  cell	  lines	  (A)	  or	  mouse	  primary	  
bone	   tumors	   (B)	   were	   plated	   and	   treated	   with	   Nilotinib	   for	   72hrs.	   Consequence	   of	   Nilotinib	   treatment	   on	   cell	  
proliferation	  in	  vitro.	  Osteosarcoma	  cell	  lines	  (OS_1706tm,	  OS_9850tm,	  OS_9850lung	  met)	  or	  primary	  osteosarcoma	  
samples	  (20928tm,	  20691tm,	  1706	  s.c.	  tm_1,	  1706	  s.c.	  tm_2)	  were	  treated	  with	  different	  doses	  of	  Nilotinib	  for	  72hrs.	  
Cell	   proliferation	   rate	   is	   normalized	   against	   untreated	   controls	   (C).	   Inhibitory	   concentration	   (IC50)	   of	   Nilotinib	   	   on	  
different	  osteosarcoma	  tissue	  cultures	  and	  primary	  osteosarcoma	  cells	  (D)	  (n	  =	  3;	  n.	  d.	  =	  not	  detectable).	  
	  
 
  
   
	   RESULTS	   	  	   	  
-114- 
  
   
	   RESULTS	   	  	   	  
-115- 
5.6 Osteoblast – HSC interaction 
 
5.6.1 Hematopoietic stem cell populations are decreased in 
ColtTA;TreMyc animals 
 
Mature osteoblasts either differentiate terminally into osteocytes to build solid bone or 
remain as osteoblasts to form the endosteum. A presumably small proportion amongst the 
latter ones, tightly interact with hematopoietic stem cells and are involved in forming a 
homing place for HSCs – the HSC niche. Thus osteoblasts play a major role in controlling 
growth and differentiation of HSCs. I used the ColtTA;TreMyc mouse model to test what 
effect c-Myc overexpression had on HSCs and to better understand how osteoblasts 
regulate the HSC niche.  
 
In a first step hematopoietic stem cells and progenitor populations in the bone marrow of 
control and mutant animals were analyzed by FACS analysis. For progenitor cell 
identification, first, differentiated cell populations in the bone marrow were excluded by 
gating on lineage negative cells (Lin-) and in a next step, cells staining positive for c-Kit and 
Sca-1 were selected (Lin- c-Kit+ Sca-1+; LSK). Multipotent progenitor cells (MPPs) of HSCs 
were then identified within the LSK population by gating on the SLAM markers, CD150+ 
and CD48-. Long-term HSCs (LT-HSC; LSK CD150+ CD48- CD34-) and short-term HSCs 
(ST-HSC; LSK CD150+ CD48- CD34+) were then identified by CD34 expression.  
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Figure	  54:	  Gating	  strategy	  for	  the	  detection	  of	  hematopoietic	  cell	  populations	  
Identification	  of	  hematopoietic	  stem	  and	  progenitor	  cells	  in	  the	  bone	  marrow	  of	  control	  (A)	  and	  mutant	  (B)	  animals.	  
Hematopoietic	  progenitors	  are	   identified	  as	  LSK	  population	   (Lin-­‐	  c-­‐Kit+	  Sca-­‐1+),	  MPPs	   (LSK	  CD150+	  CD48-­‐),	   long-­‐term	  
HSCs	  (Lin-­‐	  c-­‐Kit+	  Sca-­‐1+	  CD150+	  CD34-­‐)	  and	  short-­‐term	  HSCs	  (Lin-­‐	  c-­‐Kit+	  Sca-­‐1+	  CD150+	  CD48-­‐	  CD34+).	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Flow cytometry analysis revealed no obvious differences in the expression pattern of cell 
surface antigens between HSCs of control and mutants (Figure 54). In a next step, the 
different cell populations in the bone marrow were quantified (Figure 55).  
 
 
Figure	  55:	  Decreased	  hematopoietic	  stem	  and	  progenitor	  compartments	  in	  mutant	  animals	  
Quantification	  of	  hematopoietic	  stem	  and	  progenitor	  populations	  in	  the	  bone	  marrow	  of	  control	  (co)	  and	  mutant	  (mt)	  
animals	  (LT-­‐HSC:	  long-­‐term	  HSC,	  ST-­‐HSC:	  short-­‐term	  HSC)	  (n	  =	  19).	  
 
 
Strikingly, the portion of LT-HSCs and ST-HSCs as well as MPPs (LSK SLAM) from mutant 
animals was reduced compared to cells from control animals. In contrast LSK cells, the 
least primitive HCS progenitor cells, did not differ between mutant and control animals. 
Interestingly, the most significant reduction in cell numbers was observed in the portion of 
LT- and ST-HSCs in mutant animals. Taken together these first observations indicate that 
human c-Myc overexpression in mature osteoblasts has a major effect in transgenic 
animals. This indicates that the osteoblast – HSC interaction is modified in ColtTA;TreMyc 
animals.  
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5.6.2 Long-term hematopoietic stem cells from ColtTA;TreMyc animals 
possess normal differentiation capacities 
 
The identification of significantly less stem and progenitor cells in transgenic animals 
raised the question whether lineage differentiation was affected as well. During blood 
maturation HSCs differentiate into multipotent progenitors and these cells then mature into 
specific cell lineages in the bone marrow and the blood e.g. granulocytes, B-cells, T-cells, 
erythrocytes. To quantify the percentages of committed progenitor cell populations and 
terminally differentiated blood cells the bone marrow of control and mutant animals was 
analyzed by flow cytometry. 
 
The committed progenitor cell populations in the bone marrow can be separated into 
common lymphoid progenitors (CLPs), megakaryocyte/ erythrocyte progenitors (MEPs), 
granulocyte/ macrophage progenitors (GMPs) and common myeloid progenitors (CMPs) 
(Figure 56, A, B). Quantification of these lineage commited progenitor cells in the bone 
marrow revealed no differences between control and mutant animals. Furthermore, when 
terminally differentiated cells were quantified, no difference between control and mutant 
cells was observed (Figure 56, C). These results demonstrate that the reduced numbers of 
HSCs did not have an influence neither on lineage commitment nor on terminal 
differentiation of bone marrow cells. This indicates that the differentiation capacities of 
HSCs were not affected in transgenic ColtTA;TreMyc animals. To get further insight into 
HSC regulation in ColtTA;TreMyc mice, cell cycle analysis was performed using 
Ki67/Hoechst FACS analysis ( 
Figure 57).  
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Figure	  56:	  Identification	  of	  committed	  progenitor	  and	  terminally	  differentiated	  cells	  in	  the	  bone	  marrow	  
Committed	   lineage	   progenitors	   were	   identified	   as	   CLPs	   (Lin-­‐	   c-­‐Kitlow	   Sca-­‐1+	   CD127+),	   MEPs	   (Lin-­‐	   c-­‐Kit+	   Sca-­‐1-­‐	  
CD16/32-­‐	   CD34-­‐),	   GMPs	   (Lin-­‐	   c-­‐Kit+	   Sca-­‐1-­‐	   CD16/32+	   CD34+)	   and	   CMPs	   (Lin-­‐	   c-­‐Kit+	   Sca-­‐1-­‐	   CD16/32-­‐	   CD34+)	   (A).	  
Terminally	  differentiated	  cells	  were	  identified	  as	  immature	  B-­‐cells	  (IgM+	  B220low),	  pro-­‐pre	  B-­‐cells	  (IgM-­‐	  B220+),	  mature	  
B-­‐cells	  (IgM+	  B220+),	  erythrocyte	  progenitors	  (CD71+	  Ter119-­‐),	  erythrocytic	  blasts	  (CD71+	  Ter119+),	  erythrocytes	  (CD71-­‐	  
Ter119+),	   granulocytes	   (Gr1+	   CD11b+),	   T-­‐cells	   (CD3+)	   (B).	   Quantification	   of	   lineage	   committed	   progenitors	   and	  
terminally	  differentiated	   cell	   fractions	   in	   the	  bone	  marrow	  of	   control	   (co)	  and	  mutant	   (mt)	  animals	   (CLP	   co:	  n	  =	  9,	  
CMP	  co:	  n	  =	  12,	  GMP/	  MEP:	  co:	  n	  =	  6,	  CLP:	  mt:	  n	  =	  8,	  CMP:	  mt:	  n	  =	  11,	  GMP/MEP:	  mt:	  n	  =	  5;	  differentiated	  cells:	  co:	  n	  
=	  12,	  mt:	  n	  =	  11	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5.6.3 Cell cycle genes are de-regulated in mutant long-term hematopoietic 
stem cells 
 
The determination of the cell cycle status of LT-HSCs, ST-HSCs and LSK cells revealed no 
significant between control and mutant animals (Figure 57). There was a slight increased 
number of cells in G0 in hematopoietic stem and progenitor cells from mutant animals but 
this did not reach statistical significance. In addition cell cycle distribution did not differ 
between mutant and control animals. Interestingly, mRNA expression profiles of LT-HSCs 
from control and mutant animals showed a very distinct down-regulation of the p16INK4a 
cell cycle inhibitor. Simultaneously a slight increase in Cyclin D1 and Bmi-1 mRNA was 
identified in these cells as well. Bmi-1 is an oncogene that is essential for self-renewal of 
HSCs and blocks cell cycle progression by inhibiting p16INK4a expression (Pardal., et al., 
2005; Park, et al., 2003; Jacobs, et al., 1999). Therefore cells are retained in G0 as the 
transition between G0 and G1 is blocked. Thus the upregulation of Bmi-1 fits very well to 
the observed down-regulation of p16INK4a and further correlates with the increased 
expression of Cyclin D1.   
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Figure	  57:	  LT-­‐HSCs	  from	  mutant	  animals	  have	  impaired	  cell	  cycle	  associated	  gene	  expression	  	  
(A)	  Cell	   cycle	  profile	  of	  hematopoietic	   stem	  and	  progenitors	  of	   control	   (co)	  and	  mutant	   (mt)	  animals.	   (B)	  Cell	   cycle	  
distribution	  of	  hematopoietic	  stem	  and	  progenitor	  cells	  of	  control	  and	  mutant	  animals.	   (C)	  Fold	  change	  of	  Bmi-­‐1	  (B	  
lymphoma	  Mo-­‐MLV	  insertion	  region	  1	  homolog)	  mRNA	  in	  LT-­‐HSCs	  of	  controls	  and	  mutants.	  Cells	  are	  normalized	  to	  
SDHA	  and	  OAZ	  (n	  =	  6;	  Bmi1:	  n	  =	  8).	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5.6.4 c-Myc overexpression in osteoblasts from transgenic animals leads to 
loss of label retaining long-term hematopoietic stem cells 
 
The results so far had shown that the numbers of LT-HSCs were decreased in mutant 
animals and that expression of several cell cycle regulators was affected in these animals. 
Notably, our group recently discovered a cell population within the LT-HSCs that are even 
more quiescent and undergo cell division only a few times during the life span of a mouse 
(Wilson, et al., 2008). In the next step these so-called dormant HSCs were analyzed in 
ColtTA;TreMyc animals.  
 
To identify dormant HSCs in vivo, a label-retaining assay with Bromo-deoxy-uridine (BrdU) 
was performed. For this purpose mice were given BrdU with the drinking water for 10 days 
in order to label all dividing cells with BrdU. After this pulse-period, BrdU administration 
was stopped and a chase period of 100 – 120 days followed, during which only the 
actively cycling cells lose their BrdU label. The remaining BrdU label-retaining cells (LRCs) 
were then identified by flow cytometry (Figure 58, A). 
 
Figure	  58:	  Overview	  of	  the	  set-­‐up	  of	  the	  BrdU-­‐LRC	  assay	  
Schematic	  scheme	  of	  long-­‐term	  BrdU	  labeling	  of	  animals	  to	  identify	  dormant	  BrdU	  positively	  label-­‐retaining	  cells	  by	  
FACS	   (A).	   Effect	   of	   BrdU	   treatment	   on	  mouse	   viability	   over	   time	   of	   control	   (co)	   and	  mutant	   (mt)	   animals.	  Mutant	  
animals,	  which	  were	  dying	  during	  the	  experiment	  are	  indicated	  in	  blue	  (co,	  mt:	  n	  =	  28,	  mt	  dying	  during	  experiment	  n	  =	  
13).	  (B).	  FACS	  analysis	  of	  BrdU-­‐positivity	  in	  bone	  marrow	  cells	  after	  initital	  BrdU	  labeling	  of	  10	  days	  (n	  =	  3).	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First, the effect of BrdU treatment on mouse survival was assayed. Kaplan-Meier survival 
analysis indicated no effect on animal survival as a consequence of 10-day BrdU labeling 
between control and mutant mice (Figure 58). As expected about one third of all mutant 
animals died prematurely due to bone malignancies (compare Figure 32, chapter 1.5.1 
Transgenic animals develop bone tumors). Both groups of surviving animals showed 
normal behavior and survival statistics were identical for treated and non-treated mice. 
Therefore BrdU was non-toxic to transgenic and control animals.  
 
Subsequently the initial BrdU-labeling efficiency was determined by fluorescence-coupled 
antibody staining against BrdU. At the end of the ten-day BrdU pulse animals were 
sacrificed and numbers of BrdU positive bone marrow cells were quantified by FACS 
(Figure 58). The analysis revealed an initial BrdU labeling of about 80%, which did not 
differ significantly among LT-HSCs, ST-HSCs, MPPs and LSK cells.   
 
Finally, after a chase period of 105 days the animals were sacrificed and the percentage of 
BrdU label retaining cells in the bone marrow was assessed by flow cytometry.  
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Figure	  59:	  Dormant	  HSCs	  are	  lost	  in	  transgenic	  animals	  
Identification	  of	  BrdU-­‐positively	  labeled	  LT-­‐HSCs	  by	  FACS.	  Either	  16	  hrs	  post	  BrdU	  injection	  for	  a	  proliferation	  analysis	  
(A,	  left)	  or	  105	  days	  post	  BrdU	  pulse	  to	  measure	  dormant	  HSCs	  (A,	  right).	  Cells	  were	  pre-­‐gated	  on	  LSK	  CD150+	  CD48-­‐	  
CD34-­‐	  and	  then	  analyzed	  for	  their	  BrdU	  staining.	  BrdU	  positive	  cells	  were	  subsequently	  quantified	  (B).	  	  
 
In the next step a proliferation analysis on LT-HSCs was performed, by injecting BrdU into 
mice and analyzing LT-HSCs 16hrs post injection. Actively proliferating cells were then 
identified as BrdU positive cells. These experiments revealed equal proliferation rates of 
LT-HSCs in control and mutant animals (Figure 59). Normally the percentage of BrdU-LRCs 
is quite low and only about 15% of LT-HSCs are dormant (Trumpp, et al., 2010; Essers, et 
al., 2009; Wilson, et al., 2008). Most surprisingly, transgenic ColtTA;TreMyc animals had 
significantly less BrdU-LRCs compared to control animals. Indeed BrdU incorporation 
analysis revealed that in mutant animals the percentage of BrdU-LRCs within the LT-HSCs 
was reduced to about 5% and about 14% in control animals.  
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Initial BrdU labeling assays had shown that LT-HSC populations were equally labeled in 
control and mutant animals (Figure 58, B). Thus the loss of BrdU-LRCs in double transgenic 
animals must happen within the 105 days chase period. To further elucidate this, in a next 
step, a BrdU time course experiment was started. For this purpose, cells were again labeled 
with BrdU for 10 days and the percentage of BrdU positive cells in the bone marrow was 
monitored by FACS analysis during the chase period.   
 
For the BrdU time course experiment control and double transgenic animals were 
sacrificed after 10, 30, 75, 105 and 125 days of chase and analyzed for their BrdU content. 
Strikingly, after 75 days already, the percentage of mutant BrdU+ LT-HSCs was significantly 
reduced in ColtTA;TreMyc animals (Figure 60, A). This difference was observed for the 
remainders of the experiment and reached its maximum at 105 days post BrdU labeling. 
This indicates that mutant ColtTA;TreMyc animals do lose their BrdU label faster 
compared to control mice.  
 
With the BrdU time course experiment HSC doubling times were calculated by the 
percentage of remaining BrdU in a cell at a given time point and analyzed over time. The 
HSC turnover in mutant and control animals was modeled using a 2-population fit model 
(Figure 60, B, C).  
 
As expected the model showed that activated HSCs in control mice lose their label much 
faster than the dormant HSC population. In fact the model suggests that the activated HSC 
self-renew every 54 days while the dormant HSCs divide only once every 139 days. This 
fits well to the data published by Wilson, et al., 2008. In contrast modeling of the BrdU 
positive HSCs in mutant animals revealed that all LT-HSCs self-renew within 58 days. This 
suggests that all HSCs in ColtTA;TreMyc animals are actively cycling and these mice do 
not maintain dormant HSCs.  
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Figure	  60:	  Mutant	  animals	  show	  LRC-­‐loss	  over	  time	  
Time	  course	  of	  control	  (co)	  and	  mutant	  (mt)	  LRCs	  and	  BrdU	  loss	  over	  time	  during	  a	  BrdU	  chase	  period	  of	  125	  days	  (10	  
days:	  n	  =	  3,	  30	  days:	  n	  =	  4,	  75	  days	  n	  =	  6,	  105	  days:	  n	  =	  7,	  125	  days:	  n	  =	  3)	  (A).	  Mathematic	  2-­‐population	  modeling	  of	  
dormant	  HSC	  doubling	  time	  and	  BrdU	  loss	  over	  time	  in	  control	  (doubling	  time:	  every	  54	  days	  in	  aHSC	  and	  139	  days	  in	  
dHSCs)	  (B)	  and	  mutant	  animals	  (equal	  doubling	  time	  of	  aHSCs	  and	  dHSCs	  every	  58	  days)	  (C)	  (sensitivity	  of	  the	  assay:	  
BDT:	   BrdU	   detection	   threshold	   =	   1	   DNA	   strand	   out	   of	   80	   strands	   is	   positively	   labelled;	   estimated	   DP:	   dormant	  
population	  15%;	  arrows	  indicate	  HSC	  doubling	  time;	  LRC	  =	  label	  retaining	  cell).	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5.6.5 Differentiation capacities of LT-HSCs from mutant animals are 
unchanged in transplantation assays in vivo 
 
Most strikingly, the BrdU time course experiment revealed a loss of dormant HSCs in 
mutant animals. Dormant hematopoietic stem cells are the most competent stem cells that 
possess the ability to continuously replenish the blood system over time while ST-HSCs 
have only a limited self-renewal capacity. To corroborate these findings, in a next step, 
hematopoietic stem cell transplantations were performed to check self-renewal capacities 
in a functional assay.  
 
For this purpose bone marrow from control and mutant animals was intra-veneously 
transplanted into sub-lethally irradiated NSG mice and the chimerism analyzed 25-30 
weeks post transplantation. CD45 is the common leukocyte antigen, which is expressed on 
all hematopoietic cells and exists in two different isoforms, CD45.1 and CD45.2. Donor 
cells from control ColtTA and mutant ColtTA;TreMyc animals express a mixture of CD45.1 
and CD45.2 while the recipient NSG animals only possess CD45.1 antigen. Therefore it is 
possible to exactly identify donor cells in recipient animals by fluorescent-coupled 
antibody staining for CD45.2, as these cells can only be derived from donor animals.  
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Figure	  61:	  Mutant	  primary	  bone	  marrow	  chimeras	  show	  less	  LT-­‐	  and	  ST-­‐HSCs	  engraftment	  
Bone	  marrow	  (BM)	  of	  control	  or	  mutant	  donor	  mice	  was	  intra-­‐veneously	  transplanted	  into	  sub-­‐lethally	  irradiated	  NSG	  
recipient	  animals	  and	   the	  chimerism	  analyzed	  25-­‐30	  weeks	  post	   transplantation	   (A).	  FACS	  gating	   scheme	   to	  detect	  
donor	   (CD45.2	   positive)	   LT-­‐	   and	   ST-­‐HSCs	   in	   chimeras	   (B).	   Quantification	   analysis	   of	   CD45.2+/CD45.1+	   chimerism,	  
differentiated	  cell	  populations,	  hematopoietic	  progenitors	  and	  stem	  cell	  populations	  in	  chimeras	  (C).	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Analysis of the bone marrow from chimeric animals revealed no differences in engraftment 
capacities of bone marrow between control and mutant animals (Figure 61). In both cases 
the percentage of the engrafted CD45.2 cell population was about 50%. This indicated that 
the mutant animals do possess stem cells with the same engraftment capacities as control 
animals. Furthermore, quantification analysis of CD45.2 positive differentiated cell 
populations (B-cells, T-cells, granulocytes and erythrocytes) showed no differences 
between control and mutant animals. Neither did the percentages of the committed 
progenitor populations (CLPs, GMPs, CMPs and MEPs) in recipient animals differ between 
controls and mutant animals. Taken together, this indicates that the differentiation 
capacities of HSCs are similar between control and mutant animals. However, 
quantification of engrafted short- and long-term HSCs revealed that the number of CD45.2 
positive HSCs was significantly reduced in chimeras injected with bone marrow from 
mutant mice compared to those animals injected with control bone marrow. While 
chimeras, transplanted with cells from control animals had about 55% of CD45.2 positive 
LT-HSCs, only about 30% of LT-HSCs were identified in chimeras from mutant animals. In 
addition, analysis of ST-HSCs showed, that in chimeras from control animals 40% of ST-
HSCs were CD45.2 positive while the percentage was reduced to 10% in chimeras from 
mutant mice. Also analysis of the CD45.2 positive multi-potent progenitor (MPP) 
compartments revealed a difference between control and mutant animals in the chimera 
experiments but this was not statistically significant. Taken together this data confirms, that 
ColtTA;TreMyc animals possess less LT- and ST-HSCs in their bone marrow compared to 
ColtTA control animals (Figure 55). This supports the hypothesis that the mutant osteoblasts 
have a major effect on the hematopoietic stem cell compartment. 
 
   
	   RESULTS	   	  	   	  
-130- 
To corroborate these findings, secondary bone marrow transplantations from first line 
generated chimeras, were performed. Therefore, bone marrow from control and mutant 
chimeras was transplanted again into sub-lethally irradiated NSGs. In secondary chimeras 
the chimerism was then analyzed 25-30 weeks post transplantation by FACS analysis.  
 
Figure	  62:	  Mutant	  secondary	  bone	  marrow	  chimeras	  have	  almost	  no	  LT-­‐	  and	  ST-­‐HSC	  engraftment	  
(A)	   Bone	   marrow	   (BM)	   of	   control	   or	   mutant	   primary	   chimeras	   was	   intra-­‐veneously	   transplanted	   into	   sub-­‐lethally	  
irradiated	   NSG	   recipient	   animals	   to	   generate	   secondary	   chimeras	   and	   the	   chimerism	   analyzed	   25-­‐30	   weeks	   post	  
transplantation.	   (B)	   FACS	   gating	   scheme	   to	   detect	   donor	   (CD45.2	   positive)	   LT-­‐	   and	   ST-­‐HSCs	   in	   chimeras.	   (C)	  
Quantification	  analysis	  of	  CD45.2+/CD45.1+	  chimerism	  and	  stem	  cell	  populations	  in	  secondary	  chimeras.	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Interestingly FACS analysis of the bone marrow of secondary chimeras revealed already a 
difference in engraftment capacities of control and mutant primary bone marrow 
transplants (Figure 62). While control secondary chimeras contained about 45% CD45.2 
positive cells, the mutant secondary chimeras only contained about 30% CD45.2 
hematopoietic cells. Most importantly, differences in the percentages of CD45.2 positive 
LT- and ST-HSCs were observed again. Secondary chimeras from control animals comprise 
about 40% LT-HSC and 20% ST-HSC populations. In contrast, the analysis of secondary 
chimeras from mutant animals showed, that almost no CD45.2 positive LT- and ST-HSCs 
were present. This fits well to the initial finding that primary mutant generated chimeras 
showed decreased numbers of LT- and ST-HSCs. As expected, the secondary chimeras 
confirmed again, that the transplanted bone marrow from the mutant primary chimeras 
contained less stem cells. All together this confirms, that mutant ColtTA;TreMyc animals 
do have decreased numbers of long- and short-term HSC populations and supports the 
mathematical modeling of the BrdU experiment that suggested no dormant HSCs are 
present in these animals while the differentiation capacities of HSCs are unchanged. 
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5.6.5.1 Forced cell cycle activation is impaired in LT-HSCs from ColtTA;TreMyc animals  
 
5.6.5.2 Polyinosinic:polycytidylic acid (poly I:C) treatment of ColtTA;TreMyc animals 
does not lead to cell cycle activation  
 
These experiments showed that the c-Myc overexpression in osteoblasts in ColtTA;TreMyc 
animals had a distinct influence on hematopoietic stem cells. Most importantly, it led to 
the drastic loss of dormant stem cells, indicating that mature osteoblasts play a major role 
in the hematopoietic stem niches. Upon specific external signals like injury or infection, 
hematopoietic stem cells are activated and mobilized to help the body react fast to stress 
situations. Therefore I analyzed whether HSCs derived from double transgenic animals still 
showed functional activation in response to stress. Recently our group could show that 
interferon alpha (IFNα) leads to hematopoietic stem cell activation and proliferation (Essers, 
et al., 2009). IFNα production in the mouse can be induced by injection of 
Polyinosinic:polycytidylic acid (poly I:C, pIC), a double stranded mRNA that mimics viral 
infections. In a first set of experiments the effect of pIC treatment on hematopoietic stem 
cells from control and mutant animals was therefore evaluated. 
 
Normally, upon pIC stimuli hematopoietic stem cells are quickly activated and pushed out 
of G0 into cell proliferation. However, HSCs from double transgenic ColtTA;TreMyc 
animals did not show complete cell cycle activation upon pIC treatment. About 60% of LT-
HSCs in mutant mice remained in G0 while only 20% of LT-HSCs remained quiescent in 
control animals (Figure 63). Interstingly, a similar result was observed when ST-HSCs were 
analyzed from control and mutant animals. While about 25% of ST-HSCs from control 
mice were still present in G0, in mutant mice, about 50% of ST-HSCs remained in G0.  
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Figure	  63:	  Hematopoietic	  stem	  cells	  from	  mutant	  animals	  are	  not	  efficiently	  activated	  upon	  PolyI:C	  treatment	  
Cell	   cycle	   analysis	   of	   control	   (co)	   and	   (mt)	   LT-­‐	   and	   ST-­‐HSCs	   before	   and	   16	   hrs	   after	   pIC	   treatment	   (A)	   and	  
quantification	  of	  cells	  in	  G0	  of	  the	  cell	  cycle	  (B).	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5.6.5.2.1 Interferon	   alpha	   treatment	   leads	   to	   complete	   cell	   cycle	   activation	   of	   HSCs	   from	  
ColtTA;TreMyc	  animals	  
 
These observations indicated that manipulated osteoblasts influenced HSC behavior upon 
pIC stimuli. In a next step IFNα was directly administered to control and mutant animals to 
test whether the effects was based on interferon responsiveness of HSCs. 
 
 
Figure	  64:	  Normal	  IFNa-­‐induced	  activation	  of	  hematopoietic	  stem	  cells	  from	  ColtTA;TreMyc	  mutants	  	  
Cell	   cycle	   analysis	   of	   control	   (co)	   and	   (mt)	   LT-­‐	   and	   ST-­‐HSCs	   before	   and	   16	   hrs	   after	   IFNa	   treatment	   (A)	   and	  
quantification	  of	  cells	  in	  G0	  of	  the	  cell	  cycle	  (B).	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Surprisingly, LT-HSCs from both control and mutant animals showed complete cell cycle 
activation and G1 entry when cells were analyzed 16hrs post IFNα treatment (Figure 64). In 
detail, about 70% of quiescent LT-HSCs from control and mutant mice were in G1, while 
only about 15% of cells were left in G0 after IFNα treatment. Additionally, only about 10% 
of ST-HSCs from mutant and control animals were still in G0 upon interferon treatment and 
thereby the ST-HSC population was almost completely activated. This indicated that LT- 
and ST-HSCs from mutant animals can be normally activated upon IFNα treatment.  
 
Taken together these findings indicate that the manipulated human c-Myc overexpressing 
osteoblast seem to have an influence on normal hematopoietic stem cell activation upon 
pIC treatment, while this effect was no longer seen upon treatment of IFNα. One 
explanation for this observation might be that often treatment with IFNα binds directly to 
its receptor on HSCs, thereby circumventing indirect IFNα production via osteoblasts.  
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5.6.5.3 Lipopolysaccharide (LPS) treatment of ColtTA;TreMyc animals does not influence 
cell cycle profile of LT- and ST-HSCs 
 
To strengthen this hypothesis mice were injected with lipopolysaccharide (LPS) next. LPS 
activates HSCs by an indirect mechanism. LPS induces CD14 expression on monocytes 
and then CD14 interacts with the Toll-like receptor 4 (TLR4) on HSCs. This leads to NFkB 
activation and the production of pro-inflammatory cytokines via TRIF/TRAM as well as 
intrinsic interferon production via MyD88 signaling. The TLR4 dependent pathway seems 
to be more important to efficiently activate HSCs as TLR4 knockout mice (TLR4-/-) fail to 
activate HSCs while IFN receptor knockout mice (IFNR-/-) show normal HSC activation 
upon LPS treatment. Therefore I hypothesized that upon LPS treatment ColtTA;TreMyc 
mice should show normal HSC activation.   
 
Interestingly, LPS treatment did not lead to HSC activation in double transgenic 
ColtTA;TreMyc animals and showed instead the opposite effect as expected (Figure 65). 
While about 80% of control LT-HSCs were quiescent before LPS application, upon 
treatment with low-doses of LPS, only about 50% of cells remained in G0, while the rest of 
the cells were pushed into active cell proliferation. In contrast about 80% of LT-HSCs from 
mutant animals remained in G0 upon LPS administration. Thus, LPS induced TLR4 
signaling to activate HSCs was not functional in ColtTA;TreMyc mice. The reason for this is 
still unclear and could be based on changes in TLR4 signaling pathway in HSCs or due to 
impaired interferon production as a consequence of c-Myc overexpression in osteoblasts 
and their effect on main interferon cell producers.  More likely it could be due to slightly 
decreased monocyte populations that were observed in mutant animals (data not shown).  
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Figure	  65:	  Hematopoietic	  stem	  cells	  from	  mutant	  animals	  are	  not	  efficiently	  activated	  through	  LPS	  treatment	  
Cell	   cycle	   analysis	   of	   control	   (co)	   and	   (mt)	   LT-­‐	   and	   ST-­‐HSCs	   before	   and	   16	   hrs	   after	   LPS	   treatment	   (A)	   and	  
quantification	  of	  cells	  in	  G0	  of	  the	  cell	  cycle	  (B).	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5.6.5.4 Aberrant intrinsic interferon production in ColtTA;TreMyc animals 
 
To gain insight into IFN-dependent HSC activation the expression of proteins involved in 
TLR-independent signaling pathways were analyzed in mutant and control osteoblast and 
HSCs. Therefore mice were treated with pIC, which triggers interferon production through 
TLR3 signaling which in turn binds to the cytoplasmatic receptor retinoic acid inducible 
gene 1 (RIG-I) and IFN inducible helicase 1 (IFIH-1) and associates with mitochondrial 
anchored CARD adaptor (IPS-1) to activate IFN expression. 
 
 
Figure	  66:	  Impaired	  PolyI:C	  mRNA	  response	  in	  LT-­‐HSCs	  from	  mutant	  animals	  
The	  mRNA	  expression	  is	  represented	  as	  fold	  changes	  of	   IFN-­‐response	  genes	   in	  either	  mutant	  mature	  osteoblasts	  or	  
LT-­‐HSCs	  compared	  to	  controls	  and	  untreated	  samples,	  normalized	  to	  OAZ	  and	  SDHA	  (n	  =	  3).	  
	  
	  
In response to pIC injection, RIG-I and IPS-1 mRNA expression was only slightly increased 
in both, control or mutant osteoblasts (Figure 66). However, the RNA sensor IFIH-1 was 
highly increased in control (3-fold) and mutant (4-fold) osteoblasts in response to pIC 
treatment. The difference in IFIH-1 expression was the only significant difference between 
osteoblasts from control and mutant animals. This difference is probably insufficient to 
explain the incomplete HSC activation in mutant mice.  
 
Nevertheless, HSC activation was impaired in response to pIC as well as LPS treatment of 
double transgenic ColtTA;TreMyc mice. Therefore, expression of RIG-I, IPS-1 and IFIH-1 
was checked in LT-HSCs from control and mutant animals before and after pIC treatment. 
In control LT-HSCs a simultaneous increase in expression of IFIH-1 and IPS-1 were 
observed. Furthermore a minor increase in RIG-I expression was noticed as well. 
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Unexpectedly, the response to pIC treatment in LT-HSCs from mutant animals differed 
significantly to LT-HSCs from controls. Again upon pIC treatment IFIH-1 expression rose 
sharply similar to the expression of RIG-I. In both cases the expression increased 3-4 fold. 
In contrast IPS-1 expression, which was increased in HSCs of control mice, was unchanged 
in mutant HSCs and even slightly down-regulated upon pIC treatment. This indicates that 
the pIC induced activation of HSCs is only partially working. In the first steps of pIC 
signaling the RNA helicases RIG-I and IFIH-1 seem to work properly, however subsequent 
signal transduction seem not to be functional in LT-HSCs from mutant animals.  
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5.6.6 Gene expression profile of LT-HSCs from ColtTA;TreMyc animals 
reveals differences in DNA replication genes in  
 
To get more insight into the molecular differences between control and mutant long-term 
HSCs, in a next step, micro array analysis was performed from both cell populations. 
Therefore LT-HSCs from ColtTA and ColtTA;TreMyc animals were sorted and their mRNA  
expression profile was analyzed.  
 
	  
	  
Comparison of the gene expression profiles between LT-HSCs from ColtTA control and 
ColtTA;TreMyc mutant animals revealed that the overall difference in gene expression 
patterns between control and mutant LT-HSCs was rather low. This was not unexpected as 
the previous experiments had demonstrated that there were no major differences in 
LT-HSC differentiation or cell proliferation between mutant and control mice. Interestingly, 
however most of the genes that were differentially expressed in mutant and control mice, 
were down-regulated in LT-HSCs derived from ColtTA;TreMyc mice. Further analysis 
revealed that many of these genes are involved in cell cycle regulation and play roles in 
DNA replication, repair and cell metabolism. Only one gene was found to be upregulated, 
Table	  2:	  Short	  list	  of	  genes	  differentially	  expressed	  in	  mutant	  LT-­‐HSCs	  of	  ColtTA;TreMyc	  animals	  	  
Log2	   fold	   changes	  of	  a	   short	   list	  of	   genes	  differentially	   expressed	   in	  mutant	  LT-­‐HSCs	   compared	   to	   control	   LT-­‐HSCs.	  
Upregulated	  genes	  are	  represented	  in	  orange	  while	  down-­‐regulated	  are	  indicated	  in	  blue.	  Light	  orange	  	  and	  light	  blue	  
indicates	  genes	  where	  no	  function	  was	  known.	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namely the zinc finger CCHC domain 14 (Zcchc14), which is normally an interaction 
molecule that builds tandems with DNA, RNA or proteins. For example, Cdc45, the gene 
that is most strongly downregulated, is a replication factor that belongs to the CMG 
complex (Cdc45, MCM, GINS) and participates in the DNA replication machinery 
(Makarova, et al., 2012). In addition, Xab1 and Smug1 are enzymes for DNA repair 
mechanisms and were down-regulated in mutant LT-HSCs. This is interesting, as it might 
indicate that DNA replication and repair are impaired in mutant LT-HSCs. This would 
suggest that cell cycle control in mutant LT-HSCs is already impaired through the loss of 
important cell cycle check points that prevent cell proliferation of damaged cells.  
 
Strikingly analysis of the differentially expressed genes also identified genes that had 
previously been described as important in HSC maintenace. Most interestingly, 
Adenomatous polyposis coli (Apc) was differentially expressed and down-regulated in 
mutant LT-HSCs. Notably, Wang, et al. had observed a block in early differentiation of 
erythropoiesis in Apc-heterozygous mice. Furthermore they could show that LT-HSCs from 
these mice had reduced repopulating capacities (Wang, et al., 2010). In addition these 
mice frequently developed myelodysplastic syndrome (MDS) (Lane, et al., 2010; Wang, et 
al., 2010). Another gene, that was strongly downregulated in LT-HSCs from ColtTA;TreMyc 
mice was Matrilin-4. Matrilin-4 is an extracellular matrix protein and is a member of the 
matrilin family. Matrilin-1 and matrilin-3 are expressed in skeletal tissues, while matrilin-2 
and matrilin-4 are widely expressed throughout the body (Ko, et al., 2004). This is of 
special interest, as this might indicate that the interaction between HSCs and their niche is 
impaired due to the down-regulation of matrilin-4 extra-cellular matrix protein in LT-HSCs 
of mutant animals. 
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6 DISCUSSION 
  
 
Recently our group and others have demonstrated a pivotal role of c-Myc in maintenance, 
differentiation and development of hematopoietic stem cells (HSC) (Holien, et al., 2012; 
Laurenti, et al., 2008; Wilson, et al., 2008; Hoffmann, et al., 2002). Both, c-Myc deletion 
and induced c-Myc overexpression leads to dramatic phenotypes in mice. Deletion of Myc 
blocks the differentiation of HSCs into differentiated cells and leads to an accumulation of 
HSCs in the bone marrow. In contrast overexpression of c-Myc in HSCs induces increased 
proliferation of the long-term HSCs (LT-HSC), a HSC subpopulation that normally cycles 
only rarely. Here, the number of hematopoietic progenitor cells increases, while terminal 
differentiation is completely blocked (Wilson, et al., 2008).  
 
Differentiation and self-renewal of stem cells is in large parts controlled by the surrounding 
cell populations, the so-called stem cell niche. Two different types of HSC niches have 
been previously described in the bone marrow: the endosteal niche, close to endosteal 
osteoblasts and the vascular niche, close to sinusoids. Besides nestin+ MSCs, CAR (CXCL-
12-abundant reticular cells) cells, leptin receptor+ perivascular stromal cells (Lepr) cells and 
GFAP+ nonmyelinating Schwann cells (glial cells), macrophages and N-cadherin+ 
osteoblasts, osteoblasts and osteoclasts have been implicated in the HSC niche and appear 
to control HSC maintenance and differentiation (Ding, et al., 2012; Ehninger and Trumpp, 
2011; Yamazaki, et al., 2011; Lévesque, et al., 2010; Wilson, et al., 2008; Zhu, et al., 
2007; Nagasawa, et al., 2006; Zhang, et al., 2003; Calvi, et al., 2003). As the role of c-Myc 
is known to be cell-specific, we tested how ectopic overexpression of c-Myc in mature 
osteoblasts in the HSC niche affects the differentiation capabilities and self-renewal of 
HSCs. Furthermore as osteoblasts are heavily involved in bone formation, we also assessed 
whether c-Myc overexpression in osteoblasts leads to any overt bone phenotype in mice. 
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6.1.1 Human c-Myc overexpression in osteoblasts leads to an 
osteopetrosis-like phenotype in mice 
 
Human c-Myc overexpression in mature osteoblasts of mice was achieved, using an 
inducible tet-off system and the colIagen I (2.3kDa ColtTA) promoter, which is specific for 
mature osteoblasts. c-Myc overexpression was generally induced in three-week old double 
transgenic ColtTA;TreMyc mice. To evaluate the effects of c-Myc overexpression in 
osteoblasts, in a first step the bones of the animals were analyzed macro- and 
microscopically. Mutant animals exhibited significantly thicker and shorter bones. 
Histological sections revealed that the bone architecture was perturbed, as there was no 
clear separation between compact, solid bone and the bone marrow. In contrast compact 
bone formed extensions and cavities, and the bone marrow was partially localized in the 
brittle structures of the bone. Even though the bones were thicker, they were easily 
breakable and very fragile. 
 
As osteoblasts are the major bone forming cells, a specific bone phenotype was expected 
in transgenic ColtTA;TreMyc animals. In order to gain insight into this phenotype, the bone 
stromal cells were analyzed by FACS. Here we found that the number of mutant 
osteoblasts was significantly increased to about 15%, compared to 9% in control animals. 
Additionally, osteoclast numbers were also increased. Interestingly in human osteopetrosis 
patients the number of osteoblasts and osteoclasts are frequently elevated as well. 
Osteopetrosis is a severe human bone disease, in which the bone formation rate is higher 
than bone resorption by osteoclasts, due to a currently not fully understood impairment in 
osteoblast differentiation and osteoclast function (Lo lacono, et al., 2012; Stark, et al., 
2009; Tolar, et al., 2004). In the ColtTA mouse model it is not entirely clear, whether 
ostoclasts are fully functional. While tartrate-resistant acid phosphatase (TRAP) staining 
suggests the presence of at least osteoclast progenitors and that the cells are partially 
functional, a proof of complete osteoclast functionality requires further investigation eg. 
Cathepsin K expression (Rodan, et al., 2001; Vanaanen, et al., 2000). 
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During osteoblast development, MSCs differentiate into pre-osteoblasts, that are 
characterized by high Runt-related transcription factor 2 (RunX2) and osterix (Osx) 
expression (Wu, et al., 2011; Zhou, et al., 2010; Karsenty, et al., 2007; Zelzer, et al., 
2003). Upon external signalling, 50 – 70% of osteoblasts undergo apoptosis while the rest 
start to differentiate into osteocytes that are finally embedded into the bone matrix 
(Manolagas, et al., 2000; Parfitt, et al., 1990). It has been suggested that osteocytes form 
some sort of mechano-sensor, that controls the activity of osteoblasts and osteoclasts 
(Bonewald, et al., 2011; Winkler, et al., 2003). Previous work demonstrated that the 
transcription factor N-Myc, which is closely related to c-Myc, controls mesenchymal stem 
cell differentiation and proliferation in embryonic bone (Charron, et al., 1992), while c-
Myc is involved in osteoblast and chondrocyte differentiation (Piek, et al., 2009; Karsenty, 
et al., 2007). In addition Zhou and colleagues have shown that while early osteoprogenitor 
populations possess high c-Myc expression levels, terminally differentiated osteocytes only 
express low c-Myc levels (Zhou, et al., 2011). 
 
In the ColtTA,TreMyc mouse model this suggests that ectopic expression of c-Myc in 
mature osteoblasts inhibits their terminal differentiation into osteocytes. There are several 
lines of evidence that support this hypothesis. Masson-Goldner staining of the mutant 
bones revealed that the bone mainly consists of collagen. Collagen synthesis is performed 
by osteoblasts and indicates unmineralized bone matrix. In addition mRNA expression 
analysis revealed that collagen I expression was upregulated by mutant osteoblasts. 
Osteocytes however are embedded into mineralized bone matrix. This is achieved by 
calcium deposition and correlates to the progress of mineralization, therefore suggesting 
less osteocyte presence and pronounced proliferation of mature osteoblasts. Notably, the 
mutant bones showed a higher porosity than control bones, as detected by H&E staining. 
This is in agreement with the decreased number of osteocytes that fill up the lacunae and 
generate compact bone and less mineralization of the bones (Koshla, et al., 2012; Clarke, 
et al., 2008)  
 
While these findings suggest that osteocyte numbers are reduced in ColtTA,TreMyc mice, 
the question regarding cause-and-effect remains unanswered. Does c-Myc directly block 
the development of osteoblasts to osteocytes by blocking important signaling pathways eg. 
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calcification (Zhou, et al., 2011) or sclerostin production by osteocytes (Wijenayaka, et al., 
2011)? An alternative explanation for a reduction of osteocytes could be, that the 
mineralization of the osteoid in mutant bones is defective as osteocyte development is 
coupled to the mineralization of the bone. This line of reasoning is supported by the 
finding that vitamin D receptor is apparently upregulated in mutant osteoblasts as 
evidenced by qRT-PCR. This suggests elevated vitamin D signaling and is in agreement 
with the finding of increased PTH levels in mutant animals. It is known that PTH induces 
osteolysis through increased osteoclast activity and subsequently leads to calcium 
deposition from the bone to the blood stream. This would in turn result in a loss of 
minerals in the bone and thereby loss of bone mineralization. Reduced bone 
mineralization would in turn mean a reduced signaling to osteoblasts to differentiate into 
osteocytes. 
 
In conclusion the present results suggest that c-Myc overexpression in mature osteoblasts 
induces a strong bone phenotype characterized by increased osteoblast levels. It is 
therefore tempting to speculate that terminal differentiation of osteoblasts into osteocytes is 
blocked. Whether this occurs directly through the known effects of c-Myc on 
differentiation or indirectly due to incomplete mineralization of the osteoid remains to be 
determined (Figure 67).  
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Figure	  67:	  Mutant	  mature	  osteoblasts	  negatively	  influence	  osteocytes	  and	  bone	  mineralization	  
Human	   c-­‐Myc	   overexpression	   in	  mature	   osteoblasts	   (mutant,	  OB)	   induces	   an	   upregulation	   of	   parathormone	   (PTH)	  
that	  blocks	  sclerostin	  (SOST)	  synthesis	  in	  osteocytes.	  Upregulated	  PTH	  induces	  calcium	  release	  (Ca2+)	  from	  the	  bone	  to	  
the	   plasma	   and	   simultaneously	   blocks	   osteoprotegerin	   (OPG)	   expression	   from	   mature	   osteoblasts	   thereby	   not	  
negatively	  influencing	  RANK-­‐L	  /	  RANK	  induced	  osteoclastogenesis.	  Bone	  matrix	  formation	  relies	  on	  mineralization	  of	  
pre-­‐osteocalcin	  (unmineralized	  OCN)	  produced	  by	  mature	  osteoblasts	  that	  binds	  to	  hydroxyapatite	  with	  the	  help	  of	  
the	  co-­‐factor	  vitamin	  K	  and	  free	  calcium	  ions.	  High	  bone-­‐turnover	  in	  mt	  osteoblasts	  might	  indicate	  impaired	  function	  
of	   mature	   osteoclasts	   (OC)	   and	   decreased	   bone	   degradation	   rate	   by	   insufficient	   cathepsin	   K	   or	   matrix	  
metallopeptidase	  9	  (MMP9)	  expression.	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6.1.2 Human c-Myc overexpressing osteoblasts lead to osteosarcoma 
formation 
 
The second interesting observation in the ColtTA;TreMyc mouse model was, that about 
26% of the double transgenic mice spontaneously developed tumors. Based on the 
presence of osteoid within these tumours, they were classified as osteosarcomas. 
 
Generally, human osteosarcoma development can be grouped into two main categories, 
pediatric osteosarcomas and adult osteosarcomas (Janeway, et al., 2012; Molyneux, et al., 
2010; Benjamin, et al., 2009; Helman, et al., 2003). Pediatric osteosarcomas are the most 
frequent tumors in children and adolescents (with an average age of 15 – 20) and they 
primarily develop in the regions of fast growing bone e.g. femur, tibia and humerus. In 
contrast adult osteosarcomas mainly develop as secondary disease in elderly patients, as a 
consequence of primary bone disorders e.g Paget´s disease, osteoporosis or osteoarthritis 
(Geller, et al. 2010; Whyte, et al., 2006). Importantly, c-Myc is amplified and 
overexpressed in 8-16% of pediatric and adult osteosarcomas (Bayani, et al., 2003; 
Tarkkanen, et al., 1999; Ladanyi, et al., 1993).  
 
Similar to human osteosarcoma in the ColtTA;TreMyc mice, tumor formation occurred 
mostly in femurs, tibia, mandibular and the clavicular. While this closely resembles the 
pediatric form of osteosarcoma, these tumors developed in about 30-60 week old mice. 
Moreover in most mice, even those without tumor development, a distinct bone 
phenotype, characterized by paralyzed hind legs, was observed. This in turn resembles 
more the adult osteosarcoma phenotype. 
 
Histological and FACS analysis of the osteosarcoma demonstrated that osteoblasts and 
osteoclasts were present in tumors. Quantification of these cells showed that their levels 
were elevated compared to normal bone and that the majority of cells within osteosarcoma 
were osteoblasts. Again this finding correlates well with observations in human tumors, 
which mainly contain osteoblasts that produce malignant osteoid. Interestingly, in tumor-
bearing mice, the development of metastasis in lung and liver was observed. Again this 
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reflects closely the disease progression in patients, where metastases mainly spread to the 
lungs (Namlos, et al., 2012; Osaki, et al., 2011; Luu, et al., 2005). 
 
In order to determine how the tumor osteoblasts differ from non-tumor osteoblasts from 
ColtTA,TreMyc mice, in the next step the expression level of genes involved in osteoblast 
development was assayed by qRT-PCR analysis. 
 
Gene 
Expression level in  
osteosarcoma osteoblasts 
Expression level in 
ColtTA;TreMyc osteoblasts 
 
RunX2 
  
Osx   
ALP   
Collagen   
OCN   
Osteoglycin   
Periostin   
   
Genes involved in Wnt signaling 
   
Wnt3a   
ß-Catenin   
DKK-1   
Cyclin D1   
RunX2   
E-cadherin  n.d. 
Sox2  n.d. 
Sox9  n.d. 
Table	  3:	  Overview	  of	  differentially	  expressed	  genes	  in	  human	  c-­‐Myc	  overexpressing	  osteoblasts	  and	  osteosarcoma	  
osteoblasts	  
Comparison	  of	  differentially	  expressed	  genes	  of	  osteoblast	  maturation	  and	  Wnt	  signaling	  in	  osteosarcoma	  osteoblasts	  
and	  human	  c-­‐Myc	  overexpressing	  osteoblasts.	  Upregulated	  genes	  are	  indicated	  with	  red	  arrows	  and	  down-­‐regulated	  
with	  blue	  arrows	  (n.d.	  =	  not	  determined).	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Several aspects of these results are of particular interest: 
 
• Markers for early, immature osteoblasts were significantly increased. Most 
importantly RunX2 expression was 20-fold elevated in tumor osteoblasts in 
comparison to controls. RunX2 is a master regulator of osteoblastogenesis and 
expressed early in pre-osteoblasts, thereby leading mesenchymal stem cell (MSC) 
differentiation towards osteoblast lineage maturation (Karsenty, 2000). The role of 
RunX2 in bone development has been demonstrated by the work of Komori, et al., 
1997 and Otto, et al., 1997 who showed that RunX2-/- mice completely lack 
ossification. RunX2 is a transcription factor that possesses a Runt DNA binding 
domain and interacts with hypophosphorylated pRb to control osteoblast cell 
proliferation together with cyclin D1 (Martin, et al., 2011). It belongs to the Runt 
family of proteins, which have been shown to play a role in tumorigenicity of many 
human cancers, e.g. in leukemia onset, by loss of function mutations in the RunX1 
gene (Perry, et al., 2002). 
 
• Markers for mature osteoblasts were strongly down-regulated. Osteocalcin (OCN) 
expression in the tumor osteoblasts was reduced by about 50-fold. OCN expression 
is one of the hallmarks of mature osteoblasts and necessary for the generation of a 
functional bone matrix. It is a non-collagenous protein that interacts with 
hydroxyapatite to generate a functional bone matrix, and in addition a very good 
indicator for bone formation. Previous studies had shown that mice deficient for 
OCN show elevated bone formation capacity without an impairment of bone 
resorption (Ducy, et al., 1996). 
 
Taken together these data suggest, that the tumour osteoblasts from ColtTA;TreMyc mice 
are trapped in an immature pre-osteoblastic stage of maturation. This nicely correlates with 
human osteosarcoma, where also osteosarcoma cells are unable to fully differentiate into 
terminally differentiated human osteoblasts (Shimizu, et al., 2011; Yoshikawa, et al., 1997).  
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As demonstrated initially, c-Myc expression is induced through mitogenic signals of the 
Wnt signalling pathway. Notably, the Wnt pathway is frequently affected in human 
cancers and has already been demonstrated as a ready target for cancer treatment in 
osteosarcoma (Vijayakumar, et al. 2011; Iwao, et al., 1999), hepato-cellular carcinoma (La 
Coste, et al., 1998), melanoma (Rubinfeld, et al., 1997) and prostate cancer (Voeller, et al., 
1998). However, the effects of Wnt-signalling on Myc is no one-way street and recently an 
effect of overexpressed c-Myc on the Wnt pathway has been described in breast cancer 
cells. Gene expression studies revealed, that Dickkopf-1 (DKK-1) and secreted frizzled-
related protein 1 (SFRP1), two of the most potent repressors of Wnt signalling, were 
repressed in c-Myc overexpressing cells (Cowling 2007). In addition Wnt is known to play 
a major role in bone development. It directly forces mesenchymal stem cells (MSCs) to 
differentiate towards the osteoblast lineage and furthermore prevents osteoclastogenesis by 
inducing an upregulation of OPG, a negative regulator of osteoclastogenesis, during 
mature osteoblast differentiation.  
 
Analysis of the Wnt-signaling pathway revealed some interesting results. First of all, Wnt3a 
and ß-catenin were upregulated in tumour osteoblasts. This suggests increased Wnt-
signalling in these cells. Nicely in line with these observations is the upregulation of early 
osteoblast marker RunX2, as RunX2 is known to be a Wnt target gene (Luu, et al., 2004; 
Nelson, et al., 2004; Barker and Clevers, 2000). Surprisingly the Wnt antagonist DKK-1 
was strongly upregulated as well. DKK-1 interacts with the transmembrane protein LRP5/6 
on the cell membrane and competes for LRP5/6 with the Wnt-receptor (Hoeppner 2009). 
In earlier studies upregulation of DKK-1 had been associated with the induction of bone 
resorption and osteolysis (Yao, et al., 2011; Guo, et al., 2010; Qiang, et al., 2008; Fujita, et 
al. 2007; Rodda and McMahon, 2006). Interestingly DKK-1 expression has frequently been 
reported in multiple myeloma or hormone-resistant breast tumors (Forget 2007), while as 
mentioned above in some cases c-Myc overexpression led to repression of DKK-1. It is 
known that Wnt-signaling is repressed by DKK-1 in bone maturation during the 
differentiation from immature osteoblasts to mature osteoblasts. This suggests that DKK-1 
seems to be physiologically upregulated as Wnt-signaling is elevated in osteosarcoma 
osteoblasts that resemble an immature osteoblast phenotype. Currently, it is this unclear 
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how DKK-1 works in the context of tumor development and how in ColtTA;TreMyc 
osteosarcomas the DKK-1 overexpression can be explained.  
 
In addition Cyclin D1 was strongly overexpressed in tumor osteoblasts. Cyclin D1 is a 
known Wnt target gene and is involved in cell cycle control, especially in G1/S transition 
((Alberts 2002). Elevated Cyclin D1 level are known to contribute to cancer progression, 
metastasis development and invasion by driving cell cycle progession (Besson, et al., 
2004). This demonstrates an influence of the Wnt signaling on cell-cycle control. Therefore 
expression levels of other cell cycle control genes were analyzed in the osteosarcoma 
osteoblasts. Interestingly, I observed an increase in p16INK4a and p21Cip1 expression and a 
simultaneous decrease of cell cycle inhibitor p18INK4c. p21Cip1 is a protein belonging to the 
CIP/KIP family of cyclin-dependent kinases inhibitors (CKI) that directly binds to the Cyclin 
E-CDK2 complex. In contrast p16INK4a belongs to the INK4 (Inhibitors of CDK4) family. 
p16INK4a prevents cell cycle progression and entry of cells into G1/S transition by directly 
blocking the Cyclin D-CDK4/6 complex during the G1 phase of the cell cycle. Most 
importantly, p18INK4c expression was down-regulated in tumor osteoblasts. This indicates 
elevated cell cycle entry of osteosarcoma osteoblasts from G0 to G1. In addition, Latres, et 
al., 2000 found that loss of p18INK4c seems to be associated with neoplasia. Taken together 
these data suggest that in the mouse osteosarcoma osteoblasts cell cycle entry and 
progression is enhanced by upregulation of Cyclin D1 and down-regulation of p18INK4c. For 
p21Cip1 a role in protection against apoptosis has been discussed (Bulavin et al. 1999). This 
might explain why this cell-division blocking CKI is overexpressed in osteosarcoma cells.  
 
Interestingly, osteosarcoma development is frequently associated with a loss of tumor 
suppressors as p53, mdm2 or pRb (Tang, et al., 2008). Especially loss of p53 protein 
expression in the bone seems to be important for osteosarcomagenesis, independently of 
concomitant pRb loss (Berman, et al., 2008; Walkley, et al., 2008; Overholtzer, et al., 
2003; Guo, et al., 1996). Analysis of the expression level of p53, mdm2 and pRb in tumor 
osteoblasts revealed that in all cases, expression levels were unchanged in comparison 
with control osteoblasts. Interestingly however, when protein expression of p53 was 
analyzed directly through Western blot, no p53 protein could be seen. This suggests that 
either synthesized p53 is rapidly degraded, or that p53 mRNA is not translated into protein. 
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Recent reports have suggested p53 mRNA translation is regulated by alternative transcripts 
(Candeias et al., 2006), which might explain the present result. Interestingly the loss of 
functional p53 nicely reflects findings in human osteosarcomas where p53 is lost in about 
50% of cases (Miller, et al., 1990; Mulligan, et al. 1990). 
 
Tumorigenesis in general is a multi-step process wherein several genes or signaling 
pathways need to be de-regulated (Knudson, et al., 2001). Uncontrolled cell proliferation 
occurs when initially quiescent or slowly growing cells enter the cell cycle and when, 
additionally in a secondary event, tumor suppressor genes are lost or mutated. In the 
context of ColtTA;TreMyc mice, the enforced c-Myc expression already represents the first 
step in this progression towards tumor development, as the c-Myc overexpressing 
osteoblasts are actively pushed into cell division. This increased cell cycle activity in turn, 
renders the cells more prone to mutations, amplifications or deregulations in general. Not 
surprisingly, human osteosarcoma occurs often in children and adolescent where during 
growth, bone cells are undergoing cell division with a very high frequency. The 
ColtTA;TreMyc mouse model therefore nicely correlates with human osteosarcoma patient 
situation. Mouse osteosarcoma development occurs at the same sites of active bone growth 
as in humans e.g. femur, tibia, hips, knee, humerus, mandibular and clavicular. In addition 
mice develop these tumors spontaneously during life, which highly resembles human 
osteosarcoma disease. Furthermore the mouse model shows in addition, that about 80% of 
these tumor-bearing animals develop further metastasis to lungs and liver similar to the 
findings in humans.  
 
Although osteosarcoma is one of the most common cancers in children there are only few 
animal models available that mimic human osteosarcoma. Walkley, et al., 2008 generated 
conditional Osx-Cre+ p53fl/fl and Osx-Cre+pRbfl/fl mutant mice, to specifically delete p53 
and pRb respectively in osteoprogenitors, and induced osteosarcomagenesis within about 
120 to 370 days. Overexpression of the c-fos oncogene in mice also resulted in 
osteosarcoma induction within about four weeks post induction (Wang, et al., 1995). In 
contrast, Khanna, et al. 2001, used osteosarcoma cell lines to induce tumor development 
in xeno-transplantations. In addition, Llombart-Bosch, et al., 1988 showed successful 
engraftment of primary human osteosarcoma into Nude mice. Finally, as early as 1964, 
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Kelloff, et al., 1994 isolated virus from an osteosarcoma-bearing mouse and successfully 
induced new osteosarcoma engraftment by viral infection of mice. All these models 
therefore either eliminate cell cycle control genes, or induce tumour growth directly by the 
injection of tumor cells or the expression of oncogenes. Thus currently there is no model 
that closely mimics the multistep process observed in human osteosarcoma patients. The 
ColtTA;TreMyc model is therefore very interesting as it for the first time mimics some of the 
key features of human osteosarcomas: 
 
• In 8-16% proportion of human patients c-Myc is overexpressed 
• Tumour and metastasis formation occur in similar places as in patients. 
• Only a small percentage of mice develop tumors, probably due to the need of a 
second independent mutation in regulatory pathways.  
 
Osteosarcoma in general is one of the cancers that are hard to detect. The disease in 
patients is most frequently detected by patients themselves, when they spontaneously 
develop strong bone pain, swelling and fractures of bones. Some genetic factors lead to 
increased risk to develop osteosarcomas e.g. changes in retinoblastoma gene, Paget´s 
disease, Li-Fraumeni syndrome, Rothmund-Thomson syndrome and others. Therapy is 
mainly based on surgery, chemotherapy, radiation therapy or all in combination. Many 
conventional chemotherapeutics are based on an inhibition of DNA replication and 
patients are treated with methotrexate, doxorubicin, cisplatin, etoposide, ifosfamide, 
cyclophosphamide, epirubicin, gemcitabine and topotecan or combinations of different 
agents (Jaffe, 2009; Ferguson, et al., 2001). However, predictive markers are still elusive in 
osteosarcomas. In our mouse model system, osteosarcoma osteoblasts did show a very 
high expression of tyrosine-kinase receptor c-Kit, which interestingly is upregulated in a 
variety of human sarcomas. These include especially gastro-intestinal stromal tumors 
(GIST), soft tissue sarcomas and Ewing´s sarcoma (Scotlandi, et al., 2003; Hornick, et al., 
2002; Tuveson, et al., 2001). Furthermore, Wei, et al., 2008 observed a correlation 
between c-Kit expression in osteosarcoma patients and their survival. Nilotinib is one of 
the TKIs that specifically target c-Kit, and I therefore first screened the inhibitory effect of 
Nilotinib treatment on our mouse osteosarcoma cell lines and primary mouse 
osteosarcoma samples in vitro. The study revealed that Nilotinib treatment successfully 
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inhibits primary osteosarcoma cell growth, while cell lines were more resistant to Nilotinib 
treatment. This could be due to the fact that cell lines do only weakly express c-Kit while it 
is highly upregulated in primary tumors in vivo. Therefore it is highly interesting to test, 
whether in vivo TKI treatment of osteosarcoma mice inhibits tumor growth and thereby 
shows a link between c-Kit expression and proliferation. McGary, et al., 2002 shows the 
inhibitory effects of STI571 (Gleevec, Novartis) treatment, which inhibits mainly Bcr-Abl 
and c-Kit, on osteosarcoma cell line xeno-graft mouse model. However, in this study no 
complete growth inhibition occurred during a 6-week treatment period. While it was 
already shown that c-Kit is not a prognostic marker in osteosarcoma (Sulzbacher, et al., 
2007), it is still important to test whether c-Kit positive tumors can be treated by 
combinational TKI treatment. 
 
 
Figure	  68:	  Immature	  osteosarcoma	  osteoblasts	  show	  elevated	  Wnt	  signaling	  in	  ColtTA;TreMyc	  animals	  
Hypothetic	   tumorigenesis	   of	   human	   c-­‐Myc	   overexpressing	   osteoblasts	   (mt	  mature	   osteoblasts)	   into	   osteosarcoma	  
osteoblasts	   (tumor	   immature	   osteoblast)	   with	   an	   immature	   expression	   signature	   in	   ColtTA;TreMyc	   animals.	   (1)	   In	  
addition	  to	  human	  c-­‐Myc	  overexpression	  multiple	  secondary	  hits	  e.g.	  ß-­‐Catenin	  and	  c-­‐Kit	  upregulation	  and	  p53	  loss	  
seem	   to	   drive	   osteosarcomagenesis.	   Osteosarcoma	   osteoblasts	   express	   markers	   of	   immature	   osteoblasts	  
(upregulation	  of	  RunX2,	  Osx,	  ALP	  and	  down-­‐regulation	  of	  osteocalcin	  (OCN),	  osteoglycin	  (Ogn)	  and	  periostin	  (Postn)).	  
Therefore	   c-­‐Myc	   represses	   terminal	   differentiation	   of	   osteosarcoma	   osteoblasts.	   (2)	   Deregulated	   Wnt	   signaling	  
prevents	   terminal	   differentiation	   in	   osteosarcoma	   osteoblasts	   (up:	   Wnt,	   ß-­‐Catenin,	   DKK-­‐1).	   Human	   c-­‐Myc	  
overexpression	  in	  tumor	  osteoblasts	  leads	  to	  an	  upregulation	  of	  Wnt3a	  and	  ß-­‐Catenin	  expression.	  Mesenchymal	  stem	  
cells	  (MSC)	  differentiate	  faster	  into	  osteoblasts.	  Transcription	  of	  Wnt	  target	  genes	  effect	  tumor	  osteoblast	  behavior:	  
less	  cell	  adhesion	  by	  E-­‐cadherin	  down-­‐regulation,	  enhanced	  cell	  proliferation	  by	  upregulation	  of	  cell	  cycle	  gene	  Cyclin	  
D1	   and	   loss	   of	   terminal	   differentiation	   by	   upregulation	   of	   RunX1,	   a	   master	   regulator	   for	   differentiation	   of	   early	  
osteoblasts.	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6.1.3 Influence of overexpression of human c-Myc in osteoblasts on the 
HSC niche  
 
In numerous publications it has been shown that osteoblasts play a major role as a crucial 
part of the hematopoietic stem cell niche in the bone (Celso, et al., 2011; Lévesque, et al., 
2010; Wilson, et al., 2008; Zhu, et al., 2007; Nagasawa, et al., 2006; Zhang, et al., 2003; 
Calvi, et al., 2003). Besides osteoblasts, nestin-positive MSCs, CAR cells (CXCL-12-
abundant reticular), macrophages and nonmyelinated Schwann cells were identified to be 
part of the HSC niche (Ehninger and Trumpp, 2011; Yamazaki, et al., 2011; Méndez-
Ferrer, et al., 2010; Arai, et al., 2005; Suda, et al., 2005; Zhang, et al., 2003; Calvi, et al., 
2003). In several mouse models, manipulation of niche cells led to an impairment in the 
HSC compartment (Mercier, et al., 2012). Most interestingly, Fleming, et al. identified a 
loss of HSC quiescence by niche-associated overexpression of DKK-1 in osteoblasts 
(Fleming, et al., 2008). In addition, N-cadherin (Cdh2) deletion in murine osteoblasts did 
not lead to any alterations and effects in the hematopoietic stem cell compartment, putting 
in question, whether N-cadherin expression in osteoblasts play any role on the HSC niche 
(Bromberg, et al., 2012). 
 
I therefore took a closer look at the HSC niche in ColtTA;TreMyc mice. Interestingly I 
found that the most important HSC population, the dormant HSCs had been lost in 
ColtTA;TreMyc animals. Dormant HSCs had only been discovered relatively recent, as a 
rarely dividing cell population that represents an HSC reservoir that is activated in cases of 
injury or infection (Takizawa, et al., 2011; Essers, et al., 2009; Foudi, et al., 2008; Wilson, 
et al., 2008). Dormant HSCs divide only about 5 times during the life time of a mouse, and 
can be detected as they retain their label in the BrdU-LRC assay. Long-term analysis of the 
ColtTA;TreMyc mice revealed that by day 70 already, mutant animals have a reduced 
amount of LRCs. Analysis at day 105 to 125 showed a similar trend. In fact at these time 
points the number of dormant HSCs was even further reduced.  
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To better understand this observation, the data was subjected to mathematic modeling 
based on a 2-population model. Mathematical modeling of HSC doubling times in mutant 
animals indicate that the dormant and activated HSC compartment have identical doubling 
times. This strongly suggests that mutant animals do not possess dormant HSCs. In addition 
FACS analysis of the stem and progenitor compartment furthermore revealed a significant 
decrease in the amount of LT-HSCs, ST-HSCs and multipotent progenitors (MPPs). The loss 
of dormant HSCs in mutant animals can be explained in two different ways. One is, that 
due to the severe bone malformations the ColtTA;TreMyc mice do not provide a stable 
niche environment for dormant HSCs. The alternative explanation suggests that the 
dormant HSCs are lost over time due to a loss of cell division. Previous experiments by 
Jaworski, had shown, that human c-Myc overexpression in mature osteoblasts during 
embryonic development leads to a loss of HSCs in the bone marrow and instead leads to 
extra-medullary hematopoiesis in the spleen (Jaworski and Trumpp, thesis 2009). A similar 
mechanism might occur when c-Myc overexpression is induced in adolescent or adult 
mice. Interestingly though, I could never observe increased HSC levels in the spleen of 
adult ColtTA;TreMyc mice. However, to better understand whether the absence of 
dormant HSCs was also reflected in the more active LT and ST-HSCs, bone-marrow 
chimeras were generated. In these experiments bone marrow from either mutant 
ColtTA;TreMyc or control ColtTA animals was transplanted into NSGs and engraftment of 
the HSCs as well as their differentiation capacities were evaluated. Here I found that in 
transplantations with mutant bone marrow lower percentages of LT- and ST-HSC engrafted 
in comparison to control bone marrow. This effect was even more striking in secondary 
transplantation assays, where hardly any LT- and ST-HSCs were left in mutant chimeras. In 
contrast the differentiation capacities of the HSCs were apparently unaffected as no 
difference in lineage-committed progenitors and differentiated cell populations could be 
observed between control and mutant animals.  
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Taken together this data suggests that as a consequence of the loss of dormant HSCs the 
remaining LT-HSC and ST-HSC pool is exhausted over time due to regular cell division, as 
the HSC pool is not replenished by dormant HSCs. This hypothesis is further strengthened 
by the fact that no differences in differentiated cells were observed between mutant and 
control chimeras. Thus it is not due to impaired differentiation capacities that HSC 
numbers are decreased in the mutant mice.  
 
Finally what these experiments suggest is, that overexpression of human c-Myc exclusively 
in mature osteoblasts, has major effects on the dHSC population in mutant animals. This 
suggests that the mature osteoblasts do have a major impact on controlling the 
hematopoietic stem cell pool and its maintenance under homeostasis. 
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Figure	  69:	  Mutant	  osteoblasts	  lead	  to	  a	  loss	  of	  dHSCs	  and	  reduced	  numbers	  of	  hematopoietic	  stem	  and	  progenitors	  
(A)	  In	  ColtTA	  control	  animals	  the	  bone	  marrow	  comprises	  normal	  hematopoietic	  stem	  and	  progenitor	  cells	  (activated	  
HSCS	  (aHSCs))	  and	  dormant	  HSCs	  (dHSCs).	  (i)	  Under	  homeostatic	  conditions	  the	  dHSC	  is	  quiescent	  and	  located	  in	  its	  
endosteal	   niche	   (control	  mature	  osteoblasts).	   (ii)	  During	  bone	   turn-­‐over	   control	   osteoblasts	   are	   replaced	  by	  newly	  
synthesized	  bone	  and	  dHSCs	   leave	   their	  niche	  and	  become	  activated.	   (iii)	   Re-­‐entering	  of	  dHSCs	   into	   their	  niche	  by	  
relocation	   to	   replaced	   bone.	   (B)	   In	   ColTA;TreMyc	   mutant	   animals,	   already	   (i)	   under	   homeostatic	   conditions	   the	  
activated	  HSCs	  show	  elevated	  expression	  of	  Bmi1	  and	  decreased	  expression	  of	  p16INK4a	  cell	  cycle	  inhibitor.	  (ii)	  Mutant	  
osteoblasts	  have	  a	  high	  bone-­‐turnover	   and	  dHSCs	   are	  more	   frequently	  pushed	  out	  of	   their	   niche.	   (iii)	   dHSCs	   show	  
decreased	  re-­‐entering	   into	   their	  niche	  as	  a	  consequence	  of	  high	  mutant	  osteoblasts	   replacement.	  Therefore	  dHSCs	  
and	  stem-­‐	  and	  progenitors	  are	  decreased	  over	  time.	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Previously, our group had described that the dormant hematopoietic stem cells can be 
activated by mimicking applied stress conditions through the injection of interferon alpha 
(IFNα) (Essers, et al., 2009). Interferon alpha is normally secreted as a result of bacterial or 
viral infection. Essers et al. showed that by injection of the ds-RNA polyinosine-
polycytidylic acid (poly(I:C) or by injection of bacterial LPS, secretion of INFα and 
activation of dormant HSCs could also be achieved. Interestingly, in ColtTA;TreMyc mice 
neither pIC treatment nor LPS injection led to HSC activation while in both experiments 
control HSCs were normally activated. In contrast direct injection of IFNα induced 
dormant HSC activation even in ColtTA;TreMyc mice. This indicates that in mutant mice 
the IFNα receptor is present and functional and that signaling pathways downstream of 
IFNα are not affected. Comparing the signaling pathways upstream IFNα that lead to the 
cytokine´s secretion, it is interesting to note that the responses to pIC and LPS are very 
similar. The dsRNA pIC interacts with the toll-like receptor 3 (TLR3), which in turn 
activates Trif (TIR-domain-containing adapter-inducing interferon-β). In contrast LPS binds 
to TLR4 and transmits the activation signal through Trif and TIRAP (TIR-domain containing 
adaptor protein). Both pathways end then in the same signaling cascade that involves 
NFkB and AP-1 signaling to produce type I IFNs and inflammatory cytokines.  
 
Interferons are secreted by a large number of cells such as leucocytes, moncytes and 
fibroblasts. In monocytes and macrophages IFNα activation occurs mainly through TLR4-
mediated signaling. Thus the lack of HSC activation in mutant mice could be due to 
reduced macrophage functionality or due to reduced intrinsic IFN production in these 
cells. Chang, et al. previously demonstrated that macrophages have a major impact on the 
HSC niche. In addition the group showed that macrophage ablation in Macrophage Fas-
Induced Apoptosis (MAFIA) transgenic mice led to osteoblast reduction and HSC 
mobilization (Chang, et al., 2008). Furthermore Winkler, et al., observed a strong 
correlation between macrophage deletion, and as a consequence decreases in osteoblast 
numbers with a simultaneous HSC loss in the bone marrow (Winkler, et al., 2010). These 
data suggest a strong interplay between HSCs, osteoblasts and macrophages/monocytes in 
the HSC niche. It is therefore tempting to speculate that the interaction of the c-Myc 
overexpressing osteoblast with the niche macrophage somehow stops TL3/4 mediated IFNα 
signaling and thereby prevents HSC activation in ColtTA;TreMyc mice. 
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An alternative explanation could be based on the influence that osteoblasts exert on the 
development of macrophages and osteoclasts from HSCs. The myeloid progenitor develops 
either into macrophages or into osteoclasts. Osteoclastogenesis is regulated by secretion of 
RANK-L from the neighboring stroma or osteoblasts. The c-Myc overexpressing osteoblasts 
in ColtTA;TreMyc mice could, in a yet undetermined manner, influence either 
macrophage or osteoclast development and lead to cells with impaired functionality. A 
role of osteoclasts on HSC activation has been demonstrated as osteoclast-secreted 
Cathepsin K cleaves the cytokine CXCL12 (SDF-1), one of the key factors responsible for 
HSC maintenance in the bone marrow. Thus osteoblast-mediated defects either in the 
TL3/4 signalling pathways of macrophages or osteoclasts might therefore explain the loss 
reactivity towards pIC and LPS stress signals in ColtTA;TreMyc mice. 
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Figure	  70:	  Mutant	  osteoblasts	  prevent	  LT-­‐HSC	  activation	  by	  poly(I:C)	  and	  LPS	  respectively	  
(A)	   In	  wild-­‐type	   animals	   PolyI:C	   (pI:C)	   or	   lipopolysaccharide	   (LPS)	   treatment	   induces	   T-­‐cell	   activation	   that	   activates	  
TRAF6	   signaling	   in	   immature	   osteoclasts	   through	   RANK-­‐L	   /	   RANK	   interaction.	   Subsequently	   interferon	   production	  
(IFNα/ß)	   is	   induced	   and	   leads	   to	   IFN-­‐signalling	   in	   long-­‐term	   hematopoietic	   stem	   cell	   (LT-­‐HSCs)	   upon	   IFN-­‐receptor	  
(IFNR)	  binding.	  LT-­‐HSCs	  become	  activated	  and	  start	  to	  proliferate.	  (B)	  In	  mutant	  animals	  impaired	  mature	  osteoclast	  
functionality	  prevents	  IFN-­‐synthesis	  in	  immature	  osteoclasts,	  thereby	  preventing	  pI:C	  /	  LPS-­‐induced	  LT-­‐HSC	  activation	  
and	  cell	  proliferation.	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6.1.4 Outlook 
 
In the course of this work I have closely characterized the effects of c-Myc overexpression 
in mature osteoblasts and demonstrated that the ColtTA;TreMyc mouse model is a useful 
model system for future work.  
 
In one aspect the mutant mice can be used to further analyse the effects of an imbalance in 
the osteoblast / osteoclast ratio. The osteopetrosis-like phenotype that is characterized by 
unmineralized bone matrix and its connection to osteoblast and osteoclast development 
will help to better understand human bone aberrations in the future. Furthermore the 
mouse model serves as an ideal model system to further study human osteosarcoma. Up 
until now, all mouse models for osteosarcoma rely on the induction of bone tumor 
development through highly artifical means. The ColtTA;TreMyc mouse model is the first 
mouse wherein tumor forms spontaneously. Most likely tumor development in these mice 
is dependent on multiple additional mutations in an important signalling pathway, similar 
to the events in patients. The tumor and metastasis in the mutant mice closely resemble 
human osteosarcoma. Thus the ColtTA;TreMyc mice are ideally suited to further analyse 
tumor onset, development and also to study further therapeutic options for the treatment of 
this disease.  
 
A further interesting aspect of the ColtTA;TreMyc mouse model is, that it offers the 
possibility to better study and understand the effects that the osteoblast has on the 
hematopoietic stem cell niche. As I could show in this work the osteoblasts do not only 
exert an influence directly on the HSCs but also on other cells within the niche, such as 
osteoclasts. In future work these interactions can be analyzed in more detail, as only a few, 
very defined changes in the gene expression pattern were observed in comparison to 
control mice. Taken together the ColtTA;TreMyc mouse model offers a lot of possibilities 
for future work to study the role of osteoblasts in bone and tumor development and its 
function in the hematopoietic system. 
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7 MATERIAL & METHODS 
  
 
7.1 Animals 
 
Animals were maintained in accordance with the German Law for the Protection of 
Animals and the National Institute of Health (Guidelines for Care and Use of Laboratory 
Animals with the licence numbers G159/08 and G-99/12). All animals were kept under 
specific pathogen-free (SPF) conditions and housed in individually ventilated cages (IVC) at 
the animal facility at German Cancer Research Center. Animals used in all the experiments 
were between 20 and 30 weeks of age. Different conditions from this are noted in the text.  
 
ColtTA;TreMyc mouse lines were generated previously (Jaworski and Trumpp, thesis 2009) 
and animals used in the experiments were generated by crossing ColtTA control animals 
with TreMyc mice. Animal matings were continuously kept under doxycycline treatment 
(2mg/mL) in the drinking water. Prolonged doxycycline treatment on newborns was 
continued until mice were 3-weeks of age (weaning age). ColtTA;TreMyc animals are on a 
mixed background C57BL/6 - S129. 
 
NOD scid gamma (NSG; NOD.Cg-Prkdcscid Il2rgtm1Wjl/Sz) were purchased from The 
Jackson Laboratory.  
 
7.2 BrdU treatment 
 
BrdU was purchased from Sigma and dissolved in water with a concentration of 1g/ L and 
a final concentration of 5% glucose. Solution was substituted to mice drinking water for 10 
days and changed ones a week. For BrdU proliferation assay and as a positive control for 
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BrdU-LRC analysis mice were intra-peritoneally injected with a 1.8mg / ml BrdU solution 
in PBS and cells isolated and analyzed 16 hrs after BrdU treatment. 
7.3 Genotyping of mice 
 
Animals were tagged with numbered ear marks and DNA from tail biopsies was extracted 
in Direct Lysis buffer and the addition of proteinase K (PeqLab). Primers were designed 
with Roche Assay Designing software and used with 10 µM. Genotyping PCR was 
conducted in 10x Invitrogen Buffer with either final concentrations of 10% DMSO (++) or 
10% Triton-X100 (+) and 10mM dNTPs and 1 µL lysed DNA. Annaeling temperature of 
60°C was used and DNA amplified with 35 cycles.  
Primer Sequence 
 
3’-ColtTA++   
 
5’-CTC TGC ACC TTG GTG ATC-3’ 
5’-ColtTA++  5’-GCT GCT TAA TGA GGT CGG-3’ 
3’-TreMyc+ 5’-TTT GAT GAA GGT CTC GTC GTC C-3’ 
5’-TreMyc+ 5’-TAG TGA ACC GTC AGA TCG CCT G-3’ 
	  
Table	  4:	  List	  of	  genotyping	  primer	  
 
 
7.4 Osteoblast isolation  
 
Osteoblasts were isolated from 20 – 30 week old animals by dissecting femurs, tibia and 
the spinal cord. Briefly, bones were crushed and the bone marrow discarded. 
Subsequently, bone chips were digested with a 20 min. three-step digestion protocol by 
using trypsin (Invitrogen), collagenase P (Roche) and dispase (Roche) in aMEM (Invitrogen) 
supplemented with 10% fetal bovine serum (tet-System approved FBS, Clontech) in digest 
2 and 3 and 25mM Hepes and 1M calcium-chloride. Osteoblast enrichment was 
conducted by gradient centrifugation in Histopaque-1083 (Invitrogen) and cells were then 
either plated into 10cm tissue culture dishes or used for flow cytometry or fluorescence 
cell sorting.  
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7.5 Bone marrow isolation 
 
In general bone marrow was isolated from tibia, femurs and spinal cord. In brief, bones 
were crushed and bone marrow harvested in RPMI (Invitrogen) supplemented with 2% FCS 
(Gibco) and then centrifuged. Cell numbers were determined by automated cell counts 
with a ViCell (Beckman Coulter) and differentiated cells either removed by lineage 
depletion (Lin-) or 1x106 bone marrow single cells stained directly with specific antibodies. 
Lineage depletion was carried out by incubation of the bone marrow with rat anti-mouse 
monoclonal lineage specific antibodies, CD4 (GK1.5), CD8a (53.6.7), B220 (RA3-6B2), 
Gr1 (RB6.8C5), Ter119 (Ter119), CD11b (M1/70). Antibody-bound cells were then 
removed from bone marrow by incubation with sheep anti-rat IgG-coated dynabeads 
(superparamagnetic polystyrene beads, Invitrogen) and separated with a magnet. 
Centrifugation was conducted at 4°C, 1600 rpm and 5 min. in Eppendorf 5810r centrifuges 
and washing steps were carried out with PBS supplemented with 2% FCS.  
 
7.6 Chimera generation 
 
Recipient NSG donor mice (CD45.1) were sub-lethally irradiated with 2.5 Gy 24 hours 
before chimera generation. Donor ColtTA control and ColtTA;TreMyc mutant animals 
(CD45.1 / CD45.2 mixture) were sacrificed, hind legs removed and the bone marrow 
isolated. Bone marrow was counted with a ViCell and 1x107 cells per 1 ml RPMI 
(Invitrogen) incubated with 1:30 diluted hybridoma AT83 anti-mouse-Thy1.2 antibody (T-
cell depletion). In a next step rabbit complement (1:10) and Dnase I (1:50 / 3 ml media) 
were added and then cells were counted again to get a final cell concentration of 1x105 
cells / 100 µL in PBS. T-cell depleted 1x105 cells / 100 µL in PBS from ColtTA controla and 
ColtTA;TreMyc mutant animals were then intra-veneously injected into NSG recipient 
animals in triplicats. Bone marrow of primary chimeras was analyzed 25-30 weeks post 
transplanation and additionally secondary chimeras were generated. 
 
For secondary chimera set-up, 1x106 bone marrow cells from primary ColtTA and 
ColtTA;TreMyc chimeras were transplanted intra-veneously into sub-lethally irraded 
   
	   MATERIAL	  &	  METHODS	   	  	   	  
-168- 
(2.5Gy) NSG recipient animals following same protocol as for primary chimera generation. 
Also here, bone marrow of secondary chimeras was analyzed 25-40 weeks post 
transplantation. 
 
7.7 Fluorecent cell sorting and flow cytometric analysis 
 
Antibodies used in the experiments were titrated prior use. All antibodies were purchased 
from eBiosience. For osteoblast cell sorting cells were incubated with the following 
antibody mixture, pacific blue-CD45 (3-11), APC-CD31 (390), APC-Ter119 (Ter119), PE-
Cy5-Sca-1 (D7), PE-CD51 (RMV-7) and cell surface staining was performed in PBS 
supplemented with 2% tet-free FCS for 30 min. on ice. For hematopoietic stem cell 
identification cell were stained with lineage cocktail antibodies, fluorescently coupled to 
PE-Cy7, CD4 (GK1.5), CD8a (53.6.7), B220 (RA3-6B2), Gr1 (RB6.8C5), Ter119 (Ter119), 
CD11b (M1/70), AF700-CD34 and PE-CD34 (RAM 34), PE-CD48 and pacific blue-CD48 
(HM48.1), PE-Cy5-CD150 (TC15-12F12.2), AF400-Sca-1 and APC-Sca-1 (D7), APC-
eFluor780-c-Kit (2B8). Hematopoietic progenitors were additionally identified with PE-
CD127 or PE-Cy5 or APC (A7R34), pacific blue-CD16/32 or PE (93). Specific differentiated 
cell stainings and detection of chimerism in the bone marrow were achieved by incubation 
with APC-CD3 (17A2), FITC-CD45.1 (A20), AF-700-CD45.2 or pacific blue (104).  
 
For cell cycle analysis intra-cellular cell staining was performed after regular cell surface 
staining. Cells were then fixed with cytofix/cytoperm following traders instructions (BD 
Heidelberg). Cells were then incubated with FITC-ki67 (BD) for at least one hour on ice 
and before flow cytometry additionally 5 -10 min. stained with Hoechst33342 (Invitrogen). 
For BrdU stainings, cells were fixed and permeabilized with cytofix/cytoperm following 
traders instructions and then incubated with DNase I (BD) for one hour at 37°C and then 
intra-cellularly stained with APC-BrdU (BD) antibody.  
 
FACS was performed on either a BD LSR II or BD LSR Fortessa while FACS cell sorting was 
performed on BD Aria machines. Identification of cell populations with corresponding cell 
surface markers are indicated in (Table 5). 
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Abbreviation Population Cell surface marker 
Lin- Lineage  CD4, CD8a, CD11b, Gr1, 
B220, Ter119 
LSK 
 
LSK Lin- Sca+ c-Kit+ 
LSK SLAM 
 
LSK SLAM LSK CD150+ CD48- 
ST-HSC 
 
Short-term HSC LSK CD150+ CD48- CD34+ 
LT-HSC 
 
Long-term HSC LSK CD150+ CD48- CD34- 
CMP Common myeloid progenitor Lin- Sca-1- c-Kit+ CD34+ 
CD16/32- 
GMP Granulocyte macrophage/ 
monocyte  progenitor 
Lin- Sca-1- c-Kit+ CD34+ 
CD16/32+ 
MEP Megakaryocyte erythroid 
progenitor 
Lin- Sca-1- c-Kit+ CD34- 
CD16/32- 
CLP 
 
Common lymphoid progenitor Lin- Sca-1low c-Kitlow CD127+ 
Granulocyte 
 
Granulocyte Gr1+ CD11b+ 
Erythrocyte progenitor 
 
Erythrocyte progenitor CD71+ Ter119- 
Erythrocytic blasts 
 
Erythrocytic blasts CD71+ Ter119+ 
Erythrocyte 
 
Erythrocyte CD71- Ter119+ 
T-cell 
 
T-lymphocyte CD3+, CD4+, CD8a+ 
Pre-pro B-cell 
 
Pre-pro B-cell IgM- B220+ 
Immature B-cell 
 
Immature B-cell IgM+ B220low 
Mature B-cell 
 
B-lymphocyte IgM+ B220+ 
Osteoclast progenitor Osteoclast progenitor CD45+ Gr1- CD11blow/- 
F/480+ CD115-  
Mature osteoclast Osteoclast CD45+ Gr1- CD11blow/- 
F/480+ CD115+ 
Monocyte Monocyte CD45+ Gr1- CD11blow/- 
F/480- CD115+ 
Primitive stromal cell Stromal cell progenitor CD45- CD31- Ter119- Sca-1+ 
CD51- 
Immature osteoblast Immature osteoblast CD45- CD31- Ter119- Sca-1+ 
CD51+ 
Mature osteoblast Osteoblast CD45- CD31- Ter119- Sca-1- 
CD51+ 
Table	  5:	  Identification	  of	  cell	  populations	  in	  the	  bone	  and	  the	  bone	  marrow	  by	  cell	  surface	  markers	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7.8 RNA isolation 
All RNA preparations were performed with Arcturus RNA Isolation kit (Arcturus). Just 
briefly cells were directly lyzed in 100 µL cell lysis buffer and RNA isolated following 
manufacturer´s instructions. RNA was isolated with 11 µL cell extraction buffer and either 
used for RNA micro-array or for c-DNA synthesis. 
 
7.9 Reverse Transcription 
 
All RNA samples were transcribed with SuperScript VILO cDNA synthesis kit (Invitrogen), 
following manufacturerer´s instructions. Synthesized cDNA from LT-HSCs was diluted in a 
1:4 ratio while all the other samples were diluted 1:8 with ultra-pure water (Gibco) before 
qRT-PCR analysis. 
 
7.10  Quantitative real-time PCR 
 
Genomic DNA sequence was obtained from Genbank and primers were designed by using 
Roche Assay Designing software. Quantitative real-time PCR was performed on a Roche 
Light Cycler 480 PCR machine with ABI Power SYBR Green mastermix (Applied 
Biosystems). All reactions were performed in triplicats in 96-well plates with a final volume 
of 20 µL per reaction. The PCR program was uniquely designed and all samples were run 
with 50 cycles beginning with denaturation 95 °C 10 min, acquisition for 45 s at 60 °C and 
a continuous acquisition with 0.11 °C/s, ranging from 65 °C to 95 °C and finalized at 40 
°C for 5 min. Results were analyzed by using Roche Light Cycler Software. Data was 
normalized to the house-keeping genes OAZ and SDHA. All primers were validated for the 
appropriate cp range and DNA specificity before used in the analysis of qRT-PCR (Table 6).  
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Gene target  Forward primer  (5’-3’) Reverse primer (5’-3’) Eff. 
 
OAZ 
 
TTTCAGCTAGCATCCTGTACTCC 
 
GACCCTGGTCTTGTCGTTAGA 
 
2,041 
SDHA AAGTTGAGATTTGCCGATGG TGGTTCTGCATCGACTTCTG 1,978 
hu c-Myc CGGAACTCTTGTGCGTAAGG TGATTGCTCAGGACATTTCTGT 1,860 
p16 GGGTTTTCTTGGTGAAGTTCG TTGCCCATCATCATCACCT 1,793 
p18 AAATGGATTTGGGAGAACTGC AAATTGGGATTAGCACCTCTGA 1,990 
p19 AATGTGACCCAAGGCCACT TTTCCTCTTTTGTTGACAAGTAACC 1,986 
p21 TCCACAGCGATATCCAGACA GGACATCACCAGGATTGGAC 2,114 
p27 GAGCAGTGTCCAGGGATGAG TCTGTTCTGTTGGCCCTTTT 1,976 
p57 GAAGGACCAGCCTCTCTCG GAAGGACCAGCCTCTCTCG 1,954 
CyclinD1 GAGATTGTGCCATCCATGC CTCCTCTTCGCACTTCTGCT 1,982 
RunX2 CGAGACCAACCGAGTCATTT ACGCCATAGTCCCTCCTTTT 2,001 
ALP ACTCAGGGCAATGAGGTCAC TCACCCGAGTGGTAGTCACA 2,000 
Osx TCTCCATCTGCCTGACTCCT GGACTGGAGCCATAGTGAGC 1,696 
OCN GCGCTCTGTCTCTCTGACCT ACCTTATTGCCCTCCTGCTT 1,840 
OPN GCTTGGCTTATGGACTGAGG AGGTCCTCATCTGTGGCATC 1,708 
Col1a1 CAGTCGCTTCACCTACAGCA GACTGTCTTGCCCCAAGTTC 1,870 
Ogn GGAATTAAAGCAAACACATTCAAA TTTCTGGTAAATTAGGAGGCACA 2,183 
Postn AAGCTGCGGCAAGACAAG TCAAATCTGCAGCTTCAAGG 2,495 
Lrp5/6 CATGGACATCCAAGTGCTGA TTGTCCTCCTCGCATGGT 1.938 
Wnt3a CTTAGTGCTCTGCAGCCTGA GAGTGCTCAGAGAGGAGTACTGG 2,041 
DKK-1 CTTCAAAAATATATC ACACCAAAGGA 2,059 
APC CATGGACCAGGACAAAAACC GAACACACACAGCAGGACAGA 2.138 
Axin2 GAGAGTGAGCGGCAGAGC CGGCTGACTCGTTCTCCT 2.034 
GSK3ß CAGTGGTGTGGATCAGTTGG AATTTGCTCCCTTGTTGGTG 1,986 
ß-Cat TGCAGATCTTGGACTGGACA AAGAACGGTAGCTGGGATCA 1,978 
VDR AACCCCTCATAAAGTTCCAGGT CTGTACCCCAGGTCGGTCT 1,775 
RANK-L AGCCATTTGCACACCTCAC CGTGGTACCAAGAGGACAGAGT 1,782 
OPG GTTTCCCGAGGACCACAAT CCATTCAATGATGTCCAGGAG 1,927 
M-CSF GGTGGAACTGCCAGTATAGAAAG TCCCATATGTCTCCTTCCATAAA 1,870 
IL-6 GCTACCAAACTGGATATAATCAGGA CCAGGTAGCTATGGTACTCCAGAA 2,000 
Sox2 GGACTTCTTTTTGGGGGACT CAGATCTATACATGGTCCGATTCC 2,127 
Sox9 TATCTTCAAGGCGCTGCAA TCGGTTTTGGGAGTGGTG 2,052 
E-Cad ATCCTCGCCCTGCTGATT ACCACCGTTCTCCTCCGTA 1,962 
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Mdm2 AGGGCACGAGCTCTCAGAT TCTCCTTCAAAAGAGTCTGTATCG 2,000 
p53 ACGCTTCTCCGAAGACTGG AGGGAGCTCGAGGCTGATA 1,977 
Sca-1 TGGATTCTCAAACAAGGAAAGTAAGA ACCCAGGATCTCCATACTTTCAATA 1,996 
c-Kit GGAGCCCACAATAGATTGGTAT CACTGGTGAGACAGGAGTGG 2,000 
RIG-I GAGAGTCACGGGACCCACT CGG TCT TAG CAT CTC CAA CG 1,940 
IFIH-1 TGATGCACTATTCCAAGAACTAACA TCTGTGAGACGAGTTAGCCAAG 2,040 
IPS-1 ATGAGGTCGGCCACACAC TGGGATGGACTGAGATGGAC 1,983 
Bmi-1 AAACCAGACCACTCCTGAACA TCTTCTTCTCTTCATCTCATTTTTGA 2,201 
Table	  6:	  List	  of	  qRT-­‐PCR	  Primer	  
 
7.11  Micro array analysis 
 
Micro array analysis was performed at DKFZ Genomics & Proteomics Core Facility with 
Illumina MouseRef-6 v2.0 Expression BeadChips (Illumina, San Diego). RNA quality was 
analyzed and quantified on the Agilent Bioanalyzer 2100. Samples with sufficient RNA 
amount (> 3ng, > 500pg/ µL) and quality (RIN > 7) were amplified with Ovation PicoSL 
WTA system and labeled with Encore BiotinIL Module (NuGen) and then hybridized. 
Insufficient samples (< 500pg/ µL or < 3ng) were first amplified, using NuGen Amplicon 
kit.  
 
7.12  Histology 
 
7.12.1 Paraffin embedding  
 
Freshly isolated bones and organs were rinsed in PBS and then fixed in 4% 
paraformaldehyde (Sigma) over night at 4°C. Bones were additionally decalcified for 4 
days with 0.4 M PBS-EDTA. Tissues were then dehydrated with 70%, 80%, 95%, 100%  
ethanol, xylol and finally embedded into paraffin. For histological sectioning tissues were 
cut into 7 µm cuts and for staining procedures rehydrated with xylol, 100%, 80%, 70%, 
50% ethanol. 
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7.12.2 Hematoxylin and Eosin staining 
 
Tissue cuts were rehydrated and then rinsed in distilled water. Freshly filtered hematoxylin 
(Sigma) was added for 10 min at then slides rinsed in tap water for 10 min. Sections were 
next dehydrated with 70% and 100% ethanol and then cytoplasm was stained with freshly 
filtered eosin (Sigma) for 45 s and then in Entellan (Merck) embedded.  
  
7.12.3 Tartrate-resistant acid phosphatase staining 
 
Osteoclast staining was performed with Trap staining kit following manufacturers 
instructions (Sigma, 387A). Counterstaining was performed with Weigerts hematoxylin 
(Sigma).  
 
7.12.4 Masson Goldner staining 
 
Masson Goldner trichrome staining was performed following manufacturers instructions 
(Merck #1.00485.0001) and sections were counterstained with Weigerts hematoxylin 
(Sigma). 
 
7.12.5 Von Kossa staining 
 
For silver staining, sections were rehydrated to water, then placed in 1% silver nitrate 
solution and incubated for up to 3 hours under a 100 watt bulb. After intensive washing 
with distilled water, slides were incubated in 5% sodium thiosulfate for 5 min to remove 
un-reacted silver. Counterstaining was performed with nuclear fast red (Sigma), then slides 
were dehydrated and mounted in Entellan.  
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7.12.6 Alkaline Phosphatase Staining 
 
ALP staining was performed with ALP staining kit (Stemgent #00-0009) following 
manufacturers instructions. 
 
7.12.7 Immunofluorescence 
 
Paraffin sections were rehydrated to water and then incubated in target retrival solution 
(citrate buffer, pH 6.0, Dako #S1700) for 20 min at 100°C. Then samples were chilled at 
room temperature and then blocked with 10% goat serum (Invitrogen) in PBS (blocking 
buffer) for 1hour at room temperature. Primary antibody incubation was performed over 
night at 4°C and administered in blocking buffer. Secondary antibody incubation was 
added for 1 hour incubation at room temperature in the dark. Then DAPI mounting 
medium was used for counterstaining (Invitrogen # P-36931). Image acquisitions were 
performed with either a laser scanning microscope (Zeiss, LSM700) or a light microscope 
(Leica SFL100). 
 
7.12.8 Histomorphometry 
 
Mouse skeletons were prepared by removal of skin, muscles and inner organs and then 
skeletons were rinsed in PBS. Skeletons were then fixed in neutral phosphate-buffered 
formalin over night, next overtaken into 80% ethanol and shipped for histomorphometric 
bone analysis.Histomorphometric analysis of bones were performed by Dr. Johannes Keller 
in the group of Professor Dr. Michael Amling at Universitätsklinikum Hamburg-Eppendorf, 
Institut für Osteologie und Biomechanik.  
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7.13  Western blot 
 
For protein analysis cells or tissues were lyzed in 1x RIPA buffer (Cell Siganling) 
supplemented with proteinase inhibitor cocktail (Thermo Scientific #78430) and then 
protein concentration was measured with BCA kit (Pierce #23225). Proteins with 300 µg 
were loaded into Mini-Protean TGX precast gels (Biorad) and blottet on cellulose nitrate 
paper. Western blots were developed with SuperSignal West Pico (Pierce #34079) and x-
ray paper (Fuji-film IX50). Antibodies used for western blot are indicated in Table 7. 
 
Antibody Dilution Protein band company 
 
Actin 
 
1:1000 
 
43 kDa 
 
Abcam #ab3280 
ß-Catenin 1:1000 92 kDa Cell Signaling #9582 
Phospho-ß-Catenin 1:1000 92 kDa Cell Signaling #9587 
p53 1:1000 53 kDa Abcam #ab26 
Phospho-p53 1:500 53 kDa Abcam #ab1431 
c-Kit 1:100 120kDa/ 145kDa Cell Signaling #3074 
Phospho-c-Kit 1:100 120kDa/ 145kDa Cell Signaling #3391 
Table	  7:	  List	  of	  western	  blot	  antibodies	  
 
7.14  ELISA 
 
Mouse plasma was diluted in a 50% ratio with sample buffer from the PTH ELISA kit 
(Immutopics, #60-2700) and incubated for three hours on an orbital shaker (200 rpm). All 
other steps were performed in accordance with manufacturers instructions. OCN, Trap, 
RANK-L and OPG ELISAs were performed by Dr. Johannes Keller in the group of Professor 
Dr. Michael Amling at Universitätsklinikum Hamburg-Eppendorf, Institut für Osteologie 
und Biomechanik. 
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7.15  Tyrosine Kinase Inhibitor treatment 
 
Nilotinib (Tasigna, Novartis) was a kind gift from Dr. Ingmar Bruns, Universitätsklinikum 
Düsseldorf, Klinik für Hämatologie, Onkologie und Klinische Immunologie, Arbeitsgruppe 
Prof. Dr. Rainer Haas. Nilotinib was administered in vitro in a dose dependent manner. For 
in vitro treatment Nilotinib was dissolved in DMSO to make a 10 mM stock solution. Then 
serial dilutions were made in DMSO to obtain final dilutions (10 µM; 5 µM; 1 µM; 0.5 µM; 
0.1 µM) and osteosarcoma cell lines were treated for 72 hrs. Then cells were analyzed for 
their cell proliferation rate by using Promega Cell Titer Glo reagent according to 
manufacturers instructions (#G7570).  
 
7.16  Interferon alpha treatment 
 
Interferon alpha (IFNa) stock solution 10.000 U in PBS per mouse and is applied sub-
cutaneously, 16 hrs before the analysis. 
 
7.17  Polyinosinic:polycytidylic acid treatment 
 
Polyinosinic:polycytidylic acid (polyI:C; pIC) stock solution with 1.8 mg/ml in PBS is 
administered intra-peritoneally with 200 µl per 20 g mouse. Animals are sacrificed and 
analyzed 16 hrs post injection. 
 
7.18  Lipopolysaccharide treatment 
 
Normally lipopolysaccharide (LPS) is injected intra-peritoneally with 5 µg per mouse and 
animals are analyzed 16 – 24 hrs post injection. For low dose treatment animals were 
injected with only 0.5 µg per mouse and analyzed 16 hrs post injection. 
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7.19  In vitro infections 
 
Second generation lentivirus production was done with pSPAX2 and pMD2.G plasmids. 
pSPAX2 contains the CAG promoter and expresses the proteins necessary for viral particle 
packaging. pMD2.G plasmid encodes for the envelope for viral production. The pV2-Luc 
(MEF-1) plasmid contains both, the luciferase and venus insert (see map, xxx). Cells were 
infected with a viral titer of 2,3 x 108 PFU/ml. 
 
7.20  Bioluminescence imaging in vivo 
 
D-Luciferin (Caliper Life Sciences) was dissolved in PBS as a 15 mg/ml stock solution and 
kept at 4°C in the dark. For in vivo imaging 10 µL/ g of mouse body weight were given 
intra-peritoneally 5-10 min before measuring. The animals were anesthetized with 4.5% 
isofluorane in oxygen and maintained at 1.5% isofluorane in oxygen. Analysis was done in 
a heated camera chamber using Living Imaging software, according to manufacturer’s 
instructions (Xenogen, IVIS 200, CALIPER).  
 
7.21  Statistics 
GraphPad Prism (GraphPad Sofware) was used to set-up graph analysis. All graphs show 
the mean value and the standard deviation (SD) and were performed by Prism. To 
determine statistical significance, usually unpaired two-tailed t-tests were performed and in 
several cases, when different experimental groups were compared in addition the mean 
value was plotted with the standard error of the mean (SEM). In all the cases statistical 
significance was plotted with *** (< 0.001; extremely significant), ** (0.001 to 0.01; very 
significant), * (0.01 to 0.05; significant), ns (> 0.05; not significant).  
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8 SUPPLEMENTARY 
 
 
 
 
Figure	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  pV2luc2	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9 ABBREVIATIONS 
 
BM Bone marrow 
BrdU 5-Bromo-2-deoxyuridine 
CAR CXCL12-abundant reticular cell 
c-Kit v-kit Hardy-Zuckerman 4 feline sarcoma 
cellular homologue 
c-Myc Cellular myelocytomatosis homologue 
DKK-1 Dickkopf-1 
E14.5 Embryonic day 14.5 
FACS Fluorescence-activated cell sorting 
GFP Green fluorescent protein 
HSC Hematopoietic stem cells 
IFN interferon 
LPS lipopolysaccharide 
LRC Label retaining cell 
Mdm2 Murine double minute 2 
MSC Mesenchymal stem cell 
N-Myc Neuroblastomaamplified myelocytomatosis 
homologue 
OB osteoblast 
OCN osteocalcin 
P30 Post-natal day 30 
P53 Tumor protein 53 
pIC Polyinosinic:polycytidylic acid (PolyI:C) 
RunX2 Runt-related transcription factor 2 
Sca-1 Stem cell antigen 1 
SOST sclerostin 
Wnt Wingless INT-1 
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